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“ My life amounts to no more than one drop in a limitless ocean. Yet what is any ocean, but a 
multitude of drops?” 
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List of abbreviations, genes, proteins and 
chemicals  
All genes names are denoted in accordance with HUGO Gene Nomenclature Committee. All 
protein names are denoted in accordance with The Universal Protein Resource UniProt. 
3'UTR 3’- untranslated region 
4-OHT 4-hydroxytamoxifen 
5-FU 5-fluorouracil 
ABC ATP-binding cassette 
ABCB1 ATP binding cassette subfamily B member 1 
ABCC1 ATP binding cassette subfamily C member 1 
ABCC2 ATP binding cassette subfamily C member 2 
ABCC5 ATP binding cassette subfamily C member 5 
ABCF2 ATP-binding cassette sub-family F member 2 
ABCG2 ATP binding cassette subfamily G member 2 
ABHD10 Mycophenolic acid acyl-glucuronide esterase, mitochondrial 
ABI Applied Biosystems Instruments 
ACBD3 Golgi resident protein GCP60 
ACTB Actin, beta 
ACYP1 Acylphosphatase-1 
ADCK3 Atypical kinase ADCK3, mitochondrial 
ADME Absorption, Distribution, Metabolism and Excretion 
ADPGK ADP-dependent glucokinase 
AGO Argonaute 
AGO2 Argonaute 2, RISC catalytic component 
AIB1/NCOA3 Nuclear receptor coactivator 3 
AIP AH receptor-interacting protein 
AKAP12 A-kinase anchor protein 12 
AKR1C2 Aldo-keto reductase family 1 member C2 
AKR1D1 3-oxo-5-beta-steroid 4-dehydrogenase 
AKT V-akt murine thymoma viral oncogene homolog 1 
ALKBH2 AlkB homolog 2, alpha-ketoglutarate-dependent dioxygenase 
ALKBH3 AlkB homolog 3, alpha-ketoglutarate-dependent dioxygenase 
ANKRD17 Ankyrin repeat domain-containing protein 17 
ANOVA Analysis of variance 





APEH Acylamino-acid-releasing enzyme 
APOBEC3C DNA dC->dU-editing enzyme APOBEC-3C 
ARAP1 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-
containing protein 1 
ARF6 ADP-ribosylation factor 6 
ARFIP2 Arfaptin-2 
ARFRP1 ADP-ribosylation factor-related protein 1 
ARMT1 Protein-glutamate O-methyltransferase 
ARPC5L Actin-related protein 2/3 complex subunit 5-like protein 
ASCO/CAP American Society of Clinical Oncology/College of American 
Pathologists 
ASL Argininosuccinate lyase 
ASPDH Putative L-aspartate dehydrogenase 
ATL2 Atlastin-2 
ATM Ataxia telangiectasia mutated, serine/threonine kinase 
ATP Adenosine triphosphate 
ATP2B4 Plasma membrane calcium-transporting ATPase 4 
ATP6V1B2 V-type proton ATPase subunit B, brain isoform 
ATP6V1G1 V-type proton ATPase subunit G 1 
ATP6V1H V-type proton ATPase subunit H 
ATXN10 Ataxin-10 
B2M Beta-2-microglobulin 
BAG2 BAG family molecular chaperone regulator 2 
BAK1 BCL2 antagonist/killer 1 
BC Breast cancer 
BCAP29 B-cell receptor-associated protein 29 
BCAS2 Pre-mRNA-splicing factor SPF27 
BCL2 B-cell CLL/lymphoma 2 
BCR-ABL Breakpoint cluster region/ABL proto-oncogene 1, non-receptor 
tyrosine kinase 
BER Base excision repair 
BIRC5 Baculoviral IAP repeat containing 5 
BMI1 B cell-specific Moloney murine leukaemia virus integration site 1 
bp Base pairs 





BRCA2 Breast cancer 2 
BSA Bovine serum albumin 
BUB3 Mitotic checkpoint protein BUB3 
C11orf73 Protein Hikeshi 
C12orf57 Protein C10 
C14orf166 UPF0568 protein C14orf166 
C2orf18 Chromosome 2 open reading frame 18, isoform CRA_c 
C7orf50 Uncharacterized protein C7orf50 
CA2 Carbonic anhydrase 2 
CAB39 Calcium-binding protein 39 
CALM1 Calmodulin 
CALU Calumenin 
CAP1 Adenylyl cyclase-associated protein 1 
CARHSP1 Calcium-regulated heat-stable protein 1 
CASP3 Caspase-3 
CAV2 Caveolin-2 
CBR3 Carbonyl reductase [NADPH] 3 
CCDC144CP Putative coiled-coil domain-containing protein 144C 
CCDC22 Coiled-coil domain-containing protein 22 
CCR4-NOT CCR4-NOT transcription complex subunit 1 
CDC25C Cell division cycle 25C 
CDC42 Cell division cycle 42 
CDH1 Cadherin 1 
CDK2 Cyclin-dependent kinase 2 
CDK6 Cyclin-dependent kinase 6 
CDKN1A Cyclin-dependent kinase inhibitor 1 
cDNAs Complementary DNAs 
CENPE Centromere-associated protein E 
CEP170 Centrosomal protein of 170 kDa 
CHAPS 3-((3-cholamidopropyl) dimethylammonium)-1-propanesulfonate 
CHEK2 Checkpoint kinase 2 
CHID1 Chitinase domain-containing protein 1 
CHK2 Checkpoint kinase 2 
CHMP2B Charged multivesicular body protein 2b 





CHMP4B Charged multivesicular body protein 4b 
CHP1 Calcineurin B homologous protein 1 
CIRBP Cold-inducible RNA-binding protein 
CLL Chronic lymphocytic leukaemia 
CLPTM1 Cleft lip and palate transmembrane protein 1 
CMAS N-acylneuraminate cytidylyltransferase 
CML Chronic myeloid leukemia 
CMPK1 Cytidine/uridine monophosphate kinase 1 
c-MYC V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
CNOT7 CCR4-NOT transcription complex subunit 7 
CNP 2',3'-cyclic-nucleotide 3'-phosphodiesterase 
CO2 Carbon dioxide 
COA3 Cytochrome c oxidase assembly factor 3 homolog, mitochondrial 
COMMD8 COMM domain-containing protein 8 
COMT Catechol O-methyltransferase 
COX17 Cytochrome c oxidase copper chaperone 
COX-2 Prostaglandin-Endoperoxide Synthase 2 (Prostaglandin G/H Synthase 
And Cyclooxygenase) 
COX20 Cytochrome c oxidase protein 20 homolog 
COX6C Cytochrome c oxidase subunit 6C 
CPD Carboxypeptidase D 
CpG Cytosine-phosphate-Guanine 
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform 
c-RAF Raf-1 proto-oncogene, serine/threonine kinase 
CRK V-crk avian sarcoma virus CT10 oncogene homolog 
CRKL Crk-like protein 
CSC Cancer stem cells 
CSNK2A2 Casein kinase II subunit alpha' 
CSRP2 Cysteine and glycine-rich protein 2 
CST3 Cystatin-C 
Ct Cycle threshold 
CTBP2 C-terminal-binding protein 2 
CTNNB1 Catenin beta-1 







CXCR4 C-X-C motif chemokine receptor 4 
CYP Cytochrome P450 
CYP1B1 Cytochrome P450 family 1 subfamily B member 1 
CYP2E1 Cytochrome P450 family 1 subfamily E member 1 
CYP3A4 Cytochrome P450 family 3 subfamily A member 1 
DAB 3,3’-diaminobenzidine 
DAC 5-Aza-2′-deoxycytidine 
DCAKD Dephospho-CoA kinase domain-containing protein 
DCTD Deoxycytidylate deaminase 
DDR DNA Damage Response 
DERA 2-deoxyribose-5-phosphate aldolase homolog (C. elegans), isoform 
CRA_a 
DERL1 Derlin 
DFNA5 Non-syndromic hearing impairment protein 5 
DGCR8 DiGeorge syndrome critical region 8 
DGKA Diacylglycerol kinase alpha 
DICER1 Dicer 1, ribonuclease III 
DME Drug-metabolizing enzymes 
DMEM Dulbeccos’s Modified Eagle’s Medium Nutrient 
DMEM/F-12 Dulbeccos’s Modified Eagle’s Medium Nutrient Mixture F-12 Ham 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNAJB11 DnaJ homolog subfamily B member 11 
DNAJC3 DnaJ homolog subfamily C member 3 
DNAJC5 DnaJ homolog subfamily C member 5 
dNTPs Nucleoside triphosphates 
DOCK5 Dedicator of cytokinesis protein 5 
DOCK9 Dedicator of cytokinesis protein 9 
DOHH Deoxyhypusine hydroxylase 
DOX Doxorubicin 
DRAP1 Dr1-associated corepressor 
DRG2 Developmentally-regulated GTP-binding protein 2 
DROSHA Drosha ribonuclease III 






DUT Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 
E2 17-β-estradiol 
EBP 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase 
EDF1 Endothelial differentiation-related factor 1 
EDTA Ethylenediamine tetraacetic acid 
EFHD2 EF-hand domain-containing protein D2 
EFL1 Elongation factor-like GTPase 1 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EGFR Epidermal growth factor receptor 
EIF4A2 Eukaryotic initiation factor 4A-II 
ELOVL5 Elongation of very long chain fatty acids protein 5 
EMC4 ER membrane protein complex subunit 4 
EMC6 ER membrane protein complex subunit 6 
EMC9 ER membrane protein complex subunit 9 
EMT Epithelial-to-mesenchymal transition 
ENAH Protein enabled homolog 
endo-siRNAs Endogenous small interfering RNAs 
ENO1 Enolase 1 
ENO2 Gamma-enolase 
EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 
EPT1 Ethanolaminephosphotransferase 1 
ER Oestrogen receptor 
ERCC1 Excision repair cross-complementation group 1 
ERGIC3 Endoplasmic reticulum-Golgi intermediate compartment protein 3 
ERLEC1 Endoplasmic reticulum lectin 1 
ERLIN1 Erlin-1 
EVI1 MDS1 and EVI1 complex locus 
FAM114A1 Protein NOXP20 
FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 
FAM162A Protein FAM162A 
FAM210A Protein FAM210A 
FAM213A Redox-regulatory protein FAM213A 





FAM96A MIP18 family protein FAM96A 
FAM96B Mitotic spindle-associated MMXD complex subunit MIP18 
FBS Foetal bovine serum 
FBW7 F-box and WD repeat domain containing 7 
FFPE Formalin-fixed paraffin-embedded 
FHL2 Four and a half LIM domains protein 2 
FHL2 Four and a half LIM domains protein 2 
FKBP10 Peptidyl-prolyl cis-trans isomerase FKBP10 
FKBP2 cDNA FLJ52062, highly similar to Erythrocyte band 7 integral 
membrane protein 
FKBP3 Peptidyl-prolyl cis-trans isomerase FKBP3 
FKBP5 Peptidyl-prolyl cis-trans isomerase FKBP5 
FMNL2 Formin-like protein 2 
FMR1 Fragile X mental retardation 1 
FOG2 Zinc finger protein, FOG family member 2 
FOXO1 Forkhead box O1 
FTL Ferritin light chain 
FXN Frataxin, mitochondrial 
FZD3 Frizzled class receptor 3 
GAP Growth Associated Protein 
GATA3 GATA binding protein 3 
GBAS Protein NipSnap homolog 2 
GC Guanine Cytosine 
GCSH Glycine cleavage system H protein, mitochondrial 
GE General Electric 
GLB1 Beta-galactosidase 
GLS Glutaminase kidney isoform, mitochondrial 
GMIP GEM-interacting protein 
GMPPB Mannose-1-phosphate guanyltransferase beta 
GNB2l1 Guanine nucleotide binding protein (G protein), beta polypeptide 2-
like 1 
GNL3 Guanine nucleotide-binding protein-like 3 
GOLGA3 Golgin subfamily A member 3 
GPS1 COP9 signalosome complex subunit 1 





GSK3B Glycogen synthase kinase-3 beta 
GSTP1 Glutathione S-transferase pi 1 
GSTT2 Glutathione S-transferase theta 2, isoform CRA_a 
GTF2F2 General transcription factor IIF subunit 2 
GUK1 Guanylate kinase 
GW182 Trinucleotide repeat-containing gene 6A protein 
GYS1 Glycogen [starch] synthase, muscle 
H2AFV Histone H2A.V 
H2AX H2A histone family member X 
HACD3 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 
HAT1 Histone acetyltransferase type B catalytic subunit 
HCFC1 Host cell factor 1 
HDAC1 Histone deacetylase 1 
HEBP2 Heme-binding protein 2 
HER2/ERBB2 Human epidermal growth factor receptor 2/erb-b2 receptor tyrosine 
kinase 2 
HER3/ERBB3 Human epidermal growth factor receptor 3/erb-b2 receptor tyrosine 
kinase 3 
HERPUD1 Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-
like domain member 1 protein 
HIF1α Hypoxia Inducible Factor 1, Alpha Subunit 
HINT2 Histidine triad nucleotide-binding protein 2, mitochondrial 
HLA-C HLA class I histocompatibility antigen, Cw-12 alpha chain 
HM13 Minor histocompatibility antigen H13 
HMEpC Human Mammary Epithelial progenitor Cell line 
HMGA High Mobility Group 
HMGA1 High mobility group protein HMG-I/HMG-Y 
HMGA2 High mobility group AT-hook 2 
HMGCL 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
(Hydroxymethylglutaricaciduria), isoform CRA_b 
HMGN3 High mobility group nucleosome-binding domain-containing protein 
3 
HN1 Hematological and neurological-expressed 1 protein 
HNRNPDL Heterogeneous nuclear ribonucleoprotein D-like 





HOXD10 Homeobox D10 
HR Homologous recombination 
HSAEpC Human Small Airway Epithelial progenitor Cell line 
HSD17B2 Estradiol 17-beta-dehydrogenase 2 
HTRA2 Serine protease HTRA2, mitochondrial 
HTT Huntingtin 
HuR ELAV like RNA binding protein 1 
IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolog 
ICLs Interstrand DNA crosslinks 
IEF Isoelectric focusing 
IFI16 Gamma-interferon-inducible protein 16 
IFI35 Interferon-induced 35 kDa protein 
IFT27 Intraflagellar transport protein 27 homolog 
IHC Immunohistochemistry 
IL1A Interleukin-1 alpha 
ILK Integrin-linked protein kinase 
ILVBL Acetolactate synthase-like protein 
INF2 Inverted formin-2 
IPG Immobilized pH gradient 
IPO11 Importin-11 
IQGAP2 Ras GTPase-activating-like protein IQGAP2 
IRGQ Immunity-related GTPase family Q protein 
IRS1 Insulin receptor substrate 1 
ISCA1 Iron-sulfur cluster assembly 1 homolog, mitochondrial 
IST Instituto Superior Técnico 
ITGA5 Integrin subunit alpha 5 
ITGAV Integrin alpha-V 
ITGB3 Integrin subunit beta 3 
KCl Potassium chloride 
KCTD12 BTB/POZ domain-containing protein KCTD12 
KH2PO4 Potassium phosphate monobasic 
KIAA0196 WASH complex subunit strumpellin 
KIAA0391 Mitochondrial ribonuclease P protein 3 
KIAA1033 WASH complex subunit 7 





KRAS GTPase KRas 
KRT18 Keratin, type I cytoskeletal 18 
LACTB2 Beta-lactamase-like protein 2 
LAD1 Ladinin-1 
LAMC1 Laminin subunit gamma-1 
LASP1 LIM and SH3 protein 1 
LC/MS Liquid chromatography/Mass spectrometry 
LIFR Leukaemia inhibitory factor receptor alpha 
LNA Locked Nucleic Acid 
lncRNAs Long non-coding RNAs 
LPXN Leupaxin 
LSM4 U6 snRNA-associated Sm-like protein LSm4 
LSM5 U6 snRNA-associated Sm-like protein LSm5 
LTV1 Protein LTV1 homolog 
LUC7L2 Putative RNA-binding protein Luc7-like 2 
LXN Latexin 
MAGI2 Membrane associated guanylate kinase, WW and PDZ domain 
containing 2 
MALDI-TOF/TOF Matrix-assisted laser desorption/ionization-time-of-flight mass 
spectrometer 
MAP1B Microtubule-associated protein 1B 
MAPK14 Mitogen-activated protein kinase 14 
MAPK1IP1L MAPK-interacting and spindle-stabilizing protein-like 
MCM3 DNA replication licensing factor MCM3 
MCM6 DNA replication licensing factor MCM6 
MCMBP Mini-chromosome maintenance complex-binding protein 
MCT1 Monocarboxylate transporter 1 
MDC1 Mediator of DNA damage checkpoint 1 
MDR Multidrug resistance 
ME1 NADP-dependent malic enzyme 
MED20 Mediator of RNA polymerase II transcription subunit 20 
MERTK MER proto-oncogene, tyrosine kinase 
MET Mesenchymal-to-epithelial transition 
MF Methylated forward 





MIG6 ERBB receptor feedback inhibitor 1 
miRISC miRNA induced silencing complex 
miRNAs Micro RNAs 
MMGT1 Membrane magnesium transporter 1 
MMR Mismatch repair 
MnCl2 Manganese(II) chloride 
MNT MAX network transcriptional repressor 
MOB4 MOB-like protein phocein 
MR Methylated reverse 
mRNA Messenger RNA 
MRPL14 39S ribosomal protein L14, mitochondrial 
MRPL18 39S ribosomal protein L18, mitochondrial 
MRPL22 39S ribosomal protein L22, mitochondrial 
MRPL30 39S ribosomal protein L30, mitochondrial 
MRPL37 39S ribosomal protein L37, mitochondrial 
MRPL38 39S ribosomal protein L38, mitochondrial 
MRPL45 39S ribosomal protein L45, mitochondrial 
MRPL47 39S ribosomal protein L47, mitochondrial 
MRPL48 39S ribosomal protein L48, mitochondrial 
MRPL50 39S ribosomal protein L50, mitochondrial 
MRPL53 39S ribosomal protein L53, mitochondrial 
MRPL9 39S ribosomal protein L9, mitochondrial 
MRPS11 28S ribosomal protein S11, mitochondrial 
MRPS12 28S ribosomal protein S12, mitochondrial 
MRPS5 28S ribosomal protein S5, mitochondrial 
MRPS6 28S ribosomal protein S6, mitochondrial 
MRRF Ribosome-recycling factor, mitochondrial 
MSH2 MutS homolog 2 
MSH6 MutS homolog 6 
MSP Methylation specific PCR 
MSRB3 Methionine-R-sulfoxide reductase B3 
MT1H Metallothionein-1H 
MT1L Metallothionein-1L 
MTA1 Metastasis associated 1 





MTCH2 Mitochondrial carrier homolog 2 
MTOR Serine/threonine-protein kinase mTOR 
MTT Thiazolyl blue tetrazolium bromide 
MUC1 Mucin 1, cell surface associated 
MX Mitoxantrone 
MYC V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
MYL1 Myosin light chain 1/3, skeletal muscle isoform 
MYO1E Unconventional myosin-Ie 
MYT1 Myelin transcription factor 1 
Na2HPO4 Disodium phosphate 
NAA20 N-alpha-acetyltransferase 20 
NaCl Sodium Chloride 
NAE1 NEDD8-activating enzyme E1 regulatory subunit 
NANOG/OCT4 Nanog homeobox/POU class 5 homeobox 1 
NAV1 Neuron navigator 1 
NCAPD2 Condensin complex subunit 1 
NCEH1 Neutral cholesterol ester hydrolase 1 
NCKAP1 Nck-associated protein 1 
ncRNAs Non-coding RNAs 
NCSTN Nicastrin 
NDUFA12 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 
NDUFA13 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 
NDUFAF2 Mimitin, mitochondrial 
NDUFB4 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 
NECTIN1 Nectin cell adhesion molecule 1 
NEDD4 E3 ubiquitin-protein ligase NEDD4 
NER Nucleotide excision repair 
NFkB Nuclear Factor of Kappa Light Polypeptide Gene Enhancer In B-Cells 
NFS1 Cysteine desulfurase, mitochondrial 
NHEJ Non-homologous end joining 
NIPSNAP3A Protein NipSnap homolog 3A 
NOP16 Nucleolar protein 16 
NOS Not otherwise specified 
NPC1 Niemann-Pick C1 protein 






NT5C2 Cytosolic purine 5'-nucleotidase 
NT5C3A Cytosolic 5'-nucleotidase 3A 
NTMT1 N-terminal Xaa-Pro-Lys N-methyltransferase 1 
NUBP2 Cytosolic Fe-S cluster assembly factor NUBP2 
NUDT4 Diphosphoinositol polyphosphate phosphohydrolase 2 
NUMA1 Nuclear mitotic apparatus protein 1 
NUTF2 Nuclear transport factor 2 
OARD1 O-acetyl-ADP-ribose deacetylase 1 
OGFR Opioid growth factor receptor 
OGT UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 
110 kDa subunit 
oncomiRs Oncogenic miRNAs 
ORMDL3 ORM1-like protein 3 
OSBPL8 Oxysterol-binding protein 
OTUD6B OTU domain-containing protein 6B 
p27Kip1 Cyclin-dependent kinase inhibitor 1B 
PABPC Polyadenylate-binding protein complex 
PABPN1 Polyadenylate-binding protein 2 
PAGE Polyacrylamide gel electrophoresis 
PaK1 P21 Protein (Cdc42/Rac)-Activated Kinase 1 
PALB2 Partner and localizer of BRCA2 
PARK7 Parkinson disease (autosomal recessive, early onset) 7 
PARP Poly(ADP-ribose) polymerase 
PASRs Promoter-associated small RNAs 
PAX Paclitaxel 
PBK Lymphokine-activated killer T-cell-originated protein kinase 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCBD1 Pterin-4-alpha-carbinolamine dehydratase 
PcG Polycomb group 
PCR Polymerase chain reaction 
PDCD4 Programmed cell death 4 
PDCD5 Programmed cell death protein 5 





PEPT1 Peptide transporter 1 
PEX1 Peroxisome biogenesis factor 1 
PEX11B Peroxisomal membrane protein 11B 
PFAS Phosphoribosylformylglycinamidine synthase 
PFDN1 Prefoldin subunit 1 
PHPT1 14 kDa phosphohistidine phosphatase 
PIKK Phosphoinositide 3-kinase (PI3-kinase)-like family 
PIR Pirin 
piRNAs Piwi-interacting RNAs 
PITPNA Phosphatidylinositol transfer protein alpha isoform 
PKM2 Pyruvate Kinase, Muscle 
PLAA Phospholipase A-2-activating protein 
PLCG1 Phospholipase C gamma 1 
PLEK2 Pleckstrin-2 
PM20D2 Peptidase M20 domain-containing protein 2 
PMSF Phenylmethylsulfonyl fluoride 
PNPLA4 Patatin-like phospholipase domain-containing protein 4 
Pol II RNA polymerase II 
POLR2E DNA-directed RNA polymerases I, II, and III subunit RPABC1 
POTEE POTE ankyrin domain family member E 
PPCS Phosphopantothenate--cysteine ligase 
PPCS Phosphopantothenate--cysteine ligase 
PPCS Phosphopantothenate--cysteine ligas 
PPFIBP1 Liprin-beta-1 
PPP1CC Serine/threonine-protein phosphatase 
PPP1R14B Protein phosphatase 1 regulatory subunit 14B 
PPP1R7 Protein phosphatase 1 regulatory subunit 7 
PPP2R5D Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit 
delta isoform 
PR Progesterone receptor 
pRb Retinoblastoma 1 
PRC1 Polycomb repressor complex 1 
PRDX2 Peroxiredoxin 2 
PRDX6 Peroxiredoxin 6 





pri-miRNAs Primary miRNAs 
PRKCI Protein kinase C iota type 
PRMT3 Protein arginine N-methyltransferase 3 
PROMPTs Promoter upstream transcripts 
PSAP Prosaposin 
PSMA6 Proteasome subunit alpha 6 
PSPH Phosphoserine phosphatase 
PTEN Phosphatase and tensin homolog 
PTMA Prothymosin alpha 
PTMS Parathymosin 
PTPRN2 Protein tyrosine phosphatase, receptor type N2 
PTRH2 Peptidyl-tRNA hydrolase 2, mitochondrial 
PUS1 tRNA pseudouridine synthase 
PVDF Polyvinylidene difluoride 
PYCRL Pyrroline-5-carboxylate reductase 3 
qPCR Quantitative PCR 
R3HDM1 R3H domain-containing protein 1 
RAB22A Ras-related protein Rab-22A 
RAB4A Ras-related protein Rab-4A 
RABAC1 Prenylated Rab acceptor protein 1 
RABIF Guanine nucleotide exchange factor MSS4 
RAD23B UV excision repair protein RAD23 homolog B 
RAD51 RAD51 recombinase 
RAD52 RAD52 homolog, DNA repair protein 
RAN RAN, member RAS oncogene family 
RAS Rat Sarcoma Viral Oncogene Homolog gene family 
RBM8A RNA-binding protein 8A 
RBMXL2 RNA-binding motif protein, X-linked-like-2 
RCC1 Regulator of chromosome condensation 
RCC2 Protein RCC2 
RCN1 Reticulocalbin-1 
RDX Radixin 
REV1 REV1, DNA directed polymerase 
RFC5 Replication factor C subunit 5 





RHOA Ras homolog family member A 
RHOC Ras homolog family member C 
RNA Ribonucleic acid 
RPA2 Replication protein A 32 kDa subunit 
RPL22L1 60S ribosomal protein L22-like 1 
RPL26L1 60S ribosomal protein L26-like 1 
RPS27L 40S ribosomal protein S27-like 
RRM1 Ribonucleoside-diphosphate reductase large subunit 
RTKN Rhotekin 
RT-qPCR Reverse transcription qPCR 
S100A13 Protein S100-A13 
SACM1L Phosphatidylinositide phosphatase SAC1 
SATB1 Special AT-rich sequence binding protein 1 
SCAMP1 Secretory carrier-associated membrane protein 1 
SCC Squamous Cell Carcinoma 
SCO2 Protein SCO2 homolog, mitochondrial 
SCRIB Protein scribble homolog 
SDC1 Syndecan-1 
SDCBP Syntenin-1 
SDF2L1 Stromal cell-derived factor 2-like protein 1 
SDS Sodium dodecyl sulfate 
SEC11A Signal peptidase complex catalytic subunit SEC11 
SEC16A Protein transport protein Sec16A 
SEC23IP SEC23-interacting protein 
SEC24D Protein transport protein Sec24D 
SEC63 Translocation protein SEC63 homolog 
SEER Surveillance, Epidemiology, and End Results 
SRM Selected Reaction Monitoring 
SEP15 15 kDa selenoprotein 
SEPHS1 Selenide, water dikinase 1 
SEPT8 Septin-8 
SERPINB5 Serpin family B member 5 
SERPINB5 Serpin family B member 5 
SERPINE1 Plasminogen activator inhibitor 1 





SETD1A Histone-lysine N-methyltransferase SETD1A 
SF3A3 Splicing factor 3A subunit 3 
SF3B5 Splicing factor 3B subunit 5 
SFN Stratifin 
SH2D4A SH2 domain-containing protein 4A 
SH3BGRL SH3 domain-binding glutamic acid-rich-like protein 
SIK1 Salt inducible kinase 1 
SIRT1 Sirtuin 1 
SIX1 Sine Oculis Homeobox Homolog 1 
SKIV2L2 Superkiller viralicidic activity 2-like 2 
SLC15A1 Solute carrier family 15 member 1 
SLC16A1 Solute carrier family 16 member 1 
SLC22A1 Solute carrier family 22 member 1 
SLC22A5 Solute carrier family 22 member 5 
SLC25A1 Tricarboxylate transport protein, mitochondrial 
SLC25A22 Mitochondrial glutamate carrier 1 
SLC25A6 ADP/ATP translocase 3 
SLCO2B1 Solute carrier organic anion transporter family member 2B1 
SMAD2 Mothers against decapentaplegic homolog 2 
SMAD3 SMAD family member 3 
SMARCA4 Transcription activator BRG1 
SMCHD1 Structural maintenance of chromosomes flexible hinge domain-
containing protein 1 
SMN1 Survival motor neuron protein 
SNAI2 Snail family zinc finger 2 
SNAP29 Synaptosomal-associated protein 29 
SNAPIN SNARE-associated protein Snapin 
SNPs Single nucleotide polymorphisms 
snRNA Small nuclear RNAs 
SNU13 NHP2-like protein 1 
SNX1 Sorting nexin-1 
SOCS3 Suppressor of cytokine signalling 3 
SOX1 SRY-box 1 
SOX2 SRY-box 2 





SP1 Sp1 transcription factor 
SPC25 Kinetochore protein Spc25 
SPIN1 Spindlin-1 
SPSS Statistical Package for the Social Sciences 
SRC SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase 
SRPRA Signal recognition particle receptor subunit alpha 
SRXN1 Sulfiredoxin-1 
SSR3 Translocon-associated protein subunit gamma 
SSU72 RNA polymerase II subunit A C-terminal domain phosphatase SSU72 
ST14 Suppression of tumorigenicity 14 
StarD10 StAR related lipid transfer domain containing 10 
STAT1 Signal transducer and activator of transcription 1-alpha/beta 
STAT3 Signal transducer and activator of transcription 3 
STAT3 Signal transducer and activator of transcription 3 
STK10 Serine/threonine-protein kinase 10 
STK11 Serine/threonine kinase 11 
STK4 Serine/threonine-protein kinase 4 
STMN1 Stathmin 
STX12 Syntaxin-12 
SULT1A1 Sulfotransferase family 1A member 1 
SUMO1 Small ubiquitin-related modifier 1 
SUZ12 SUZ12 polycomb repressive complex 2 subunit 
SYAP1 Synapse-associated protein 1 
SYMPK Symplekin 
SYNGR2 Synaptogyrin-2 
TBC1D9B TBC1 domain family member 9B 
TBCD Tubulin-specific chaperone D 
TBRG4 Protein TBRG4 
TEMED Tetramethylethylenediamine 
TERT Telomerase reverse transcriptase 
TGF-β Transforming Growth Factor, Beta 
THEM6 Protein THEM6 
THYN1 Thymocyte nuclear protein 1 
TIAL1 Nucleolysin TIAR 





TIMM8B Mitochondrial import inner membrane translocase subunit Tim8 B 
TIMP3 TIMP metallopeptidase inhibitor 3 
tiRNAs Transcription initiation RNAs 
TLR7 Toll-like receptor 7 
TMED4 Transmembrane emp24 domain-containing protein 4 
TMED5 Transmembrane emp24 domain-containing protein 5 
TMEM205 Transmembrane protein 205 
TMEM41B Transmembrane protein 41B 
TMEM65 Transmembrane protein 65 
TMEM70 Transmembrane protein 70, mitochondrial 
TMSB10 Thymosin beta-10 
TMX3 Protein disulfide-isomerase TMX3 
TNBC Triple-negative breast cancers 
TNC Tenascin C 
TNM Tumour Node Metastasis 
TOP1 DNA topoisomerase 1 
TP53 Tumour protein p53 
TP53INP1 Tumour protein p53 inducible nuclear protein 1 
TPBG Trophoblast glycoprotein 
TPI1 Triosephosphate isomerase 1 
TPM Tropomyosin 
TPM1 Tropomyosin 1 
TPM2 Tropomyosin beta chain 
TPM3 Tropomyosin 3 
TPP1 Tripeptidyl-peptidase 1 
TPRKB EKC/KEOPS complex subunit TPRKB 
TRAPPC5 Trafficking protein particle complex subunit 5 
TRBP Transactivation-responsive RNA-binding protein 
TRIM25 E3 ubiquitin/ISG15 ligase TRIM25 
TRIM32 E3 ubiquitin-protein ligase TRIM32 
Tris.base Tris(hydroxymethyl)aminomethane 
Tris.HCl Tris(hydroxymethyl)aminomethane hydrochloride 
TRKB Neurotrophic receptor tyrosine kinase 2 
TRMT1 tRNA (guanine(26)-N(2))-dimethyltransferase 





TSR3 Ribosome biogenesis protein TSR3 homolog 
TSSa-RNAs Transcription start site associated RNAs 
TTC1 Tetratricopeptide repeat protein 1 
TTP Tristetraprolin 
TUBA1b Tubulin alpha 1b 
TYMS Thymidylate synthase 
TYMS Thymidylate synthase 
UBA2 SUMO-activating enzyme subunit 2 
UBA3 NEDD8-activating enzyme E1 catalytic subunit 
UBC9 Ubiquitin conjugating enzyme E2 I 
UBE2C Ubiquitin-conjugating enzyme E2 C 
UBE2D1 Ubiquitin-conjugating enzyme E2 D1 
UBE2D2 Ubiquitin-conjugating enzyme E2 D2 
UBE2D3 Ubiquitin-conjugating enzyme E2 D3 
UBE2O (E3-independent) E2 ubiquitin-conjugating enzyme 
UBQLN2 Ubiquilin-2 
UCSC University of California Santa Cruz 
UF Unmethylated forward 
UHRF2 Ubiquitin-like with PHD and ring finger domains 2 
UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial 
UR Unmethylated reverse 
USP24 Ubiquitin carboxyl-terminal hydrolase 24 
UV Ultraviolet 
VEGF-A Vascular endothelial growth factor A 
VMA21 Vacuolar ATPase assembly integral membrane protein VMA21 
VPS26A Vacuolar protein sorting-associated protein 26A 
VPS28 Vacuolar protein sorting-associated protein 28 homolog 
VPS37B Vacuolar protein sorting-associated protein 37B 
WDR77 Methylosome protein 50 
XDH Xanthine dehydrogenase/oxidase 
xenomiRs Exogenous origin miRNAs 
XPO5 Exportin-5 
YARS2 Tyrosine--tRNA ligase, mitochondrial 
YBX3 Y-box-binding protein 3 





ZBTB1 Zinc finger and BTB domain containing 1 
ZBTB10 Zinc finger and BTB domain containing 10 
ZC3H4 Zinc finger CCCH domain-containing protein 4 
ZC3HAV1 Zinc finger CCCH-type antiviral protein 1 
ZCCHC6 Terminal uridylyltransferase 7 
ZEB1 Zinc finger E-box-binding homeobox 1 
ZEB2 Zinc finger E-box-binding homeobox 2 
ZFP36L1 Zinc finger protein 36, C3H1 type-like 1 













Os microRNAs (miRNAs) são pequenos RNAs não codificantes com função reguladora que 
regulam a expressão génica ao ligar-se a sequências específicas na região 3’ UTR dos 
mRNAs. Diversos estudos mostraram que os miRNAs regulam mecanismos fundamentais 
para o normal funcionamento celular, como crescimento celular, proliferação, 
diferenciação e apoptose. A expressão de alguns miRNAs é alterada em diversos tipos de 
cancro, nomeadamente em cancro da mama. Estudos de análise funcional em linhas 
celulares mostraram que os miRNAs podem funcionar como supressores de tumor ou ter 
actividade oncogénica. Assim, o valor clínico dos miRNAs como potenciais marcadores 
para cancro da mama está a ser amplamente estudado de momento. No entanto, apenas se 
conhecem efeitos de alguns miRNAs. A maior dificuldade, neste âmbito, depreende-se com 
a identificação de possíveis alvos com relevância biológica para cancro da mama. Visto que 
os programas bioinformáticos predizem um elevado número de falsos positivos e falsos 
negativos, é de extrema importância identificar experimentalmente alvos relevantes. 
Nesta tese procuramos explorar diferentes abordagens da influência de miRNAs em 
cancro da mama. Começamos por estudar os mecanismos que estão por trás da regulação 
dos próprios miRNAs. Colocámos a hipótese de serem mecanismos epigenéticos, tais como 
a metilação de citosinas no DNA, que estão a influenciar os níveis de expressão dos 
miRNAs. Para tal, tratámos linhas celulares de mama com um agente capaz de desmetilar o 
DNA e verificámos que os níveis de miRNAs são alterados. Contudo, não conseguimos 
encontrar uma associação entre a metilação de ilhas CpG nas regiões promotoras dos 
genes que codificam para os miRNAs. No entanto, não podemos excluir a possibilidade de 
os níveis de expressão de miRNAs estarem a ser regulados por metilação das suas zonas 
promotoras, dado que não estudámos todas as regiões promotoras existentes. 
De seguida, abordámos a influência de dois miRNAs, miR-200c e miR-203, na resistência 





tal fizemos expressar ambos os miRNAs na linha celular MDA-MB-231 e inibir os mesmos 
na linha celular MCF-7. Infelizmente não fomos capazes de encontrar significado 
estatístico nos resultados obtidos. Contudo pudemos concluir que o miR-200c parece ter 
um efeito contrário nas linhas MCF-7 e MDA-MB-231 no que diz respeito ao tratamento 
com Paclitaxel e o miR-203 parece aumentar a resistência para o mesmo comporto na 
linha celular MDA-MB-231. O tratamento com 5-fluoruacil não mostrou qualquer 
diferença em ambas as linhas. 
Dado que os estudos in vitro, nesta área, devem ser transpostos para humanos e/ou 
tecidos humanos, seguidamente procurámos estudar os níveis de expressão do miR-200c 
e do miR-203 em tecido tumoral mamário, bem como a expressão de dois alvos hipotéticos 
encontrados utilizando ferramentas bioinformáticas, SIX1 e SOX2. Relativamente ao miR-
200c, não encontrámos quaisquer diferenças entre tecido normal e tecido tumoral de 
mama, nem conseguimos relacionar este miRNA com características clinicopatológicas. 
Comparativamente detectaram-se diferenças para o miR-203 e conseguimos relacionar 
este com os estadios iniciais de desenvolvimento tumoral. Conseguimos também 
demonstrar que o miR-203 pode ser um potencial marcador para discriminar os tumores 
lobulares invasivos. No que diz respeito à expressão do SOX1 e SOX2, observámos que 
ambos possuem uma incidência baixa na nossa população e que não se associam com a 
expressão dos miRNAs em estudo. 
Por último, procurámos validar alguns alvos do miR-200c e do miR-203. Para tal, 
efectuámos um estudo comparativo de proteómica, onde fizemos expressar o miR-200c e 
o miR-203 na linha celular MDA-MB-231 e inibimos os mesmos miRNAs na linha celular 
MCF-10A. Este estudo exploratório, ainda por terminar, revelou aproximadamente 3000 
proteínas diferentemente expressas nas linhas celulares. No entanto, até ao momento 
conseguimos reduzir esta vasta lista para uma menor com aproximadamente 10 proteínas 






Devido ao facto da população recolhida ser recente, o seguimento clínico nos próximos 
anos permitirá tirar algumas conclusões relativas à resistência à terapia utilizada e a sua 
relação com a expressão dos miRNAs em estudo. 
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MicroRNAs (miRNAs) are small non-coding regulatory RNAs that modulate gene 
expression by binding to their target mRNAs. By these means, miRNAs control normal 
rates of all major cellular pathways. A subset of miRNAs, which are differentially detected 
between normal and tumour tissue samples, has been identified in breast cancer, and 
functional analysis in cell line systems has revealed tumour suppressive and oncogenic 
functions of some of these miRNAs. Hence, the clinical value of these as novel biomarkers 
for cancer is being actively investigated. However, the function of only a few of these 
miRNAs in breast cancer has been investigated. One major difficulty is the identification of 
target mRNAs and proteins with biological significance in breast cancer and consequently 
the identifications of the pathways they influence. Given the relatively high rates of both 
false-positives and false-negatives from current miRNAs targets prediction programs, it is 
critically important to experimentally identify relevant miRNAs targets and the pathways 
involved in carcinogenesis. 
In this thesis our main goal was to study the role of miRNAs in breast cancer. Thus, we 
started by addressing the mechanisms behind regulation of miRNAs expression levels. We 
hypothesized if that epigenetic mechanisms, such as DNA methylation, could influence 
miRNAs expression levels. Therefore, we treated breast cell lines with demethylating 
agents and observed that miRNAs expression levels were altered. However, we failed to 
prove a direct correlation between the methylation of CpG islands in promoter regions of 
the miRNAs studied and their expression. Nevertheless, we cannot exclude the possible 
regulation of miRNAs levels by methylation since we did not study all possible promoter 
regions of miRNAs genes as their promoter regions have not been fully identified. 
Next, we addressed the possible effect of miRNAs in breast cancer therapy resistance. For 
that, we treated breast tumour cell lines with Paclitaxel and 5-fluoruacil, two known 





200c and miR-203. Unfortunately, we did not find any statistical difference between 
untreated and treated cells. However, miR-200c seems to have contrary effects in MCF-7 
and MDA-MB-231 cells regarding treatment with Paclitaxel and miR-203 seem to augment 
resistance to Paclitaxel in MDA-MB-231 cells. Both miRNAs did not show any effect in cells 
treated with 5-Fluoruacil. 
Since in vitro studies, always lack studies using human tissues. We subsequently studied 
the expression levels of miR-200c and miR-203 in breast tumour tissues and two putative 
targets found by bioinformatics tools, SIX1 and SOX2. Concerning miR-200c, we did not 
detect significant differences between normal breast and tumour tissues in our 
population. Additionally, we failed to correlate miR-200c with clinicopathological features. 
Regarding miR-203, we detect statistically differences between normal and tumour tissue 
and it seems that miR-203 is involved in breast cancer development, mainly in early stages 
of development. We also show that miR-203 might be a potential marker to discriminate 
stages in invasive lobular carcinoma. About the expression levels of SIX1 and SOX2, we 
observe relatively low levels of both proteins through immunohistochemistry and do not 
found any statistically difference between their expression and their regulators, miR-200c 
and miR-203. 
Finally, we address the validation of putative targets of the miR-200c and miR-203. Thus, 
we conducted a comparative proteomic study to find differently expressed proteins when 
miR-200c and miR-203 were ectopically expressed or inhibited in breast cell lines. This 
exploratory study, until now, revealed a small list out of approximately 3000 proteins that 
are putative targets of both miRNAs and are differently expressed. Further studies will be 
conducted in order to validate these putative targets. 
With this thesis, we believe we provide new insight into the involvement of miRNAs in 
breast cancer and also important knowledge of how miRNAs levels are being regulated 





during this thesis, which allow future correlations on therapy outcomes and survival with 
the biomarkers studied. 
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One of the most important landmarks of recent scientific history was the completion of the 
first draft of the human genome (Lander et al., 2001; Venter et al., 2001). The myriad 
opportunities that derive from the total sequencing of the human genome are priceless 
and the knowledge of human genetic diseases resulting therefrom is limitless. However, 
precaution is needed when interpreting the substantial data from human genome 
sequencing and subsequent studies. Indeed, no better words than those uttered by Venter 
and colleagues (Venter et al., 2001):  
“(…) There are two fallacies to be avoided: determinism, the idea that 
all characteristics of the person are “hard-wired” by the genome; and 
reductionism, the view that with complete knowledge of the human genome 
sequence, it is only a matter of time before our understanding of gene 
functions and interactions will provide a complete causal description of 
human variability. (…)” 
The sequence of the human genome confirmed the idea that only approximately 2% of the 
genome codes for proteins, corresponding to 25.000 to 30.000 genes. The remaining of 
our genome was referred to as “junk DNA”, a term first used by Susumu Ohno (Ohno, 
1972). This term could not be less accurate. Indeed, the past few years revealed an 
immensity of data contradicting that notion and rewriting the central dogma of molecular 
biology postulated by Francis Crick (Crick, 1970). It is now clear that coding DNA isn’t 
more important than non-coding DNA in cell homeostasis and that RNA is not only a 
molecule of information transmission, through messenger RNA (mRNA), but a group of 
molecules capable of other biological functions, namely in structural, catalytic and 
regulatory functions that are transcribed from all the genome [reviewed in (Alexander et 
al., 2010; Eddy, 2001; Esteller, 2011)]. Thus, every day, studies regarding the transcripts 
from non-coding DNA are increasingly becoming relevant, giving rise to a new meaning to 





New high-throughput sequencing technologies have enabled the identification of countless 
non-coding transcripts (ncRNAs), many of which are categorized into distinct RNA classes. 
Although classification of ncRNAs is not consensual, it can be classified in two main 
classes: 1) short or small ncRNAs; 2) and long ncRNAs (lncRNAs). Small ncRNAs are 
characterized as having less than 200 nucleotides in length and almost all seem to have 
regulatory function. This type of ncRNAs will be further discussed. LncRNAs have more 
than 200 nucleotides in length and only recently have emerged as key molecules in 
chromatin structure, transcriptional activity and mRNA stability, processing and 
translation (Esteller, 2011; Ponting et al., 2009; Quinn and Chang, 2015; Silva et al., 2015). 
Thus, aberrant expression of lncRNAs has been linked to several diseases (Kim et al., 2016; 
Pastori and Wahlestedt, 2012; Schonrock et al., 2012; Tye et al., 2015) including cancer 
(Shen et al., 2015; Silva et al., 2015). 
1.1. Small non-coding RNAs 
By far, the most studied small ncRNAs are microRNAs (miRNAs). Studies motivated by the 
discovery of miRNAs revealed other small ncRNAs, such as endogenous small interfering 
RNAs (endo‑siRNAs), piwi‑interacting RNAs (piRNAs), transcription start site associated 
RNAs (TSSa-RNAs), transcription initiation RNAs (tiRNAs), promoter-associated small 
RNAs (PASRs) and promoter upstream transcripts (PROMPTs) [revised in (Esteller, 
2011)]. With the exception of PASRs, whose mechanism of action is not known, all small 
ncRNAs are involved in gene expression regulation. The focus of this thesis will be miRNAs 
and their regulatory action in cancer. 
miRNAs are short (approximately 22 nucleotides) non-coding RNAs that were first 
described in 1993 when two independent groups (Lee et al., 1993; Wightman et al., 1993) 
published, in the same number of  Cell,  experiments on the C. elegans lin-4 gene which 
code for a pair of small RNAs with antisense complementarity to multiple sites on the 3’- 





amount of lin-14 protein without noticeably changing the level of lin-14 mRNA. Soon the 
presence of another regulatory RNA, let-7, was observed in C. elegans (Reinhart et al., 
2000) and in other species (Pasquinelli et al., 2000). This group of regulatory small RNAs 
were later designated as miRNAs (Lee and Ambros, 2001), an evolutionary conserved 
class of small RNAs that was found to control many developmental and cellular processes 
in eukaryotic organisms. Mammalian miRNAs are highly conserved and their genes also 
have multiple isoforms (paralogs), which are probably generated by duplication, one 
example is the human let-7 gene that accounts for 8 different isoforms distributed across 
11 genomic loci (Lee et al., 2016). Most miRNA genes are located in regions distant from 
coding genes, suggesting that they represent single transcriptional units and several 
miRNA genes are clustered and normally transcribed as multicistronic RNA transcripts. 
Some miRNAs are instead intragenic, being located inside other genes and use the regular 
transcriptional machinery. miRNA paralogs that are clustered usually have identical seed 
regions and act redundantly. The biggest online database of miRNAs is the miRbase with 
the latest version of June 2014 (miRbase 21) listing 24521 miRNA loci from 206 species, 
processed to produce 30424 mature miRNA products. Of these, 1881 sequences belonged 
to the human genome (Kozomara and Griffiths-Jones, 2014). 
1.1.1. miRNAs biogenesis and target regulation 
The biogenesis of miRNAs is a complex process that takes place in the nucleus and in the 
cytoplasm (Figure 1.1). The main aspects and the proteins involved in this process have 
been already reviewed by several authors, some in a more broad perspective, some with a 
more specific viewpoint, but all with elucidating schemes (Breving and Esquela-Kerscher, 
2010; Lin and Gregory, 2015; Ohtsuka et al., 2015; Pasquinelli, 2012). In the canonical 
pathway, miRNA genes are transcribed by RNA polymerase II (Pol II) into stem-loop 
structures called primary miRNAs (pri-miRNAs) and processed (capped, spliced and 
polyadenylated) in the nucleus. An individual pri-miRNA can either produce a single 





primary transcript [e.g. miR-17-92 (He et al., 2005)]. Pri-miRNAs are then cleaved by the 
double-stranded RNase III enzyme DROSHA and its cofactor, DiGeorge syndrome critical 
region 8 (DGCR8). DROSHA contains two RNase III domains, each of which cleaves one 
strand of the double-stranded RNA towards the base of stem–loop secondary structures 
contained within pri-miRNAs to liberate a 60 to 70 nucleotide hairpin-shaped precursor 
miRNA (pre-miRNA). In the non-canonical pathway, miRNAs can be processed from 
introns of protein-coding genes and bypass DROSHA/DGCR8 process. In this case the pri-
miRNA is designated by mirtron and is processed by the regular mRNA splicing 
mechanisms (Westholm and Lai, 2011). The pre-miRNAs are then exported to the 
cytoplasm by exportin 5 (XPO5) and processed by DICER1, an RNase III enzyme. DICER1 
binds to the end of the pre-miRNA with its two catalytic RNase III domains cleaving the 
double-stranded RNA stem, close to the terminal loop sequence and producing the mature 
miRNA duplex with 2‑nucleotide 3ʹ overhangs. DICER1 associates with transactivation-
responsive RNA-binding protein (TRBP) which binds to double-stranded RNA. Although, 
TRBP is not essential to process pre-miRNA, it enhances the fidelity of DICER1‑mediated 
cleavage and bridges DICER1 with Argonaute proteins that participate in the assembly of 
the miRNA induced silencing complex (miRISC), the final step of miRNAs biogenesis. 
Target recognition and regulation by miRNAs is by itself a complex process. The small size 
of miRNAs and the pairing between a miRNA and a target site that does not need to be 
perfect, offers a wide selection of genes that can be subject to regulation. Indeed, one 
miRNA can regulate multiple mRNAs. However, the property that makes miRNAs versatile 
also hampers the prediction of putative targets. Although there are some exceptions, in 
animals, miRISC form partial duplexes with their targets and usually in the 3’ UTR. The 
ordinary pairing between miRISC and mRNA is perfect between nucleotides 2 and 8 at the 
5′ end of the miRNA, known as the ‘seed’ region, and the target site (Figure 1.2). Due to the 





and with different conformations of the bulge. These different conformations can alter 
miRNA repression efficiency. 
 
Figure 1.1 - miRNAs biogenesis. miRNAs genes are transcribed into pri-miRNA transcripts (1) 
that undergo processing by Drosha complexes (2). The resulting hairpin precursor, pre-miRNAs, 
are transported to the cytoplasm by XPO5. miRNAs can also be encoded in the introns of genes. 
These miRNAs can circumvent Drosha complexes and produce pre-miRNA precursors directly from 
byproducts of intron splicing, these miRNAs are denominated mirtrons. At the cytoplasm, the Dicer 
complex removes the loop region from pre-miRNAs (3), and one strand of the resulting duplex is 
bound by Argonaute to form miRISC (4), which  targets mRNAs for regulation. Depending on the 
target recognition, gene repression can be by mRNA cleavage or translational repression followed 
by mRNA degradation. Scheme from (Breving and Esquela-Kerscher, 2010). 
 
The mechanism of miRNAs action has been under scrutiny, since it can occur by mRNA 
destabilization, translational repression and contrary to what is assumed, activates gene 
expression. Perfect pairing of the miRNA–mRNA duplex leads to endonucleolytic cleavage 
of the mRNA by Argonaute. This mechanism is more common in plants, but nevertheless 





a common outcome of miRNA regulation in animals (Figure 1.3). The miRISC complex 
usually associates with GW182 proteins. Depending on what proteins GW182 recruits 
next, the process of destabilization is different. Thus, if GW182 recruits CCR4-NOT 
complex, the mRNA becomes susceptible to exonucleolytic degradation of its poly(A) tail. 
If GW182 recruits CCR4-NOT complex and PABPC protein, mRNA repression will be prior 
to translation initiation, if it does not recruit PABPC it will be after translation initiation. 
Finally, miRISC can associates with fragile X mental retardation protein 1 (FMR1), 
stimulating gene expression (Cheever and Ceman, 2009). This is a much rarer 
destabilization mechanism. 
This mode of action makes miRNAs extremely versatile and relevant to many cell 
mechanisms. Thus, their expression deregulation easily becomes involved in many 
diseases. Indeed, miRNAs have already been described as being relevant in viral diseases 
(Jopling et al., 2005; Linnstaedt et al., 2010), bacterial infections (Xiao et al., 2009), 
multiple sclerosis (Keller et al., 2009), type 2 diabetes (Karolina et al., 2011), Parkinson’s 
disease (Martins et al., 2011), Alzheimer’s disease (Nunez-Iglesias et al., 2010) and cancer 
(Balatti et al., 2015; Masood et al., 2015; van Schooneveld et al., 2015), among others. 
Here, I will focus on how miRNAs influences cancer and how cancer influences miRNAs 
expression. 
 
Figure 1.2 – Target recognition by miRNAs. Target base paring is perfect and contiguous from 
nucleotides 2 to 8. This region is called the ‘seed’ region. Although the pairing of nucleotide 1 and 9 
isn’t necessary, an A residue in position 1 of the miRNA, and an A or U in position 9 improve the site 
efficiency. Usually, bulges or mismatches are in the central region of the miRNA–mRNA duplex. 







Figure 1.3 – Most frequent mechanisms of gene expression regulation by miRNAs in animals. 
Depending on the Argonaute (AGO) association with other accessory proteins, the mechanism of 
mRNA regulation can be different. (a) When AGO associates with fragile X mental retardation 
protein 1 (FMR1), it can stimulate gene expression. (b and c) When miRISC is in association with 
GW182 proteins, it represses translation. It can be after translation initiation or through inhibition 
of the translation process (when GW182 recruits CCR4-NOT complex and PABPC). (d) When AGO 
associates with GW182 and this one recruits only CCR4-NOT complex the repression is done by 
deanylation and degradation of mRNA. Scheme adapted from (Pasquinelli, 2012). 
 
1.1.2. miRNAs and cancer 
Due to their characteristics and their broad influence in cell homeostasis, soon after their 
discovery, miRNAs were associated with cancer (Calin et al., 2002; He et al., 2005; Johnson 
et al., 2005; O'Donnell et al., 2005). In the past years it became evident that miRNAs 
expression levels differ between normal and tumour cells, have tissue-specific expression 
signatures and promote or suppress tumour development and progression, thereby 
influencing all the hallmarks of cancer (Figure 1.4) postulated by Hanahan and Weinberg  






Figure 1.4 – miRNAs involvement in hallmarks of cancer. Several miRNAs can be involved in 
more than one hallmark. Scheme from (Ross and Davis, 2011). 
Recently, miRNAs have also been found in body fluids [e.g. urine and plasma (Armstrong 
et al., 2015), saliva (Xie et al., 2015), sperm (Metzler-Guillemain et al., 2015) and milk 
(Melnik et al., 2014)] and seem to exert a role as intercellular messengers by exosome-
mediated transfer between different cells in a ‘hormone-like’ manner (Nishida-Aoki and 
Ochiya, 2015). Also recently, the idea that miRNAs can have an exogenous origin 
(xenomiRs), like in milk or plants, and then exert their role in several cell types have come 
to discussion (Fabris and Calin, 2016). As a matter a fact, miR-200c present in cow milk 
has been shown to be absorbed in the human intestine and its presence then detected in 
peripheral blood mononuclear cells (PBMCs) (Baier et al., 2014). The implications of these 
studies are still not clear, yet they give a new perspective to exposure studies and how diet 
could influence cancer. 
Cancer development involves multiple-step alterations in oncogenes and tumour 





respect to how important the role of miRNAs is among many pathways involved in the 
pathogenesis of cancer. MiRNAs can function as oncogenes or tumour suppressors in the 
majority of cancers. Tumour suppressor miRNAs act by repressing oncogenes. These are 
usually down-regulated in cancer and the majority of the miRNAs are considered tumour 
suppressors. However, only few miRNAs have been already described as truly tumour 
suppressors, with functional data published. Curiously, some miRNAs can act as both 
suppressors and oncogenes, depending on the microenvironment. Oncogenic miRNAs, also 
known as oncomiRs, are much less frequent and tend to up-regulate oncogenes or supress 
tumour suppressor genes. 
As stated before, the last revision of miRBase lists 1881 miRNAs in humans (Kozomara 
and Griffiths-Jones, 2014), many of these being connected to several types of cancer. One 
of the most known tumour suppressor miRNAs, because it was the first to be associated 
with cancer, is the miR-15/16 cluster. This cluster was first described by Calin and 
colleagues (Calin et al., 2002) in chronic lymphocytic leukaemia (CLL) and later confirmed 
that it has a pro-apoptotic action by binding to BCL2 (Cimmino et al., 2005). Other authors 
also confirmed a tumour suppressor effect of these miRNAs in other cancers like multiple 
myeloma (Roccaro et al., 2009) and prostate cancer (Bonci et al., 2016). Another known 
tumour suppressor miRNA is the let-7 family. It was first reported as influencing the 
oncogene RAS (Johnson et al., 2005), which is overexpressed in many tumour types. 
Although not directly, recently, it was showed that let-7a regulates PKM2 in gastric cancer 
(Tang et al., 2016) and exerts influence on cell proliferation, migration, and invasion of 
tumour cells. This protein is a key enzyme in aerobic glycolysis, being also associated with 
tumour size and stage. Even though the authors do not show a molecular interaction 
between let-7a and PKM2, they showed an inverse correlation of their expression. Due to 
the fact that PKM2 can be regulated by c-MYC and this in turn can be regulated by let-7a 
(He et al., 2010; Liu et al., 2012), the regulation must occur through c-MYC down-





signal transducer and activator of transcription 3 (STAT3) gene and ubiquitin-like with 
PHD and ring finger domains 2 (UHRF2) gene are also targets of let-7 (Wang et al., 2012b), 
thus influencing cell cycle and cell proliferation.  One further recognised group of tumour 
suppressor miRNAs is the miR-34 family (miR34a, miR-34b and miR-34c). BCL2 and c-
MYC are described as miR-34a targets (Bommer et al., 2007; Christoffersen et al., 2010). 
Consequently, miR-34 family influences apoptosis and cell cycle regulation. Indeed, up-
regulation of miR-34a was associated with oncogene-induced cellular senescence 
(Christoffersen et al., 2010). The most know feature of this family is that their promoter 
region is located in a CpG island, thus being methylated in many cancers (Vogt et al., 
2011). Perhaps the most studied tumour suppressor miRNAs are from the miR-200 family 
(miR-200a, miR-200b, miR-200c, miR-141, and miR-429) due to their critical role in the 
suppression of the epithelial-to-mesenchymal transition (EMT) and tumour cell adhesion, 
migration, invasion, and metastasis by targeting zinc finger E-box-binding homeobox 1 
(ZEB1) and zinc finger E-box-binding homeobox 2 (ZEB2). Also, loss of miR-200 family 
members correlates with a lack of E-cadherin expression (Korpal et al., 2008). The 
mesenchymal-to-epithelial transition (MET) is considered to be critical for the late stages 
of metastasis, enabling the tumour cells to colonize and grow at distant sites. Of thirteen 
miRNAs with higher expression in metastases compared to primary tumours, four were 
members of the miR-200 family: hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-
miR-141 (Gravgaard et al., 2012) once again suggesting their involvement in metastasis 
and contradicting the idea that the miR-200 family is tumour suppressive. Surprisingly, 
another study revealed the dual effect of miR-200 family. In this study the authors showed 
that tumour cells use the tumour suppressor ability of miR-200 family and overexpress it 
in metastasis. This will enable MET, thus enabling anchorage in distant organs (Banyard et 
al., 2013). A new published study suggested the same mechanism (Perdigao-Henriques et 
al., 2016). So, the miR-200 family is down-regulated in the primary tumour to enable cells 





facilitate anchorage by MET.  DNA methylation was also shown to play an important role 
in regulating the expression of the miR-200c/141 cluster (Vrba et al., 2010).  The miR-200 
family was associated with almost all cancer types and other targets were described, 
however the main action of this miRNA family is its influence in EMT/MET (Gao et al., 
2016; Shi and Zhang, 2016). miR-203 is also designated as a tumour suppressor and is 
known to be regulated by epigenetic mechanisms in oral cancer (Kozaki et al., 2008), 
hepatocellular carcinoma (Furuta et al., 2010), breast cancer (Zhang et al., 2011), 
haematological malignancies (Chim et al., 2011) and rhabdomyosarcoma (Diao et al., 
2014). miR-203 also influences metastasis by direct targeting of SNAI2 (Shi et al., 2015; 
Zhao et al., 2015). As for almost all miRNAs, contradictory data has been published 
regarding miR-203. Very recently, two articles were published showing that miR-203 
induces proliferation, migration and invasion in pancreatic ductal adenocarcinoma (Ren et 
al., 2016) and inhibits proliferation and self-renewal of leukaemia stem cells (Zhang et al., 
2016). Although these results seem to be contradictory, they are from different types of 
cancer and the targets are completely different. In the first study, the authors show that 
SIK1 is an inhibitor of proliferation, migration and invasion in pancreatic ductal 
adenocarcinoma and is a direct target of miR-203. Thus, high levels of miR-203 down-
regulates SIK1 and consequently increases proliferation, migration and invasion. On the 
contrary, the second study shows that miR-203 is in an axis with BIRC5 and BMI1 in 
leukaemia stem cells and that its low levels induce a more oncogenic phenotype. This 
shows how versatile miRNAs can be, depending on the microenvironment and tissue.   
1.1.2.1. Regulation of miRNAs expression levels in cancer 
It is known that miRNAs are deregulated in cancer. Nevertheless, how this deregulation 
occurs is still not fully understood. Most probably, the deregulation occurs during miRNAs 
biogenesis (Figure 1.5) and tumour cells acquire mechanisms of ‘defence’ in order to 
down-regulate miRNAs with tumour suppresser capability and up-regulate miRNAs with 





2015). The control of miRNAs expression can begin in the DNA by inhibiting the miRNAs 
genes from being transcribed. Tumour cells can acquire genetic alterations, such as 
mutations or deletions, in the miRNAs genes or Pol II, undergo epigenetic regulation, such 
as methylation of promoter sequences and histone modifications, and be repressed by 
oncogenes through targeting of transcription factors. Next in line, DROSHA/DGCR8 can be 
target of transcriptional regulation themselves by oncogenic proteins or each gene can be 
mutated in a tumour cell. This can deregulate both proteins levels, thus deregulating the 
initial processing into pre-miRNAs. Indeed, a feedback loop can occur in DROSHA/DGCR8 
complex, where high levels of DROSHA and DGCR8 in the cell leads to a cleavage of DGCR8 
mRNA, which results in the reduction of DGCR8 and in turn reduction of DROSHA (Han et 
al., 2009). XPO5 and DICER1 can also be subject to genetic alterations and transcriptional 
regulation. Loss of TRBP, an accessory protein of DICER1, destabilizes DICER1/TRBP 
complex following impairment of miRNA processing and enhancement of cellular 
transformation. Finally, mutations in target recognition sites can inhibit the miRISC action. 
Furthermore single nucleotide polymorphisms (SNPs) in target sites have been studied as 
well as in miRNAs sequences. As an example, rs72552316 SNP in the miRNA binding sites 
of toll-like receptor 7 (TLR7) has been associated with bladder cancer (Cheng et al., 2014) 
and T8473C SNP of cyclooxygenase-2 (COX-2) interferes with miR-542-3p action (Moore 
et al., 2012). A recent meta-analysis was published showing an association of rs3746444 
SNP in miR-499 with cancer (Xu et al., 2015), and that rs11614913 SNP of mir-196a-2, 
rs4919510 SNP of mir-608, rs6505162 of mir-423, rs11671784 SNP of mir-27a, 
rs2292832 of mir-149 and rs12355840 SNP of mir-202 are associated with many cancer 
types in several populations (Pipan et al., 2015). However, these studies need further 







Figure 1.5 – Causes of deregulation of miRNAs expression levels in human cancer. miRNAs 
expression deregulation most probably happen during their biogenesis. It can happen at: a) DNA 
level, with genetic alterations, epigenetic modifications and negative or positive regulation by 
oncogenes and tumour suppressors, respectively; b) pri-miRNA processing, by genetic mutations 
and transcriptional regulation control of DROSHA and DGCR8 expression and by RNA-binding 
proteins and other cell signalling pathways; c) Genetic mutations and transcriptional regulation of 
XPO5; d) pre-miRNA processing, by genetic mutations and transcriptional regulation control of 
DICER1 expression and function to cleave pre-miRNA and phosphorylation of Argonaute inhibiting 
miRISC assembly; and e) mutations of miRNA-binding sites in target genes. Scheme adapted from 






1.1.2.2. miRNAs and drug resistance 
Perhaps one of the most studied topics in cancer is resistance to drugs. Soon after their 
discovery, miRNAs were associated with drug resistance. However, contradictory data 
have been published and what seemed to be a gold mine to  personalized therapy revealed 
poor results and a lack of applicability. MiRNAs has been linked with all drug resistance 
pathways (drug metabolism, drug transporters, DNA repair, EMT and cancer stem cells). 
In Table 1.1 several miRNAs involved in drug resistance mechanisms are described, as 
well as the type of tumour associated and the drug. 
1.1.2.2.1. Drug metabolism 
Drug metabolism is a complex pathway of xenobiotic biotransformation that involves 
several proteins, and is a part of the general steps of drug fate in the organism: Absorption, 
Distribution, Metabolism and Excretion (ADME). Biotransformation involves two main 
phases before excretion: Phase I and Phase II. Xenobiotics are foreign compounds (such as 
drugs) that are not normally produced or expected to be present in an organism. 
Concerted actions of drug-metabolizing enzymes (DME) lead primarily to an increase in 
the polarity of xenobiotics, in Phase I reactions, followed by conjugation reactions (Phase 
II reactions) that increase their polarity but block the reactivity of polar groups introduced 
in Phase I reactions. Thereafter the transmembrane transport of the resulting metabolite 
is performed by membrane transporter proteins, essentially ATP-binding cassette (ABC) 
transporters (Phase III reactions). Besides an increase in transport mediated by ABC 
transporters, cancer cells tend to overexpress DMEs and evade cancer treatment thus 
becoming resistant to many drugs.  
Although extensive studies have been performed on transcriptional regulation of the 
DMEs, there is a lack of understanding of their post-transcriptional regulation (Urquhart 
et al., 2007). One of the key players of the Phase I are cytochrome P450 (CYP) enzymes 








Table 1.1 - Pathways of drug resistance regulated by miRs. (NS - not specified). Table published in (Gomes et al., 2016) 
Target gene microRNA Type of cancer/established cell line Drug Reference 
Drug 
Metabolism     
CYP1B1 miR-27b 
Human uterine cervix adenocarcinoma cell line HeLa; 
Human breast adenocarcinoma cell line MCF-7; 
Human embryonic kidney cell line HEK293; 
Human leukemic T-cell line Jurkat; 
Breast cancerous and adjacent noncancerous tissue 
NS (Tsuchiya et al., 2006) 
CYP2E1 miR-378 Human embryonic kidney cell line HEK293 NS (Mohri et al., 2010) 
CYP3A4 miR-27b 
Human pancreas cancer PANC1; 
Human colon carcinoma LS-180; 
Human embryonic kidney cell line HEK293 
cyclophosphamide (Pan et al., 2009a) 
SULT1A1 miR-631 
Human breast cancer cell lines ZR75-1 and MCF7; 
Human mammary epithelial cell line MCF10A; 
actinomycin D (Yu et al., 2010) 
GSTP1 miR-133a 
Human head and neck Squamous Cell Carcinoma (SCC); 
Human oesophageal SCC and bladder cell lines 
cisplatin and 
carboplatin 
(Moriya et al., 2012) 
Drug transport 
    
ABCB1 miR-451 Human breast adenocarcinoma cell line MCF-7 doxorubicin 
(Kovalchuk et al., 2008); 
(Zhu et al., 2008) 
ABCB1 miR-200c 
Breast cancerous tissue; 
Human breast adenocarcinoma cell line MCF-7 
doxorubicin (Chen et al., 2012) 
ABCB1 miR-298 Human breast adenocarcinoma cell lines MCF-7 and MDA-MB-231 doxorubicin (Bao et al., 2012) 









Table 1.1 (continued) - Pathways of drug resistance regulated by miRs. (NS - not specified). Table published in (Gomes et al., 2016) 
ABCB1 miR-145 
Human colon carcinoma cell line Caco-2; 
Human embryonic kidney cell line HEK293 
NS (Ikemura et al., 2013) 
ABCB1 miR-381 Human chronic myelogenous leukemia cell line K562 adriamycin (Xu et al., 2013) 
ABCB1 miR-495 Human chronic myelogenous leukemia cell line K562 adriamycin (Xu et al., 2013) 
ABCG2 miR-181a Human breast adenocarcinoma cell line MCF-7 mitoxantrone (Jiao et al., 2013) 
ABCG2 miR-328 Human breast adenocarcinoma cell line MCF-7 mitoxantrone (Pan et al., 2009b) 
ABCG2 miR-487a Human breast adenocarcinoma cell line MCF-7 mitoxantrone (Ma et al., 2013) 
ABCG2 miR-519c 
Human embryonic kidney HEK293;  
Human breast adenocarcinoma cell line MCF-7 
mitoxantrone (Li et al., 2011b) 
ABCG2 miR-328 
Human embryonic kidney HEK293; 
Human breast adenocarcinoma cell line MCF-7 
mitoxantrone (Li et al., 2011b) 
ABCC1 miR-326 
Normal and tumour breast tissues; 
Human breast adenocarcinoma cell line MCF-7 
VP-16 and 
doxorubicin 
(Liang et al., 2010) 
ABCC1 miR-345 Human breast adenocarcinoma cell line MCF-7 cisplatin (Pogribny et al., 2010) 
ABCC1 miR-7 Human breast adenocarcinoma cell line MCF-7 cisplatin (Pogribny et al., 2010) 
ABCC1 miR-1291 
Human pancreatic carcinoma cell line PANC-1; 
Human small lung cancer cell line H69; 
Human embryonic kidney cell line HEK293 
doxorubicin (Pan et al., 2013) 
ABCC2 miR-297 
Human ileocaecal colorectal adenocarcinoma cell line HCT-8 and HCT-
116; Colorectal cancerous and adjacent noncancerous tissue 
oxaliplatin and 
vincristine 
(Xu et al., 2012b) 









Hepatoma cell line mhAT3F; 
Pancreatic beta cell line MIN6; 
Human embryonic kidney cell line HEK293 
NS (Pullen et al., 2011) 
SLC16A1 miR-29b 
Hepatoma cell line mhAT3F; 
Pancreatic beta cell line MIN6; 
Human embryonic kidney cell line HEK293 
NS (Pullen et al., 2011) 
SLC16A1 miR-124 
Hepatoma cell line mhAT3F; 
Pancreatic beta cell line MIN6; 
Human embryonic kidney cell line HEK293 
NS (Pullen et al., 2011) 
DNA Repair 
    
RAS let-7 family Human non-small cell lung cancer cells cell line A549 
 
(Weidhaas et al., 2007) 
ERCC1 miR-138 Human non-small cell lung cancer cells cell line A549 cisplatin (Wang et al., 2011) 
MSH2 miR-21 
Human Dukes' type C, colorectal adenocarcinoma cell lines Colo-320 DM 
and SW620; 
Human colorectal adenocarcinoma cell line HCT-116; 
Human Dukes' type B, colorectal adenocarcinoma cell line SW480; 
Human colon carcinoma cell line RKO 
5-fluorouracil (Valeri et al., 2010a) 
MSH6 miR-21 
Human Dukes' type C, colorectal adenocarcinoma cell lines Colo-320 DM 
and SW620; 
Human colorectal adenocarcinoma cell line HCT-116; 
Human Dukes' type B, colorectal adenocarcinoma cell line SW480; 
Human colon carcinoma cell line RKO 
5-fluorouracil (Valeri et al., 2010a) 
REV1 miR-96 
Human Bone Osteosarcoma Epithelial Cell line U2OS; 
Human uterine cervix adenocarcinoma cell line HeLa; 
Human breast cancer cell line HCC1937; 
Human breast adenocarcinoma cell line MDA-MB-231 
cisplatin; PARP 
inhibitor AZD2281 










Table 1.1 (continued) - Pathways of drug resistance regulated by miRs. (NS - not specified). Table published in (Gomes et al., 2016) 
RAD51 miR-96 
Human Bone Osteosarcoma Epithelial Cell line U2OS; 
Human uterine cervix adenocarcinoma cell line HeLa; 
Human breast cancer cell line HCC1937; 
Human breast adenocarcinoma cell line MDA-MB-231 
cisplatin; PARP 
inhibitor AZD2281 
(Wang et al., 2012c) 
RAD51 miR-155 
Human breast adenocarcinoma cell line MCF-7; 
triple-negative breast cancer tissue 
NS (Gasparini et al., 2014) 
BRCA1 miR-182 
Human acute promyelocytic leukemia cell line HL60; 
Human chronic myelogenous leukemia cell line K562; 
Human breast adenocarcinoma cell line MCF-7 
PARP inhibitor (Moskwa et al., 2011a) 
BRCA1 miR-146a Breast cancer tissue NS Garcia et al. 2011 [102] 
BRCA1 miR-193a-5p 
Human Mammary Epithelial progenitor Cell line HMEpC; 
Human Small Airway Epithelial progenitor Cell line HSAEpC; 
Human breast cancer cell lines MDA-MB-231, MDA-MB-157 and SK-BR-3 
cisplatin 
(van Jaarsveld et al., 
2014) 
BRCA1 miR-296-5p 
Human Mammary Epithelial progenitor Cell line HMEpC; 
Human Small Airway Epithelial progenitor Cell line HSAEpC; 




(van Jaarsveld et al., 
2014) 
BRCA1 miR-183 
Human Mammary Epithelial progenitor Cell line HMEpC; 
Human Small Airway Epithelial progenitor Cell line HSAEpC; 
Human breast cancer cell lines MDA-MB-231, MDA-MB-157 and SK-BR-3 
 
(van Jaarsveld et al., 
2014) 
BRCA1 miR-16 HSAEpCs 
cisplatin and 
doxorubicin 
(van Jaarsveld et al., 
2014) 
EMT 
    
 
miR-200c Human breast adenocarcinoma cell line MCF-7 doxorubicin (Chen et al., 2013b) 
 
miR-200b Human breast adenocarcinoma cell line MCF-7 and resistant derivate 
4-hydroxytamoxifen; 
fulvestrant 









miR-200c Human breast adenocarcinoma cell line MCF-7 and resistant derivate 
4-hydroxytamoxifen; 
fulvestrant 
(Manavalan et al., 2013) 
 
miR-200c Human breast cancer cell line SKBr-3 trastuzumab (Bai et al., 2014) 
MIG6 miR-200c Several human cancer cell lines 
 






Human lung adenocarcinoma cell lines A549, LC2/ad, 
PC3, PC9, RERF-LCKJ, RERF-LCMS, PC14, and ABC-1 
gefitinib (Kitamura et al., 2014) 
 
miR-147 
Human colon cancer cell line HCT116 and SW480; 
Human lung cancer cell line A549 
gefitinib (Lee et al., 2014) 
SMAD3 miR-489 Human breast adenocarcinoma cell line MCF-7 doxorubicin (Jiang et al., 2014) 
FBW7 miR-223 The human pancreatic  cancer cells AsPC-1 and PANC-1 gemcitabine (Ma et al., 2015) 
Stem cells 
    
NANOG/OCT4 let-7a Human head and neck cancer tissues cisplatin (Yu et al., 2011) 
OCT4 and SOX2 miR-145 Glioblastoma temozolomide (Yang et al., 2012) 
TP53INP1 miR-130b Human liver tumour and adjacent non-tumour tissue doxorubicin (Ma et al., 2010b) 
TP53/NANOG miR-214 Human ovarian cancer A2780, OV2008, OV8 and SKOV3 
cisplatin and 
doxorubicin 
(Xu et al., 2012a) 
ABCB1 miR-451 
Human colon carcinoma cell lines DLD1, HT29, LS513, SW620, LoVo, and 
RKO; 
Colorectal cancer tissue 
irinotecan (Bitarte et al., 2011) 
 
miR-302 Human head and neck squamous cell carcinoma (HNSCC) cell line HSC-3 Cisplatin 






(Rodriguez-Antona and Ingelman-Sundberg, 2006). More than 90% of the reactions 
involved in the metabolism of all chemicals, whether environmental chemicals, natural 
ones, physiological compounds, and drugs, are catalysed by P450s (Rendic and 
Guengerich, 2014). Three-fourths of the human CYP reactions can be accounted for by a 
set of five CYPs: 1A2, 2C9, 2C19, 2D6, and 3A4, whit the largest fraction of the CYP 
reactions being catalysed by CYP 3A enzymes (Rendic and Guengerich, 2014). Therefore, 
the regulation of DMEs is crucial to drug efficacy and may be related to drug failure or 
drug resistance.  
Recent studies have shown that miRNAs also control the expression of some DME 
(Ikemura et al., 2014; Koturbash et al., 2012; Tsuchiya et al., 2006). However few studies 
have shown a direct involvement of miRNAs and DME with drug resistance. Indeed, there 
are only some studies regarding the effect of miRNAs, such as on CYP1B1 (Tsuchiya et al., 
2006), that is highly expressed in oestrogen target tissues, and catalyses the metabolic 
activation of various pro-carcinogens and the 4-hydroxylation of 17β-estradiol, and is also 
abundant in cancerous tissues (Crewe et al., 2002); on CYP2E1 (Mohri et al., 2010) that 
catalyses numerous low-molecular-weight xenobiotics and several pro-carcinogens, such 
as N-nitrosodimethylamine and N-nitrosomethylethylamine; on CYP3A4 (Pan et al., 
2009a) that is highly important in metabolic reactions of  several drugs; in the 
sulfotransferase isoform 1A1 (SULT1A1), a member of the sulfotransferase (SULT) family 
of phase II detoxification enzymes that catalyse a variety of xenobiotic and endogenous 
compounds, such as 4-hydroxytamoxifen (Duffel et al., 2001; Mercer et al., 2010; Yu et al., 
2010); and on GSTP1 (Moriya et al., 2012), a member of the GST enzyme superfamily that 
catalyses the conjugation of electrophiles to glutathione in phase II detoxification 
reactions, including platinum drugs such as cisplatin and carboplatin (McLellan and Wolf, 
1999). All these targets and respective miRNAs are summarized in Table 1.1 In spite of 
these results, miRNA-dependent regulation of expression in DMEs does not seem to be the 





of DME genes. Furthermore, the miRNA binding sites described for most of the DMEs are 
poorly conserved, leading one to speculate that other forms of regulation are more 
important.   
1.1.2.2.2. Drug transport  
Drug transport through cell membranes is a critical step in allowing access of 
pharmacologic agents to intracellular targets and also extrusion of xenobiotics. The 
involvement of drug transport is probably the most studied mechanism in cancer drug 
resistance (Gottesman et al., 2002). Multidrug resistance (MDR) is frequently linked to 
over-expression of one or more of drug transport proteins present in the cytoplasmic 
membrane. The ABC transporters have an important cellular role in the efflux and influx of 
several substrates necessary to the cell and also in the efflux of toxic endogenous 
molecules and xenobiotics (Gromicho et al., 2013; Rodrigues et al., 2012). Up to now, 49 
different ABC transporters were identified and classified in 7 families from ABCA through 
ABCG (Dean et al., 2001; Kathawala et al., 2014). The relevance of miRNAs in regulating 
the expression of ABC transporters has been recently reviewed (Haenisch et al., 2014; 
Ikemura et al., 2014).   
One of the most well-known ABC transporters is ABCB1, also known as MDR1 or P-gp 
transporter. In chemotherapeutic-resistant cancer cell lines, ABCB1 is often observed to be 
up-regulated. Until now, some reports have been published regarding association of 
miRNAs, ABCB1 and resistance to doxorubicin. These miRNAs can be seen in Table 1.1 
Most drug transport-associated miRNAs are down-regulated, which in turn increases the 
levels of ABCB1 and consequently enhances resistance to doxorubicin. As an example, 
diminished expression of miR-451 correlated with higher expression of ABCB1 in drug 
resistant cells (Kovalchuk et al., 2008; van Jaarsveld et al., 2010). On the contrary, in a 
human ovarian cancer cell line, and its multidrug resistant counterpart, as well as in a 





27a and miR-451 were up-regulated in multidrug resistant cells as compared with their 
parental lines, in effect down-regulating expression of the ABCB1 gene (Zhu et al., 2008). 
These results show that at the moment caution should be taken in evaluating the 
involvement of specific miRNAs in drug resistance, since results could depend on various 
factors, including the cell lines under study.  
One more ABC transporter is ABCG2 (also known as BCRP) that, in normal tissues, 
functions as a defence mechanism against xenobiotics. ABCG2 recognizes and transports a 
variety of chemotherapeutic drugs out of cancer cells, thereby resulting in reduced drug 
concentration, and subsequent drug resistance. Consequently ABCG2 plays a critical role 
in the development of MDR in breast cancer (Natarajan et al., 2012). Increased ABCG2 
expression has been found in breast cancer cells that exhibit resistance to mitoxantrone 
(MX), topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) (Shiozawa et al., 2004). Up-
regulation of ABCG2 also confers resistance to tamoxifen in breast cancer cells (Selever et 
al., 2011). In addition, ABCG2 expression correlates with chemotherapeutic response to 
anthracycline in patients with breast cancer (Burger et al., 2003). Differential expression 
patterns of miRNAs that target ABCG2 have been published (Table 1.1). Interestingly, most 
studies regarding ABCG2 and miRNAs only associates with MX. 
Another well-known ABC transporter is ABCC1, also known as MRP1. The main subtracts 
of ABCC1 are vincristine and etoposide and ABCC1 also confers resistance to 
anthracyclines (doxorubicin, daunorubicin, epirubicin), MX, flutamide, and methotrexate. 
Curiously, many drugs are only transported in the presence of glutathione (Cole, 2014). 
Regarding ABCC1, only three reports were published to date showing a regulation by 
miRNAs (Table 1.1) (Liang et al., 2010; Pan et al., 2013; Pogribny et al., 2010).  
ABCC2, also known as MRP2, and ABCC1 share a 49% amino acid identity. As ABCC1, this 
efflux pump need the presence of glutathione and can transport MX, cisplatin, irinotecan, 





colon, breast, lung, ovary, and as well as in cells from patients with acute myelogenous 
leukaemia (Chen and Tiwari, 2011). Regarding ABCC2, to our knowledge, only one article 
has been published associating miRNAs and ABCC2, showing that miR-297 targets the 
3’UTR region of ABCC2 transcripts and consequently down-regulates its expression (Xu et 
al., 2012b).  
Intestinal epithelial cells are responsible for the absorption of most cancer drugs, and they 
express a variety of influx transporters specific for drugs, amino acids, peptides, organic 
anions, organic cations, and other nutrients. Peptide transporter 1 (PEPT1/SLC15A1), 
organic cation/carnitine transporter 2 (SLC22A5), organic anion transporting polypeptide 
2B1 (SLCO2B1), and monocarboxylate transporter 1(MCT1/SLC16A1) are expressed at 
the brush-border membrane, whereas organic cation transporter 1 (SLC22A1) is mainly 
expressed at the basolateral membrane in the small intestine (Ikemura et al., 2014). 
Recent studies have indicated that the regional differences in the expression of these 
transporters are dependent on the differentiation of intestinal epithelial cells (McKenna et 
al., 2010). Hence, misexpression of miRNAs could have a marked impact on absorption of 
cancer drugs. There are a limited number of reports on the SLC transporters regulated by 
miRNAs (Table 1.1). One example is mR-92b that was showed to regulate SLC15A1, 
causing decreased influx activity (Dalmasso et al., 2011). MiR-29a, miR-29b, and miR-124 
can target SLC16A1 also, resulting in decreased expression at the protein level. The 
authors refer that this regulation mechanism is not the main regulator but complement 
other transcriptional mechanisms and mutations that alter SLC16A1 expression (Pullen et 
al., 2011). 
1.1.2.2.3. DNA repair 
DNA damage by endogenous or exogenous agents elicits a powerful cellular response 
called the DNA Damage Response (DDR), which evokes concerted molecular pathways to 





lesions or irreparable damage, apoptosis or cellular senescence (d'Adda di Fagagna, 2008; 
Harper and Elledge, 2007; Jackson and Bartek, 2009; Pearl et al., 2015). In the past years 
evidence has accumulated that drug resistance is also linked to alterations in these 
pathways (Helleday et al., 2008; Kelley, 2011; Kelley, 2012; Kelley and Fishel, 2008). The 
DDR pathways include DNA tolerance mechanisms by error-prone polymerases, the direct 
reversal of lesions, essentially de-alkylation of alkylated bases by O6-methyl-guanine-DNA 
methyltransferase (MGMT), alkylation repair homolog 2 (ALKBH2) and alkylation repair 
homolog 3 (ALKBH3); nucleotide excision repair (NER); base excision repair (BER); 
mismatch repair (MMR); and the double strand break (DSBs) repair by homologous 
recombination (HR) and non-homologous end joining (NHEJ) (Hoeijmakers, 2001; 
Hoeijmakers, 2009). Besides these signalling cascades, the DDR also elicits the induction of 
several ncRNAs, including miRNAs. A large number of miRNAs are transcriptionally 
induced upon DNA damage and the level of induction is variable depending on cell type 
and the nature and the intensity of DNA damage and time after DNA damage (Chowdhury 
et al., 2013; d'Adda di Fagagna, 2014; Pothof et al., 2009; Sharma and Misteli, 2013; 
Templin et al., 2011; van Jaarsveld et al., 2014). Conversely, many miRNAs target DDR 
genes, thus controlling feed-back and feed-forward loops to fine-tune the response (for a 
review see (Bottai et al., 2014; Sharma and Misteli, 2013; Wouters et al., 2011)). Seventy-
four (52% of the total) mammalian DNA repair and DNA damage checkpoint genes contain 
conserved miRNA target sites  predicted in their 3’-UTR by the algorithms Targetscan, 
Miranda or both (Wouters et al., 2011).  
The knockdown of the miRNA biogenesis pathway proteins DICER and AGO2 results in 
increased sensitivity to ultraviolet light (UV) and altered cell cycle after UV damage 
(Pothof et al., 2009). This was one of the first indications that miRNAs are implicated in 
the regulation of the DDR. Following this study many reports have shown that different 





2011). Thus, it is conceivable that alterations in miRNAs are involved in tumour response 
to anti-cancer agents. 
A few examples indicate indeed that aberrant expression of miRNAs is associated with 
DNA-damage by radiation or chemicals (Blower et al., 2008; Weidhaas et al., 2007). 
Members of the let-7 family of miRNAs are rapidly down regulated upon ionizing radiation 
in A549 lung cancer cells. Conversely, over-expression of the let-7 family leads to 
radiosensitization in vitro of lung cancer cells and in vivo in a C. elegans model of radiation-
induced cell death. In C. elegans, this was shown to occur partly through control of the 
proto-oncogene homologue let-60/RAS and genes in the DNA damage response pathway 
(Weidhaas et al., 2007). In another example, miR-138 was shown to target the ERCC1 
gene, involved in NER, increasing the sensitivity of A549/DDP cells to cisplatin in vitro and 
increase apoptosis (Wang et al., 2011). Similarly, MMR proteins MSH2 and MSH6 are 
inhibited by miR-21 over-expression causing a reduction in 5-fluorouracil (5-FU) induced 
G2/M damage arrest and apoptosis, in vitro (Valeri et al., 2010b). REV1, an error-prone Y-
family DNA polymerase required for translesion synthesis across interstrand crosslinks, 
was validated as target of miR-96. Equally, overexpression of miR-96 promoted cellular 
hypersensitivity to cisplatin in vitro and in vivo and enhanced sensitivity to the PARP 
inhibitor AZD2281. This miRNA also targets RAD51, a recombinase that promotes HR 
repair of DSBs and interstrand DNA crosslinks (ICLs) (Wang et al., 2012c). Over-
expression of miR-155 was related with low levels of RAD51 and with better overall 
survival of patients with triple-negative breast cancers (TNBC) (Gasparini et al., 2014). 
This raises the possibility of personalized therapy in TNBC patients, knowing the miR-155 
levels.  
BRCA1 is an important component of the DDR pathway implicated in HR but also involved 
in other DNA repairs pathways. BRCA1 encodes a nuclear phosphoprotein and primarily 





cycle checkpoint control, transcriptional regulation, apoptosis and mRNA splicing (Savage 
and Harkin, 2015). Mutations in BRCA1 are associated with an increased risk of 
developing breast and ovarian cancer. BRCA1 is also a target of miR-182 (Moskwa et al., 
2011b). Indeed, the authors showed that high expression of this miRNA in various breast 
tumour lines impacts BRCA1 levels and sensitivity to PARP1 inhibition. MiR-146a and 
miR-146-5p also bind to the same site in the 3’-UTR of BRCA1 and down-regulate its 
expression. In breast tumours, levels of these miRNAs are inversely correlated with BRCA1 
protein. Likewise, these miRNAs are over-expressed in TNBC, the most common type of 
breast cancer in women with BRCA1 mutations (Garcia et al., 2011).  
1.1.2.2.4. Epithelial to mesenchymal transition (EMT) 
Metastasis is a dreadful event as it may lead ultimately to death in most cancers. The 
growth of cancer cells at distant organs from a different tissue requires complex processes 
of detaching from the original tissue; invasion through the basement membrane; 
movement in the bloodstream or lymphatic system; and anchorage in other organs. The 
initial process is called EMT and is characterized by a phenotypic change of the tumour 
cells from cell–cell adhesion and polarity to motility, invasiveness and some of the features 
of stem cells. This process not only enables the spread of the tumour cells but also their 
anchorage in distant organs, since tumour cells that undergo EMT can reverse this 
characteristic and acquires the epithelial phenotype again, in a process called 
mesenchymal-to-epithelial transition (MET). In EMT, cells lose the expression of E-
cadherin and gain the expression of vimentin, N-cadherin, and fibronectin, markers of 
mesenchymal phenotype. Presumably, EMT is sustained by transient molecular changes 
and not by permanent genetic alterations. Indeed, the reversible nature of EMT must be 
associated with reversible epigenetic mechanisms, which allows stable but reversible 
modifications that do not directly affect the DNA primary sequence (Li and Li, 2015; 





MiRNAs, as post-transcriptionally regulators, are good candidates as EMT regulators and, 
as epigenetic mechanisms, do not affect the primary DNA sequence and can press tumour 
cells to acquire an EMT phenotype in the tumour microenvironment. The most studied 
case is the miR-200 family that targets at least two transcriptional repressors of E-
cadherin, ZEB1 and ZEB2. This subject will be later detailed in chapter 4 of this thesis. 
In lung adenocarcinoma it was shown that the miR-134/miR-487b/miR-655 cluster 
promotes the EMT through TGF-β signalling and induces resistance to gefitinib by directly 
targeting MAGI2, whose suppression encompassed loss of PTEN stability (Kitamura et al., 
2014). Another example is the over-expression of miR-147, which alone induced reversal 
of EMT and consequently reversal of the native drug resistance of the colon cancer cell line 
HCT116 to gefitinib. Although the specific mechanism of action of miR-147 is still 
unknown, the authors found that miR-147 significantly up-regulates CDH1 and represses 
ZEB1, known EMT markers, and inhibited TGF-β1 expression and also repressed AKT 
phosphorylation, leading to gefitinib sensitivity (Lee et al., 2014). MiR-489 under-
expression in a MCF7/DOX was also connected with EMT. On the contrary, SMAD3, 
involved in TGF-β-induced EMT, is over-expressed in the same cell line. Ectopic expression 
of mir-489 not only reversed mesenchymal features, but also sensitized the breast cell line 
to doxorubicin, through inhibition of SMAD3 (Jiang et al., 2014). These studies underline 
the importance of TGF-β signalling in EMT and the regulation of EMT influenced drug 
resistance by miRNAs. MiR-223 was also associated with drug resistance and EMT in 
pancreatic cancer. In fact, it is up-regulated in gemcitabine-resistant pancreatic cancer 
cells, thus acting as an oncogene, most probably, through inhibition of FBW7 which 
consequently overexpresses NOTCH1. The authors also showed that by inhibiting miR-







1.1.2.2.5. Cancer stem cells and drug resistance  
Although it is accepted that most tumours arise from a single mutated cell, a monoclonal 
event, the tumour itself is a sum of numerous types of cells, due to the heterogeneity 
derived from a continuous evolution of the primitive cancer cell. Although cancer stem 
cells (CSC) have been well characterized in haematological malignancies, their existence in 
other tissues has been much debated (for a review see (Pattabiraman and Weinberg, 
2014)). Over the past years CSC have been identified using stem cell specific markers in 
several solid tumours including breast, brain, colon, prostate and pancreatic cancer (Al-
Hajj et al., 2003; Li et al., 2007; O'Brien et al., 2007; Singh et al., 2003). Moreover, the 
possible existence of CSCs within tumours is intimately linked to tumour heterogeneity 
and tumour dedifferentiation.  
Several miRNAs have been shown to regulate stemness, or what we consider as properties 
of tumour-initiating and maintaining cancer cells, of different cancer types. Recent studies 
showed differential expression of certain miRNAs between CSC and their differentiated 
counterparts (Liu and Tang, 2011; Shimono et al., 2009a; Tay et al., 2008), suggesting that 
miRNAs could also be involved in the regulation of CSC. Therefore, several miRNAs have 
been reported to regulate stem cell properties and drug resistance concomitantly (Table 
1.1) (Raza et al., 2014). 
As an example, was showed that let-7a expression was significantly decreased while 
NANOG/OCT4 expression was increased in head and neck cancer tissues as compared to 
adjacent normal cells (Yu et al., 2011). Likewise, the authors showed that these differently 
expressed proteins and miRNA is associated with resistance to cisplatin.  Similarly, it was 
observed that human head and neck squamous cell carcinoma derived HSC-3 cells contain 
a subpopulation of CSCs characterized by the expression of stem cell markers (OCT4, 
SOX2, and NANOG) and shows an up-regulation of miR-302 which, in turn, up-regulates 





resistance (Bourguignon et al., 2012). However, the authors do not show a direct target of 
miR-302. Similarly, miR-214 regulates ovarian cancer cell stemness and chemoresistance 
towards cisplatin and doxorubicin treatment by targeting TP53/NNANOG, and expression 
of p53 abrogated miR-214-induced ovarian CSC properties (Xu et al., 2012a). In another 
study, expression of miR-145 was showed to be inversely correlated with the levels of 
OCT4 and SOX2 in glioblastoma-CD133+ (GBM-CD133+) cells and malignant glioma 
specimens (Yang et al., 2012). Additionally, miR-145-treated GBM-CD133+ cells 
suppressed the expression of stemness (NANOG, c-MYC, and BMI1), drug-resistance 
(ABCG2, ABCC5, ABCB1) and anti-apoptotic genes (BCL2, BCL-xL) and increased the 
sensitivity of the cells to radiation and temozolomide (Yang et al., 2012). In hepatocellular 
carcinoma, miR-130b was shown to be associated with CSC growth that leads to worse 
overall survival and more frequent recurrence of cancer in patients. Also, cells transfected 
with miR-130b presented a higher resistance to doxorubicin (Ma et al., 2010b). 
Several of these studies have used cell lines in vitro that express stem cell markers, 
however, one must keep in mind that these cell lines have vastly altered karyotypes (e.g. 
several translocations, insertions and deletions) that will obviously alter their biological 
behaviour. Therefore, caution must be exercised in interpreting the results described. 
1.1.3. miRNAs and breast cancer 
In spite of the huge scientific progression in breast cancer investigation, much is still 
needed to better understand this heterogeneous disease.  After all these years of research, 
physicians still have a paucity of tools to a better diagnose breast cancer and its genetics 
can still be divided in high (BRCA1, BRCA2, PTEN, TP53, CDH1, and STK11), moderate 
(CHEK2, BRIP1, ATM, PALB2) and low (e.g. SNPs in several genes) penetrance genes 
(Shiovitz and Korde, 2015). Furthermore, physicians, more often than not, use gene panels 
currently available for breast cancer risk assessment in cases where a hereditary 





2002). Since hereditary breast cancer only accounts for approximately 10% of the cases, 
the remaining 90% still do not have accurate panels for risk assessment or to better 
diagnosis. In this matter, many studies attempted to correlate individual SNPs with 
individual susceptibility to sporadic breast cancer (Conde et al., 2009; Silva et al., 2009; 
Silva et al., 2006a; Silva et al., 2006b; Silva et al., 2007; Silva et al., 2010). In fact, since 
genetic variations may show very little effect individually but a strong effect conjointly, we 
explored the applicability of decision trees, in association with Professor Arlindo Oliveira 
in the Department of Computer Science and Engineering of Instituto Superior Técnico 
(IST), in order to ascertain significant differences when several variants of the same gene 
were analysed together (Anunciação et al., 2010). In this study we obtained a significant 
association between two SNPs of BRCA2 and alcohol consumption. Although these results 
were promising, as currently sequencing costs dropping to affordable prices, breast cancer 
genome sequencing can provide much more information at several levels, including point 
mutations, insertions, deletions, copy number variations and translocations (Campbell et 
al., 2008; Dieci et al., 2016; Dunning et al., 2016; Shah et al., 2009; Verigos and Magklara, 
2015). Thus, further studies in bigger populations were abandoned. New technologies also 
allow a further classification of breast cancer into Luminal A, Luminal B, HER2 and Basal-
like after the initial characterization in 2000 by Perou and colleagues (Perou et al., 2000). 
This molecular classification of breast cancer is routinely accomplished by pathologists 
through immunostaining of the tumour tissues for oestrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth receptors (HER2), the proliferation marker Ki-67 
and various cytokeratins (Figure 1.6) (Dowsett et al., 2011; Hammond et al., 2010; Wolff et 






Figure 1.6 - Major molecular subtypes of breast cancer determined by gene profiling. Luminal 
A (Panels A-D): ER+ and/or PR+, HER2−, and low Ki67 (<14%); Luminal B (Panels E-H): ER+ 
and/or PR+ and HER2+ (luminal-HER2 group), or ER+ and/or PR+, HER2−, and high Ki67 (>13%); 
HER2 (Panels I-L): ER−, PR−, and HER2+; Basal-like (Panels M-P): ER−, PR−, HER2−, and CK5/6 
and/or EGFR+. Figure from (Sandhu et al., 2010). 
Approximately 70% of invasive breast cancers are ER positive. These are classified as 
luminal cancers which are sub-classified into luminal A and luminal B subtypes based on 
their proliferation rate (Ki-67 expression) and HER2. The majority of ER positive tumours 
also express PR. The ER negative breast cancers are sub-classified as HER2 positive 
(approximately 15% of all the breast cancer) and as triple-negative, based on HER2 over-
expression/gene amplification. Basal-like breast cancers (approximately 15% of all breast 
carcinomas) are distinguished from other kind of triple-negative breast cancers by 
expression of citokeratins 5, 6, 14, 17, 34 or P63. More recently, additional sub-types, such 
as the claudin-low, have been identified, while the existence of the normal-like subtype is 
still debatable as it could be an artefact of gene profiling due to a disproportionally high 





subtype is better than basal-like and HER2 but worse than that of luminal group (Lavasani 
and Moinfar, 2012; Perou, 2010; Prat and Perou, 2011; Sabatier et al., 2014). 
The ER positive breast cancer subtypes (luminal A and luminal B) usually show a good 
prognosis and excellent long-term survival (approximately 80%–85% 5-year survival). 
This must be due to the availability of effective therapy, mainly, tamoxifen and aromatase 
inhibitors. The low-grade luminal A tumours are regularly treated only with anti-
oestrogens, whereas the high proliferative luminal B tumours often have lower expression 
levels of ER, lower or no PR expression, and are considered to have lower sensitivity to 
endocrine treatment and higher sensitivity to chemotherapy. In contrast, HER2 positive 
and basal-like tumours are difficult to treat and are associated with poor prognosis 
(approximately 50%–60% 5-year survival). Although HER2 positive tumours have an 
aggressive progression, the survival rate has improved in the last decade due to the use of 
targeted therapies like trastuzumab, an antibody against HER2, which have been shown to 
be effective in 20% of patients. Basal-like tumours, although more aggressive than other 
tumour types, can be especially sensitive to chemotherapy but promising strategies are 
being developed to treat these type of cancer, such as poly-ADP ribose polymerase-1 
(PARP) inhibitors. Regarding claudin-low breast cancer, this subtype has a poor long-term 
prognosis (Ignatiadis and Sotiriou, 2013). 
As stated before, these protein biomarkers are used as surrogates for gene expression 
analysis to determine molecular subtype. If from one side it has been argued that the 
definition of breast cancer subtypes using immunohistochemistry (IHC) is not able to 
recapitulate the information provided by the gene expression, from the other side it has 
been suggested that the additional clinical value of the molecular classification is limited 
by its close correspondence to ER and HER2 status and proliferation markers defined by 
IHC. Nevertheless, these biomarkers have shown limited capacity to predict individual 
patient outcomes since patients with the same clinicopathological features can have 





In recent years miRNAs have been extensively associated with breast cancer. The use of 
genome-wide approaches has enabled the production of miRNAs fingerprints in tumours 
and in its normal counterpart. As a result, miRNA expression signatures (miRNome) 
allowed different types of cancer to be discriminated with high accuracy and the tissue of 
origin of poorly differentiated tumours to be identified (Volinia et al., 2006). With this, 
improved prognostics and better decisions regarding therapy can be made. Indeed, many 
miRNAs have been associated with different subtypes of breast cancer. A comprehensive 
review by Serpico and colleagues (Serpico et al., 2014) show a vast list of miRNAs 
differently expressed in luminal, HER2, basal-like and normal-like subtypes of breast 
cancer (Table 1.2). In this case the targets regulated by these miRNAs are not the most 
important, but the signature in these subtypes. In a near future these signatures could 
enhance treatment due to a better classification. 
Table 1.2 – Differently expressed miRNAs in breast cancer subtypes. Table adapted from 
(Serpico et al., 2014) 
Subtype miRNAs signature  
Luminal A 
Up-regulated miR-191, -26, -126, -136, -100, -99a, -145, -146b, -10a, -
199a/b, -130a, -30a, -224, -214, let-7a/b/c/f, -342 
Down-regulated miR-206, -15b, -107, -103 
Luminal B 
Up-regulated miR-191, -26, -106a/b, -93, -25, -10a, -30a, -224, let-
7b/c/f and -342, -15b, -107, -103 
Down-regulated miR-206, -100, -99a, -130, -126, -136, -146b 
HER2 positive 
Up-regulated miR-150, -142, -148a, -106b, -93, -155, -25, -187, -375 
Down-regulated miR-125a/b 
Basal-like Up-regulated 
miR-150, -142, 148a, -106a/b, -18a, -93, -155, -25, -187, -
135b 
Normal-like Up-regulated 
miR-142-5p, -135b, -126, -136, -100, -99a, -145, -10a, -
199a/b, -130a, -30a-3p, -214, -7a/c 
 
Many of these miRNAs have been described as influencing cancer and particularly, breast 
cancer (Hemmatzadeh et al., 2016; Serpico et al., 2014). In spite of several studies 
performed through the years, few miRNAs have been associated with breast cancer and 
with validated targets. In Table 1.3, some miRNAs known to have oncogenic or tumour 





shown in Table 1.3, many miRNAs has redundant target regulation and can influence many 
cell pathways. Others have been associated, however the mechanisms of action are not 
known.  
As mentioned before, miRNAs have an important role in regulating multi-drug resistance. 
Table 1.1 shows several miRNAs affecting DME in breast cancer, mostly in human breast 
cell lines. Few studies though have shown an association between miRNAs and drug 
resistance in patients. As an example, a recent study revealed that miR-200c was up-
regulated in BC tissues from chemoresistant patients compared to responders (Lv et al., 
2014). Conversely, Chen and colleagues (Chen et al., 2012) showed a correlation of the low 
expression of miR-200c with poor response to neoadjuvant chemotherapeutics using 
breast cancer tissues. In these cases the actual mechanism behind the drug resistance is 
not known, however through studies performed in cell lines, some clues can be identified. 
Other pathways can influence drug resistance and consequently be target of miRNAs. As 
an example, miR-15a/16 down-regulation leads to an increase of the anti-apoptotic 
protein BCL2 and consequently resistance to tamoxifen. In fact, this happens through an 
alternative regulation of miR-15a/16 cluster by oncogenic HER2Δ16 that is detected in 
more than 30% of the ER positive tumours (Cittelly et al., 2010). Consequently, this could 
be a justification for the poor therapy results in some patients. On the contrary, miR-
221/222 cluster functions as an oncogenic miRNA by targeting the cell cycle inhibitor 
p27Kip1. Low levels of p27Kip1 were associated with tamoxifen resistance (Miller et al., 
2008).  Interestingly, increased level of miR-221/222 cluster, probably by targeting the 
same protein mentioned before, influences fulvestrant resistance. In this case, miR-
221/222 can function as a tumour suppressor and an oncogenic miRNA. With fulvestrant 
treatment, miR-221/222 levels increase and by targeting ERα acts like a tumour 
suppressor. However, long periods of estradiol deprivation can lead to a constitutive 
increased expression of miR-221/222 that becomes oncogenic by targeting cell cycle 





demonstrated (Rao et al., 2011). Another example is miR-128a, a hormone-responsive 
miRNA, which is over-expressed in letrozole-resistant cell lines and by targeting TGFβ can 
enhance cell growth and resistance to letrozole. Indeed, inhibiting miR-128a, the 
inhibitory effect of TGFβ is restored and cells became sensitized to letrozole. Here, the 
potential effect of miR-128a in drug resistance and also the mechanism of miR-128a 
expression regulation was demonstrated, since it is highly expressed in cells with high 
levels of hormones (Masri et al., 2010).  Indeed, miR-125b is up-regulated in a drug 
resistant cell line. Precisely, miR-125b is over-expressed in taxol-resistant cell lines 
inhibiting the apoptotic effect of taxol. This resistance must due to the fact that miR-125b 
targets BAK1, a pro-apoptotic protein (Zhou et al., 2010). Interestingly, the concomitant 
administration of a miR-21 inhibitor and taxol, improved the toxicity of this 
chemotherapeutic agent and consequently apoptosis in the MCF-7 cell line. This study 
shows the potential of using miRNAs inhibitors in some tumours. However, precaution 
and much more studies must be performed regarding possible side effects of using 
miRNAs/anti-miRNAs as a therapy (Mei et al., 2010). Regarding targeted therapy to 
HER2/3, trastuzumab seems to be influenced by miR-21(Gong et al., 2011) and lapatinib 






Table 1.3 – miRNAs with known oncogenic and tumour suppressor effect in breast cancer. 
Table adapted from (Hemmatzadeh et al., 2016) and (Serpico et al., 2014) 
miRNA effect miRNA Target in breast cancer 
Oncogenic miR-9 LIFR, E-cadherin 
 
miR-10b RHOC, HOXD10 
 
Cluster 17/20 AIB1, cyclin D1 
 




ST14, ZBTB10/MYT1, FOXO1 
 miR-29 TTP 
 miR-92 ERβ 
 miR-103/107 DICER 





 miR-127a ZBTB1 
 miR-132 p120, RAS, GAP 
 miR-181 family ATM 




miR-155 RHOA, SOX1 
 
miR-221/222 ERα, p27(kip1), p57 
 
miR-210 MNT, RAD52 
 miR-335 SOX4, TNC, PTPRN2, MERTK 
Tumour 
suppressor 
miR-205 HER3, VEGF-A 
 miR-206 CyclinD2, Erα, SRC1/2, GATA3 
 miR-224 CDC42, CXCR4 
 miR-34a BCL2, SIRT1, NOTCH1 
 miR-7 PaK1, MRP1, EGFR 
 
miR-200 family 
BMI1, ZEB1, ZEB2, FOG2, PLCG1, SUZ12, Moesin, 
Fibronectin, TRKB 
 miR-30a Vimentin 
 miR-30e ITGB3, UBC9 
 miR-17-5p AIB1 
 let-7 RAS, HMGA2 
 miR-20b HIF1α 
 miR-22 CDK6, HER3, ERα, CDC25C, SP1, EVI1 
 miR-27b CYP1B1 
 miR-31 RHOA, RDX, ITGA5, FZD3 
 miR-125a/b HER2/HER3, HuR, c-RAF, MUC1, BAK, RTKN, CYP24, ERα 
 miR-126 VEGF, IRS1, CRK 
 miR-145 RTKN, ERα, MUC1 
 miR-335 SOX4, TNC 
 miR-146 NFkB 
 miR-448 SATB1 





2. Aim of this thesis 
Fourteen years have passed since George Calin first published the association of miRNAs 
and cancer (Calin et al., 2002). At that time, there was a suspicion that a deletion on 
chromosome 13 was implicated in leukemogenesis. Indeed, this deletion is the most 
frequent abnormality in patients with CLL and back then, several studies failed to identify 
a causal gene in this region. Calin and colleagues demonstrated that two miRNAs genes 
(miR-15 and miR-16) were located within that region and that patients with CLL have a 
downregulation or absence of these two miRNAs when compared to normal tissue or 
lymphocytes. Shortly after, three other studies came to associate cancer and miRNAs. Two 
reporting the relationship of miR-17-92 cluster and the MYC oncogenic pathway (He et al., 
2005; O'Donnell et al., 2005) and a third demonstrating that let-7 directly regulates Ras 
(Johnson et al., 2005). Since then, hundreds of studies are published every year showing 
an association of miRNAs and several oncogenic pathways. 
There are three interesting questions about miRNAs in neoplastic diseases: 
1. How do tumour cells deregulate miRNAs expression in order to benefit themselves? 
2. How do miRNAs influence tumour cells? 
3. What is the actual expression of miRNAs in patient tumour cells? 
It is established that miRNAs are post-transcription regulators of gene expression and that 
in most tumour cells they are differently expressed when compared with normal cells. 
However, the mechanisms involved in this expression deregulation are still poorly 
understood. Thus, in Chapter 3 of this thesis we tried to address this topic by studying 





mammary cells (MCF-10A – non-tumour cell line; MCF-7 – tumour cell line; MDA-MB-231 
– tumour with metastatic capability) and how these statuses influence miRNAs expression. 
Once the deregulation of miRNAs is established, cells start to behave differently and 
acquire new phenotypes, including invasiveness, metastasis and drug resistance, for 
example. Thus, in Chapters 4 and 6 of this thesis our approach was to study the effect of 
two miRNAs (miR-200c and miR-203) in human breast cell lines (MCF-10A, MCF-7 and 
MDA-MB-231). 
Last but not least, although functional studies in cell lines are extremely important and 
give us plenty of knowledge, they need to be confirmed in tumour cells of patients with 
cancer, and in this case breast cancer. Thus, in Chapter 5, our approach was to study the 
expression patterns of two miRNAs (miR-200c and miR-203) in breast tumour cells of 
several patients and some putative targets of these miRNAs. 
Finally, I summarize the main results and some conclusions about the work showed in this 







3. Regulation of miRNAs expression in human 
breast cell lines 
 
3.1. State of the art 
Expression of miRNAs is deregulated in cancer and their impact in disease progression is 
now well documented [for further reading about miRNAs expression deregulation in 
specific types of tumours see: (Balatti et al., 2015; Chruscik and Lam, 2015; Lyra-Gonzalez 
et al., 2015; Masood et al., 2015; Rusek et al., 2015; van Schooneveld et al., 2015)]. 
However, how miRNAs expression became deregulated is still poorly understood, mainly 
because their behaviour in cells depends on the tissue and microenvironment. Thus, the 
influence of a miRNA in breast tissue may not be the same for lung cancer.  
Some articles have been published reporting evidences that miRNAs might be regulated 
post-transcriptionally by proteins involved in their biogenesis, such as XPO5 (Iwasaki et 
al., 2013), DICER (Ueda et al., 2009)  or other biogenesis partners (Shen and Hung, 2015). 
Oestrogens are also regulators of miRNAs expression. Indeed, Carolyn M. Klinge recently 
published an excellent review with all miRNAs regulated by estradiol, tamoxifen and other 
endocrine disrupting chemicals (Klinge, 2015). There is also evidence that telomerase 
reverse transcriptase (TERT) regulates miRNAs expression in early biogenesis, however 
the real mechanism is not known but certainly is not related with the canonical function of 
the TERT  (Lassmann et al., 2015).  
One of the most studied but less conclusive regulators of miRNAs expression is DNA 
methylation (Lopez-Serra and Esteller, 2012), nevertheless much is still needed to 
understand DNA methylation and its role in miRNAs expression. 
Regarding breast cancer, DNA methylation-silencing associated repression of some 





et al., 2008), miR-34a (Lodygin et al., 2008), miR-148a (Lujambio et al., 2008), cluster miR-
200c/141 (Neves et al., 2010), miR-335 (Png et al., 2011), and let-7a-3 (Vrba et al., 2013). 
Indeed, a study published by Vrba and colleagues described a set of miRNAs promoters 
aberrantly methylated in breast cancer cell lines and also aberrantly methylated in breast 
cancer tissues, being thus clinically relevant.  
Therefore, we decided to study basal levels of several miRNAs in MCF-10A, MCF-7 and 
MDA-MB-231 breast cell lines and then verify if the expression levels of these miRNAs are 
altered by challenging the cell lines with 5-Aza-2′-deoxycytidine (DAC), a demethylating 
agent. Additionally we performed a profile of the differentially expressed proteins after 
treatment with DAC.  
3.2. Materials and methods 
3.2.1. Cell lines 
Human breast cell lines MCF-10A (non-tumour), MCF-7 (tumour) and MDA-MB-231 
(tumour with metastatic capability) were kindly provided by Professor Nuno Oliveira 
from Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade 
de Lisboa. MCF-10A cells were cultured in Dulbeccos’s Modified Eagle’s Medium Nutrient 
Mixture F-12 Ham (DMEM/F-12; Sigma-Aldrich D8437), 5% horse serum (Sigma-Aldrich 
H1270), 1% penicillin-streptomycin (with 10,000 units penicillin and 10 mg streptomycin 
per mL) (Sigma-Aldrich P0781), 10 µg/mL insulin (Sigma-Aldrich I9278), 20 ng/mL 
epidermal growth factor (EGF; Sigma-Aldrich E9644), 0.5 µg/mL hydrocortisone (Sigma-
Aldrich H0888) and 100 ng/mL cholera toxin (Sigma-Aldrich C8052). MCF-7 cells were 
cultured in DMEM (Sigma-Aldrich D6046), 10% foetal bovine serum (FBS; Sigma-Aldrich 
F7524), 10 µg/mL insulin (Sigma-Aldrich I9278) and 1% penicillin-streptomycin (with 
10,000 units penicillin and 10 mg streptomycin per mL) (Sigma-Aldrich P0781). MDA-MB-





and 1% penicillin-streptomycin (with 10,000 units penicillin and 10 mg streptomycin per 
mL) (Sigma-Aldrich P0781). 
All cell lines were incubated at 37 °C with 5% CO2 in a humidified chamber. 
In order to test the demethylating effect of 5-Aza-2′-deoxycytidine (DAC; Sigma-Aldrich 
A3656), the breast tumour cell lines were cultured for five days in the presence of 2.5 µM 
of DAC. As a control we used dimethyl sulfoxide (DMSO; Merck Millipore #1029522500) at 
a percentage of 0.1% (v/v). 
3.2.2. Nucleic acid purification 
RNA, miRNAs and DNA were purified with AllPrep DNA/RNA Mini kit (Qiagen # 80204) 
and RNeasy MinElute Cleanup Kit (Qiagen # 74204). Cells were harvested and lysed in 
RLT buffer in a proportion of 350 µL per 3⨯106 cells. Up to 700 µl lysed cells were loaded 
into an AllPrep DNA spin column and centrifuged for 30 seconds at ≥8000 ⨯ g. The flow-
through was used for RNA purification and the DNA spin column stored at room 
temperature until further use. One volume of 70% ethanol was added to the flow-through 
and mixed by pipetting. Up to 700 μl of the sample, including any precipitate that may 
have formed, was loaded into an RNeasy spin column and centrifuged for 30 seconds at 
≥8000 ⨯ g. The flow-through was stored at room temperature to later miRNAs 
purification. A wash was done by adding 700 μl of buffer RW1 to the RNeasy spin column 
and centrifuged for 30 seconds at ≥8000 ⨯ g. The flow-through was discarded. A second 
wash with 500 μl of RPE buffer was done, followed by a centrifugation for 30 seconds at 
≥8000 ⨯ g. The flow-through was also discarded. A third wash with 500 μl of RPE buffer 
was done, followed by a centrifugation for 2 minutes at ≥8000 ⨯ g. The flow-through was 
again discarded. Next, 30 μl of nuclease-free water was added directly to the spin column 
membrane and centrifuged for 1 min at ≥8000 ⨯ g to elute the RNA. This RNA was then 
stored at -80 °C until further use. One volume of 100% ethanol was added to the flow-





RNeasy MinElute Cleanup column and centrifuged for 30 seconds at ≥8000 ⨯ g. The flow-
through was discarded. A wash was done by adding 500 μl of RPE buffer and centrifuged 
for 30 seconds at ≥8000 ⨯ g and discarding the flow-through. A second wash with 500 μl 
of 80% ethanol was done and centrifuged for 2 minutes at ≥8000 ⨯ g. The flow-through 
was discarded and a centrifugation for 5 minutes at full speed was done in order to dry the 
filter. Next, 14 μl of nuclease-free water was added to the column and centrifuged for 1 
minute at full speed. The miRNAs were then stored at -80 °C until further use. At last, the 
genomic DNA was purified by adding 500 μl of AW1 buffer to the AllPrep DNA spin column 
that was stored before and centrifuged for 30 seconds at ≥8000 ⨯ g. The flow-through was 
discarded and 500 μl of AW2 buffer were added to the column and centrifuged for 2 
minutes at full speed. After discarding the flow-through, 100 μl of elution buffer was 
added to the column and incubated for 1 minute at room temperature. Then, the column 
was centrifuged for 1 minute at ≥8000 ⨯ g. The genomic DNA was then stored at -80 °C 
until further use. 
All samples were quantified using a NanoDrop™ spectrophotometer. 
3.2.3. Reverse transcription qPCR 
A profiling of 95 miRNAs in MCF-10A, MCF-7 and MDA-MB-231 was done by using 
QuantiMir Cancer Array from System Biosciences (#RA610A-1) in a real time PCR 7300 
system (ABI). The protocol was divided into 4 steps: a) polyA tail formation - 100 ng of 
purified miRNAs were added to a mix of 2 µl of 5⨯ polyA buffer, 1 µl of 25 mM MnCl2, 1.5 
µl of 5 mM ATP and 0.5 µl of polyA polymerase to a total volume of 10 µl. This mixture was 
then incubated at 37 °C during 30 minutes in a thermal cycler (9700 ABI); b) Anneal 
Anchor dT Adaptor - 0.5 μl Oligo dT Adaptor was added to the mixture in step a), followed 
by an incubation for 5 minutes at 60 °C and a cooling to room temperature for 2 minutes; 
c) Syntheses of cDNAs – to the mixture of step b) were added 4 μl of 5⨯ RT buffer, 2 μl of 





reverse transcriptase. Then, an incubation for 60 minutes at 42 °C and an enzyme 
inactivation for 10 minutes at 95 °C was done. The cDNAs were stored at - 20 °C until 
further use; and d) qPCR Reaction – A mixture of 1,750 μl of 2⨯ 2X SYBR® Green qPCR 
Mastermix buffer, 60 μl of 10 μM Universal Reverse Primer, 20 μl of cDNA and 1,670 μl of 
RNase-free water was done. From this mixture, 29 μl were loaded per well in a 96-well 
plate and then 1 μl of specific primers were loaded per well. U6 snRNA was used as 
endogenous control. The miRNAs studied and the plate arrangement can be seen in Table 
3.1. This methodology was used with all cell lines in normal conditions and MCF-7 cells 
treated with 2.5 µM of DAC for 5 days. 
Table 3.1 - microRNAs studied with QuantiMir Cancer Array and plate arrangement 
 









































































































































































































Individual reverse transcription qPCR was done by using Universal cDNA synthesis kit 
(Exiqon # 203300) and SYBR® Green master mix, Universal RT (Exiqon # 203450).  This 
methodology was performed in order to confirm the expression of miR-199b, miR-203, 
miR-200c, miR-24, miR-154 and let-7a in breast cell lines cultured in normal conditions. 
Universal cDNA synthesis started with a dilution of purified miRNAs to a concentration of 
1 ng/μl in nuclease-free water. A reverse transcription reaction mix was then prepared by 





of template RNA at 1 ng/μl. This mixture was incubated at 42 °C for 60 minutes, followed 
by an enzyme inactivation for 5 minutes at 95 °C and immediately cooled to 4 °C. The 
cDNA was then stored at -20 °C until further use. In order to proceed to real-time PCR, 
cDNA previously synthesized was diluted 80⨯. Then, a PCR master mix was done by 
mixing 5 μl of SYBR® Green master mix, 1 μl of PCR primer mix and 4 μl of diluted cDNA 
template to a total volume of 10 μl. The mixture was loaded into a 96-well PCR plate and 
then the real-time PCR was performed in a Roche 480 LightCycler instrument with the 
following conditions: polymerase activation at 95 °C for 10 minutes; 45 cycles of 
amplification at 95 °C for 10 seconds and 60 °C for 1 minute (with a ramp-rate of 1.6 °C 
/s). The primers used were: hsa-miR-199b-5p (Exiqon, LNA™ PCR primer set # 204152); 
hsa-miR-203 (Exiqon, LNA™ PCR primer set # 204285); hsa-miR-24 (Exiqon, LNA™ PCR 
primer set # 204260); hsa-miR-154 (Exiqon, LNA™ PCR primer set # 204518); hsa-let-7a 
(Exiqon, LNA™ PCR primer set # 204775); hsa-miR-200c-3p (Exiqon, LNA™ PCR primer 
set # 204482) and as endogenous control U6 snRNA (Exiqon, PCR primer set # 203907). 
Relative expression of miRNAs was determined by 2-ΔCt, where ΔCt is Ct (miRNA) - Ct (U6 
snRNA).   
QuantiMir Cancer Array was analysed in duplicate and individual reverse transcription 
qPCR was analysed in triplicate independent experiments. 
3.2.4. Primer selection and design 
All promoter sequences of miRNAs genes and CpG islands were selected in The UCSC 
Genome Browser (http://genome.ucsc.edu/index.html) and miRStart 
(http://mirstart.mbc.nctu.edu.tw/). In all, 20 promoter regions were selected for 12 
miRNAs, Table 3.2. CpG islands were predicted with 50% or greater GC content, length 
greater than 200 base pairs (bp) and a ratio greater than 0.6 of observed number of CG 
dinucleotides to the expected number on the basis of the number of G’s and C’s in the 





This software retrieves specific primers to methylated and non-methylated regions by in 
silico transforming DNA sequences. In the case of the promoter regions of XPO5 and RAN 
was UCSC Genome Browser was used. The selection of CpG islands was done as described 
before and the primer design made in methyl primer express® software v1.0. All primers 







Table 3.2 - Selected gene promoters; primer sequences for unmethylated and methylated 
regions of the promoters; and annealing temperatures for each pair of primers. 




UF 5' TTTTTATAAATTTTGTGTTATGT 3' 
50 
UR 5' TACATACCCACTAAACACACAA 3' 
MF 5' TTATAAATTTCGCGTTACGC 3' 
45 
MR 5' TACGTACCCACTAAACGCA 3' 
miR-34a 
UF 5' GGAGTTTTTTTTTTATGGTGGT 3' 
50 
UR 5' CCCTTTCCACACTACCCTACA 3' 
MF 5' AGTTTTTTTTTTATGGCGGC 3' 
MR 5' CTTTCCACGCTACCCTACG 3' 
let-7a-3 
UF 5' GAGGAGATGGTATGTTTGTGAAGTTG 3' 
55 
UR 5' AAACATACAAATACCCACCCTACTCA 3' 
MF 5' GACGGTACGTTCGTGAAGTCG 3' 
MR 5' CATACGAATACCCACCCTACTCG 3' 
miR-145 
UF 5' AGTTGAGTGTTAATTTGTTAGTGTT 3' 
51 
UR 5' ATTTTACCCAACAAAACATCTCC 3' 
MF 5' CGAGCGTTAATTCGTTAGC 3' 
MR 5' ATTTTACCCGACGAAACATC 3' 
miR-150 
UF 5' TTTGAAGGTTAAGGTGGATTTT 3' 
51 
UR 5' ATAAAAAAACCCAAACACTACTA 3' 
MF 5' GAAGGTTAAGGCGGATTTC 3' 
MR 5' AAAAAACCCGAACGCTACTA 3' 
miR-200c 
UF 5' GTTTTTTGTTAGATGGATGTGG 3' 
51 
UR 5' ATCAACCATCATCTCAATACTTT 3' 
MF 5' CGTTTTTCGTTAGACGGAC 3' 
MR 5' GTCAACCGTCATCTCGATAC 3' 
miR-203 
UF 5' GTTAGGTGTGTTTAGGTTAGGT 3' 
53 
UR 5' CCCATAAATCCCACAACTAATCC 3' 
MF 5' AGGTGCGTTTAGGTTAGGC 3' 
MR 5' CATAAATCCCGCGACTAATC 3' 
miR-199b 
UF 5' GGGATTTAGTGTTTTTTTGGGGG 3' 
53 
UR 5' CCAAAACCAACCATTTCTATCCC 3' 
MF 5' CGGGATTTAGCGTTTTTTCG 3' 
MR 5' CAAAACCGACCGTTTCTATC 3' 
miR-124-1 (*) 
UF 5' ATAAGGAGAGTAGTGGGGATTT 3' 
58 
UR 5' ACAACAAACAAATTCCAAAAAAC 3' 
MF 5' AGGAGAGTAGCGGGGATTC 3' 
MR 5' CAACAAACGAATTCCGAAAA 3' 
UF – unmethylated forward; UR – unmethylated reverse; MF – methylated forward; MR – 






Table 3.2 - (continued) – Selected gene promoters, primer sequences for unmethylated 
and methylated regions of the promoters and annealing temperatures for each pair of 
primers. 





UF 5' GTTTAGGTTTTTGGTTTGGTTT 3' 
56 
UR 5' ACTCAACAATCAACATTAAAAAT 3' 
MF 5' TAGGTTTTCGGTTTGGTTC 3' 
MR 5' CGACGATCAACGTTAAAAAT 3' 
miR-124-1 
(***) 
UF 5' TTTGGTTGGGTTGGTTGAATT 3' 
62 
UR 5' CACAACAACCACACATATTCTAAA 3' 
MF 5' GGTTGGGTCGGTTGAATC 3' 
MR 5' AACGACCACGCGTATTCTAAA 3' 
miR-124-2 
UF 5' GGTGTATTTTGGGGTTTTTGT 3' 
58 
UR 5' TACAAACAAAACCCTCTACACA 3' 
MF 5' CGTATTTTGGGGTTTTTGC 3' 
MR 5' TACGAACGAAACCCTCTACG 3' 
miR-124-3 
UF 5' GTTGGGATTGGTAATTATGTTT 3' 
56 
UR 5' CAAAAAAACACTCAAACTATTC 3' 
MF 5' CGGGATTGGTAATTACGTTC 3' 
MR 5' CGAAAAAACGCTCGAACTAT 3' 
miR-17-92 
UF 5' GGTTTTTTAAATTTTGTATGTGT 3' 
50 
UR 5' ACTACCCACACAAACTAACAAA 3' 
MF 5' TTTTTAAATTTTGTACGCGC 3' 
MR 5' ACTACCCACGCGAACTAAC 3' 
miR-219-1 
UF 5' AATTGAGGTTAAGGTTGTTGGTT 3' 
51 
UR 5' ATAAAACAAAACATAAACACCACA 3' 
MF 5' CGAGGTTAAGGTTGTTGGTC 3' 
MR 5' ATAAAACGAAACGTAAACGCC 3' 
miR-219-2 
UF 5' TTTGTTTTTTTGTGGTTGAGTT 3' 
50 
UR 5' CACAAACACTACAAATAACCCA 3' 
MF 5' CGTTTTTTTGTGGTTGAGTC 3' 
MR 5' CACGAACGCTACAAATAACC 3' 
miR-126 (‡) 
UF 5' ATTTTGGAAGATGTTATGTTTTT 3' 
47 
UR 5' TACCATAAACAACACATTATTAC 3' 
MF 5' TTGGAAGACGTTACGTTTTC 3' 
51 
MR 5' TACCGTAAACGACGCATTAT 3' 
miR-126 (‡‡) 
UF 5' GAATTTTGGAGTTAGTAGTGT 3' 
50 
UR 5' AACACTAACAAACCCCTCA 3' 
MF 5' AATTTCGGAGTTAGTAGCGC 3' 
53 
MR 5' ACACTAACGAACCCCTCG 3' 
UF – unmethylated forward; UR – unmethylated reverse; MF – methylated forward; MR – 







Table 3.2 - (continued) – Selected gene promoters, primer sequences for unmethylated 
and methylated regions of the promoters and annealing temperatures for each pair of 
primers. 




UF 5' TTTATGGAGTTTTTAGTTGAGGT 3' 
52 
UR 5' CCTCAAACACTTACAAACACAAA 3' 
MF 5' ACGGAGTTTTTAGTTGAGGC 3' 
MR 5' TCGAACACTTACAAACACGA 3' 
miR-24-2 
UF 5' GAAGGGAATAGAGGTTGGGTT 3' 
52 
UR 5' TCCCCAAAAACATTACAAAAAAA 3' 
MF 5' GGGAATAGAGGTCGGGTC 3' 
MR 5' CCCAAAAACGTTACGAAAAA 3' 
RAN (†) 
UF 5’ AGTTGGTGTTGTTATGGTAATT 3’ 
51 
UR 5’ AACTCCCACTAAAAAACACTACC 3’ 
MF 5’ CGGCGTTGTTACGGTAATC 3’ 
54 
MR 5’ CTCCCGCTAAAAAACGCTAC 3’ 
RAN (††) 
UF 5’ TTATGTTTGTTTGAGTGAGTATT 3’ 
49 
UR 5’ ACACACATACACTAAAAACAAAA 3’ 
MF 5’ CGTTTGTTCGAGCGAGTATC 3’ 
52 
MR 5’ CGCATACGCTAAAAACGAAA 3’ 
XPO5 (§) 
UF 5’ TTTATTTTTTAGATGGGGTGGT 3’ 
53 
UR 5’ AACTATCTCAATCTTTACCACCAC 3’ 
MF 5’ ATTTTTTAGACGGGGTGGC 3’ 
MR 5’ CTATCTCAATCTTTACCGCCG 3’ 
XPO5 (§§) 
UF 5’ TTATTTTAGTTATAGGTGGTGTT 3’ 
47 
UR 5’ TCAAATAAACACACTATACAAAC 3’ 
MF 5’ TTTTAGTTATAGGCGGCGTC 3’ 
51 
MR 5’ TCAAATAAACGCGCTATACG 3’ 
UF – unmethylated forward; UR – unmethylated reverse; MF – methylated forward; MR – 
methylated reverse. (†) CpG island 75. (††)CpG island 126. (§) CpG island 46. (§§) CpG 
island 94. 
 
3.2.5. Methylation specific PCR 
Methylation specific PCR (MSP) was done by using EZ DNA Methylation-Gold™ Kit (Zymo 
Research D5005) to perform a bisulfite conversion of GC-rich DNA and ZymoTaq™ DNA 
Polymerase (Zymo Research E2002) to perform PCR. 
Bisulfite conversion was done by adding 130 µl of CT conversion reagent to 20 µl of DNA 





nuclease-free water, 300 μl of M-Dilution buffer, and 50 μl M-Dissolving buffer to a tube of 
CT conversion reagent that was provided with the kit. Next, the mixture was incubated for 
10 minutes at 98 °C, followed by 150 minutes at 64 °C and a cooling to 4 °C. After cooling 
the sample, the converted DNA was cleaned up by loading it to a Zymo-Spin™ IC Column 
and 600 μl of M-Binding buffer. The mixture was then mixed by inverting the column 
several times and centrifuged during 30 seconds at full speed (>10,000 ⨯ g). Then, 100 μl 
of M-Wash buffer was added to the column and centrifuged at full speed for 30 seconds. 
Next, 200 μl of M-Desulphonation buffer was added to the column and let to stand at room 
temperature (20-30°C) for 15 minutes, followed by a centrifugation at full speed for 30 
seconds. Two successive washes were done by adding 200 μl of M-Wash buffer to the 
column and centrifuged for 30 seconds at full speed. Finally, 10 μl of M-Elution buffer was 
directly added to the column matrix and centrifuged for 30 seconds at full speed to elute 
the DNA. The cleaned up converted DNA was then stored at -20 °C until further use. 
In order to do the PCR, two separately mixes were prepared using primers for 
unmethylated sequence and primers for methylated sequence (all primers used can be 
seen in Table 3.2). The mixes only differed in the primer sequences used. Thus, 50 µl 
reaction mixes containing 25 µl of 2⨯ buffer, 0.5 µl dNTPs (0.25 mM each dNTP), 3 µl of 
reverse and forward primer at 10 µM each, 0.4 µl of ZymoTaq™ DNA polymerase (5 U/μl), 
17.1 µl of nuclease-free water and 1 µl of converted DNA (50 ng) was prepared and placed 
into a thermal cycler. The PCR conditions were: initial denaturation at 95 °C for 10 
minutes; 40 cycles of denaturation at 94 °C for 30 seconds, annealing at the primers 
specific temperatures referred in Table 3.2 for 30 seconds and extension at 72 °C for 30 
seconds; followed by a final extension at 72 °C for 7 minutes and a cooling to 4 °C. The PCR 
products were then subject to electrophoresis in 2% (w/v) agarose gel stained with 
ethidium bromide (1µg/ml) and visualized under ultra-violet light. All PCR reactions were 





3.2.6. Protein purification and quantification 
In order to proceed to protein purification, human breast cell lines in ordinary medium 
culture and treated with 2.5 µM of DAC and 0.1% (v/v) of DMSO were harvested and 
washed twice with cold phosphate-buffered saline (PBS) solution. Next, a lysis buffer (50 
mM Tris.base pH=8; 150 mM NaCl; 5 mM Ethylenediamine tetraacetic acid (EDTA); 1% 
(v/v) Nonidet P-40; 1 mM phenylmethylsulfonyl fluoride (PMSF); and protease inhibitor 
cocktail (Roche # 11 697 498 001)) was added to pelleted cells (in a proportion of 25 µl 
per 1⨯106) and roughly mixed by vortex and left on ice for 30 minutes. The lysis buffer 
containing the cells was then centrifuged for 10 minutes at 4 °C and 14,000 ⨯ g. The 
supernatant containing total protein extract was recovered and stored at -80 °C until 
further use. 
Protein quantification was done by Bradford assay using protein assay dye reagent 
concentrate (Bio-Rad # 500-0006) and bovine serum albumin (BSA) standard (Bio-Rad 
#500-0206). Standard concentrations of protein (0; 1; 5; 10; 20; 25; 30; 35; 40 µg) were 
prepared in deionized water to a final volume of 800 µl. Then, 200 µl of protein assay dye 
reagent concentrate were added. The samples were then loaded in a 96-well plate and 
read in a plate-reader spectrophotometer at 595 nm. The same procedure was done using 
the protein extracts and then by linear regression the exact concentration determined. 
3.2.7. Protein analysis by 2-D SDS-PAGE Gels and MALDI-TOF/TOF 
After protein quantification, total protein was cleaned-up by using 2D clean-up kit from GE 
Healthcare Life Sciences (#80-6484-51). To 100 µg of total protein were added 300 µl of 
precipitant reagent, mixed by vortex and left on ice for 15 minutes. Then, 300 µl of co-
precipitant were added and mixed by pipetting. The mixture was centrifuged at 12,000 ⨯ g 
for 5 minutes and the supernatant discarded. 40 µl of co-precipitantwere added to the 
pellet layer and left on ice for 5 minutes. The mixture was centrifuged at 12,000 ⨯ g for 5 





pellet and dispersed by vortex. Then, 1 ml of chilled wash buffer and 5 µl of wash additive 
were added to the dispersed pellet and mixed by vortex. This mixture was left on ice for 30 
minutes, assuring that every 10 minutes a mixture by vortex was done. After 30 minutes 
the mixture was centrifuged at 12,000 ⨯ g for 5 minutes and the supernatant removed. 
The pellet was air dried and finally resuspended in 150 µl of rehydration buffer (2% (v/v) 
CHAPS detergent; 7 M urea; 2 M tiurea; 0.5% (v/v) immobilized pH gradient (IPG) buffer; 
0.5% (v/v) DeStreak reagent; 1 mM PMSF; 15 mM DTT; protease inhibitor cocktail). After 
2 hours at room temperature the samples were ready to load in IPG gel (Immobiline 
DryStrip Gels pH 3-10 non-linear 7 cm, #17-6001-12 from GE Healthcare Life Sciences). 
Isoelectric focusing (IEF) was then made using the following conditions: 30 V for 12 hours, 
100 V for 30 minutes, 500 V for 30 minutes, 1000 V for 30 minutes and finally 5000 V for 1 
hour. After protein separation by its isoelectric point, strips were submerged in 
equilibration buffer (Tris.HCl 1.5 M pH 8.8; 6 M Urea; 2% (w/v) sodium dodecyl sulfate 
(SDS); glycerol 30%; and traces of bromophenol blue) with 1% (w/v) DTT for 15 minutes 
and then 15 minutes in equilibration buffer with 2.5% (w/v) iodoacetamide. After 
equilibration, the strips were positioned in the polyacrylamide gel (2.5 ml Tris.HCl 0.4 M 
pH 8.8; 75 µl APS 10%; 10 µl TEMED; 4 ml bisacrylamide 30%; and 3.5 ml deionized 
water) and subject to electrophoresis at 150 V. After electrophoresis, the gels were stained 
with Coomassie blue and scanned in order to acquire a picture of the gel. Pictures were 
then analysed in Progenesis Samespots software. This software aligned different pictures 
from different experimental conditions and analysed differences between them. After 
triplicates from independent experiments the differentially expressed spots from different 
cell conditions were excised from gels and sent to analysis to identify proteins with 
MALDI-TOF/TOF under the responsibility of Professor Deborah Penque from Laboratory 






3.2.8. Protein analysis by western blot 
Total protein was denatured in Laemmli buffer 2⨯ (4% (w/v) SDS 10%; 20% (v/v) 
glycerol 50%; 0.02% (w/v) bromophenol blue; 125 mM Tris.HCl pH 6.8; and 10% (v/v) 2-
Mercaptoethanol) in a proportion of 1:1 and heated at 95 °C for 10 minutes. Samples were 
then loaded into precast gels (4–20% Mini-PROTEAN® TGX™ Precast Protein Gels, Bio-
Rad #4561093S) and subject to electrophoresis at 100 V for 90 minutes in running buffer 
1⨯ (25 mM Trizma-base; 192 mM Glycine; 0.1% (w/v) SDS; pH 8.3). The gels were 
equilibrated in transfer buffer 1⨯ (25 mM Trizma.base; 192 mM Glycine; 0.1% (w/v) SDS; 
and 10% methanol) for 20 minutes as well as the PVDF membranes. Next, proteins were 
transferred from gel to PVDF membrane in transfer buffer 1⨯ for 60 minutes at 100 V. 
Membranes were then blocked using blocking buffer from WesternDot™ 625 Goat Anti-
Mouse Western Blot Kit (# W10132) for 1 hour and then washed with wash-buffer also 
provided with the kit. The membranes were incubated at room temperature for 1 hour 
with primary antibodies for RAN (GeneTex #GTX13049) and β-actin (Santa Cruz # sc-
47778) and after three successive washes incubated at room temperature for one hour 
with secondary antibody provided with the kit. At last, and after three more washes, the 
membranes were incubated at room temperature with streptavidin conjugate for one 
hour. The membranes were then visualized under ultra-violet light and photographed. 
3.2.9. Statistical analysis 
Data were analysed with GraphPad Prism 5 software, using one-way ANOVA with Dunn’s 
multiple comparison post hoc test and two-way ANOVA with Bonferroni multiple 
comparison post hoc test with confidence intervals of 95%. All graphs were made with 
GraphPad Prism 5 software and values represented are mean expression + range or mean 








MCF-10A, MCF-7 and MDA-MB-231 cell lines have different patterns of miRNAs 
expression 
In order to ascertain how miRNAs expression is regulated, we used three human breast 
cell lines with different phenotypes and measured the expression of 95 miRNAs known to 
have importance in tumourigenesis (in general and not only in breast cancer). Considering 
the 95 miRNAs as a whole we can observe that MDA-MB-231 levels of miRNAs are much 
lower when comparing with MCF-10A and MCF-7 (p < 0.05; Figure 3.1). In contrast, the 
MCF-7 cell line has a higher expression of miRNAs, but without statistically significant 
differences when compared with MCF-10A. Figure 3.2 shows the expression levels of the 
miRNAs individually.  
 
Figure 3.1- Relative expression of all miRNAs from QuantiMir Cancer Array in MCF-10A, MCF-
7 and MDA-MB-231. The values represented are mean values + range of relative expression of 95 
miRNAs to U6 snRNA. p values were determined by one-way ANOVA and Dunn’s multiple 










Figure 3.2 - Expression patterns of the miRNAs from the QuantiMir Cancer Array in 
MCF-10A, MCF-7 and MDA-MB-231 cell lines. Values are represented as mean relative 









Figura 3.2 (continued) - Expression patterns of the miRNAs from the QuantiMir 
Cancer Array in MCF-10A, MCF-7 and MDA-MB-231 cell lines. Values are represented 








Figura 3.2 (continued) - Expression patterns of the miRNAs from the QuantiMir 
Cancer Array in MCF-10A, MCF-7 and MDA-MB-231 cell lines. Values are represented 








MCF-7 cell line overexpress miRNAs levels after DAC treatment  
In order to ascertain if miRNAs levels increase with DAC treatment, MCF-7 cell line was 
treated with 2.5 µM of DAC for five days and then the miRNAs levels were measured with 
the QuantiMir Cancer Array. Compared with its counterpart without treatment (only with 
0.1% of DMSO as negative control) we observed that almost all levels of miRNAs increased 
(p < 0.001 given by two-way ANOVA; Figure 3.3). Definitely, DAC influences miRNAs 
expression levels and Figure 3.3 shows which miRNAs are significantly increased. Thus, 
we also treated MCF-10A and MDA-MB-231 cell lines with 2.5 µM of DAC for 5 days and 
analysed 20 putative promoter regions of 12 miRNAs (miR-26b, miR34a, let-7a-3, miR-
145, miR-200c, miR-203, miR-199b, miR-124, miR-17-92, miR-219, miR-126 and miR-24) 
in the three cell lines. Not all miRNAs overexpressed with DAC treatment were analysed 
because their promoter regions weren’t described or didn’t have predicted CpG islands. 
Thus, the miRNAs and promoter regions selected were those which were previously 
described as methylated in several types of cancer or those for which we obtained 
overexpressed with DAC treatment and had promoter regions described. In order to 
analyse if the selected promoter regions were methylated we performed a bisulfite 
conversion of the DNA, where unmethylated cytosines are replaced by uracil and allows us 
to distinguish between unmethylated and methylated sequences. Through PCR with 
specific primers for both sequences we obtained the methylation status of each promoter 
region. Figure 3.4 shows the PCR products we obtained. Among the 20 promoter regions 
we shall focus on let-7a-3, miR-199b, miR-124 and miR-24.  
The putative promoter region studied of Let-7a-3 seems to be totally methylated in MDA-
MB-231 and partially methylated in the other two cell lines. Indeed, looking at Figure 3.4 
we can see that the unmethylated sequence disappears with the aggressiveness of the cell 
line when not treated with DAC. When treated with DAC, the unmethylated sequence 





visible. In order to confirm if the methylation status is related with let-7a expression, we 
performed RT-qPCR and found contradictory results. The MDA-MB-231 is the cell line that 
expresses higher levels of let-7a (Figure 3.5). Regarding the putative gene promoter of 
miR-199b, we found that in MCF-10A it was totally unmethylated while being partially 
methylated in MCF-7 and MDA-MB-231 cells (Figure 3.4). With DAC treatment we were 
unable to detect changes in band intensity. Once again, we confirmed the methylation 
status through RT-qPCR of miR199b. However we did not detect expression of this miRNA 
in any of the cell lines. With respect to miR-124, we studied 3 promoter regions of miR-
124-1, one of miR-124-2 and another of miR-124-3. All these regions express the same 
miR-124, the only difference between miR-124-1, miR-124-2 and miR-124-3 is the 
chromosome region. Thus, the human genome has three copies of this gene but the one 
transcribed is not known. For that reason we studied the 3 regions and found CpG islands 
in all of them. From all regions, the most revealing were 124-1 (CpG island 70), miR124-1 
(CpG island 170) and miR-124-3 (Figure 3.4). However, these results are contradictory 
with the miR-124 expression levels (Figure 3.5). MiR-24 also displays differences in 
methylation status of the promoter sequence, but once again the expression of miR-24 
does not confirm the methylation status. Levels of miR-200c and miR-203 were also 
assessed in spite of being totally unmethylated. Interestingly, we obtained visible 









Figure 3.3 - Expression patterns of the miRNAs from the QuantiMir Cancer Array in 
MCF-7 and MCF-7 treated with 2.5 µM DAC for 5 days. Values are represented as mean 
relative expression ± standard deviation. p values were determined by two-way ANOVA 
and corrected with Bonferroni multiple comparison post hoc test with 95% confidence 








Figura 3.3 (continued) - Expression patterns of the miRNAs from the QuantiMir 
Cancer Array in MCF-7 and MCF-7 treated with 2.5 µM DAC for 5 days. Values are 
represented as mean relative expression ± standard deviation. p values were determined 
by two-way ANOVA and corrected with Bonferroni multiple comparison post hoc test with 








Figura 3.3 (continued) - Expression patterns of the miRNAs from the QuantiMir 
Cancer Array in MCF-7 and MCF-7 treated with 2.5 µM DAC for 5 days. Values are 
represented as mean relative expression ± standard deviation. p values were determined 
by two-way ANOVA and corrected with Bonferroni multiple comparison post hoc test with 









Figure 3.4 - Methylation status of the miRNAs gene promoters studied. UF – 
unmethylated forward; UR – unmethylated reverse; MF – methylated forward; MR – 
methylated reverse. (*) CpG island located at the transcription binding site of P53 gene; 










Figure 3.5 – Expression levels of let-7a, miR-203, miR-200c, miR-124 and miR-24 in 
MCF-10A, MCF-7 and MDA-MB-231 cell lines assessed by RT-qPCR. Values are mean 







DAC influences protein expression in MCF-10A, MCF-7 and MDA-MB-231 
After treatment with 2.5 µM of DAC, proteins were extracted in order to see if there are 
differences between cell lines in respect to protein profile. Figure 3.6 and Figure 3.7 
represents the differentially expressed proteins in MCF-10A, MCF-7 and MDA-MB-231 
cells. Interestingly, we obtained more differences in MCF-10A. After separation with 2-D 
SDS PAGE and protein analysis with MALDI-TOF/TOF, we observed that TPI1, PRDX2, 
CMPK1, ENO1, PRDX6, PSMA6, SERPINB5, ACTB, SFN, TPM1 and TPM3 were 
overexpressed in cells treated with DAC. While in MCF-7 + DAC, TUBA1b and RAN were 
overexpressed and in MDA-MB-231, GNB2l1, PARK7 and RAN were overexpressed. 
As we observed that RAN seems to be methylated in MCF-7 and MDA-MB-231 and it is one 
of the genes involved in miRNAs biogenesis we hypothesized if this could be a mechanism 
of regulation of miRNAs. Thus we performed MSP of two promoter regions of two 
biogenesis genes - RAN and XPO5 (Figure 3.8). Only the XPO5 CpG island 46 was 
methylated. However, treatment with DAC seems to be ineffective. This could be a 
methodological problem rather than a positive result. The experiment was repeated with a 
different batch of cells with treatment and the results remain the same. In order to confirm 
the sequencing results with MALDI-TOF/TOF we performed western blot of RAN (Figure 
3.9). We did not find differences in MCF-7 and MDA-MB-231 after treatment with DAC, in 






Figure 3.6 - Differentially expressed proteins in the MCF-10A cell line with and 








Figure 3.7 - Differentially expressed proteins in the MCF-7 and MDA-MB-231 cell 






Figure 3.8 - Methylation status of the gene promoters of RAN and XPO5. UF – 
unmethylated forward; UR – unmethylated reverse; MF – methylated forward; MR – 




Figure 3.9 - Confirmation of the RAN protein expression by western blot.  
 
3.4 Discussion 
Gene expression can be regulated at various levels. Indeed, from gene to protein synthesis, 
there are many steps suitable for being regulated. Post-transcriptional regulation is one of 
those levels and since the discovery of miRNAs it has been markedly studied. In normal 
conditions, steady miRNAs levels can preserve cell homeostasis by regulating genes that if 





miRNAs are not an exception. In fact, miRNAs can be regulated through the same 
mechanisms of coding genes, like epigenetic and post-transcriptionally modifications that 
concomitantly deregulate proteins involved in miRNAs biogenesis. 
Based on this assumption and taking into account our exploratory results regarding this 
matter, we decided to study epigenetic changes in putative miRNAs gene promoters and 
one protein involved in their biogenesis as possible reasons for misexpression. 
In an exploratory study we analysed 95 miRNAs in MCF-10A, MCF-7 and MDA-MB-231. 
These three cell lines represent, respectively, non-tumour mammary epithelium, tumour 
mammary epithelium and tumour with metastatic capability mammary mesenchymal-like. 
These cell lines have distinct morphologic aspects and as we showed their miRNAs 
expression pattern is also distinct (Figure 3.1 and Figure 3.2). Overall, MDA-MB-231 has 
low levels of miRNAs compared with the other two cell lines. These results are in 
accordance with a previous report (Lee et al., 2008) showing that that a large number of 
miRNAs are transcribed as precursors but are not processed to mature miRNA in cancer 
cell lines. The authors also state that is unlikely that a reduction in DROSHA or DICER 
levels, per se, explain the under-expression of miRNAs since other miRNAs are efficiently 
processed to mature in the same cell lines or tissues. Thus, some other aspect must be 
interfering with the process. One explanation is the transport of pre-miRNAs from the 
nucleus to the cytoplasm. Supporting this data was our exploratory results with respect to 
protein expression. Indeed, after treatment with DAC, tumour cell lines seem to over-
express RAN (Figure 3.7), an accessory protein of XPO5 that enables the miRNAs export to 
the cytoplasm. With this data, we also hypothesized that RAN promoter region must be 
hypermethylated. However, after studying the promoter methylation status of RAN we 
found that it was not hypermethylated (Figure 3.8). Thus, our explanation to this fact is 
that we observed an over-expression of RAN not because its methylation status but 
because other macromolecules need to be transported to the cytoplasm after treatment 





conditions and not a demethylation of this gene. This explanation is probably the same for 
the increased expression of RAN in MCF-7 cell line (Figure 3.7). Further studies of this 
protein through western blot did not show increasing levels of RAN after treatment with 
DAC (Figure 3.9). These discrepancies may be related with the specificity of the techniques 
and most probably with antibody affinities, impeding us to confirm the results obtained 
with mass spectrometry. Although, we were unable to infer if RAN is actually regulating 
miRNAs expression in breast cancer cell lines, the augmented expression of RAN is 
associated with cancer. In fact, several reports have been published showing that RAN is 
associated with poor prognosis in several types of cancer such as prostate (Harada et al., 
2008), breast (Kurisetty et al., 2009), colon (Hung et al., 2009), renal (Abe et al., 2008) and 
lymphoma (Hartmann et al., 2008). Interestingly, cancer cells seem to be RAN dependent, 
due to its role in mitotic spindle and mitosis (Xia et al., 2008).  
We then decided to study methylation status of miRNAs genes promoters. After the 
exploratory results that showed usndicated that miRNAs are differentially expressed in 
the cell lines, we studied the effect of DAC in the expression of miRNAs. The generalized 
increase of miRNAs expression levels after treatment (Figure 3.3) that we observed was 
expected and prompted us to look for promoter regions of miRNAs genes. After an 
exhaustive search in the data bases and publications we found 20 putative promoter 
regions in 16 miRNAs genes and studied their methylation status. Unfortunately, it was 
not possible to study all overexpressed miRNAs existing in the quantification array since 
the promoter regions were not described.  In spite of our efforts, we cannot associate 
methylation status with miRNAs expression due to the fact that both results are 
contradictory (Figure 3.4 and Figure 3.5).  After we initiated this approach a study was 
published regarding let-7a-3 (Vrba et al., 2013). The authors showed that the promoter 
region of let-7a-3 in MCF-7 and MDA-MB-231 is hypermethylated, which is in agreement 
with our results. However, the authors do not show let-7a-3 expression level. It would be 





Another article confirms our results of miR-124 promoter region (Lv et al., 2011) and 
assume that miR-124 is regulated by methylation. In fact, the authors used the same 
regions as we and found that the promoter regions of miR-124-1, miR-124-2 and miR-124-
3 were highly methylated in MDA-MB-231. However, the authors used bisulfite sequencing 
instead of MSP. In spite of the technique, the methylation status showed by the authors is 
quite similar to ours and they detected an increased expression of miR-124 after 
treatment with DAC. Without treatment the authors showed that miR-124 expression is 
attenuated in MDA-MB-231, as we do. If the promoter regions are methylated and yet miR-
124 is expressed we can only conclude that these regions are not influencing miR-124 
expression levels. Otherwise, the miR-124 must not be expressed or is expressed in much 
lower levels. Thus, the assumption made by these authors is not fully correct and further 
studies regarding miR-124 and methylation status are needed. 
Interestingly, miR-200c (Neves et al., 2010) and miR-203 (Sandhu et al., 2012; Sandhu et 
al., 2014) were described as being hypermethylated in breast cancer and in MDA-MB-231 
cell lines, disagreeing from our results. However, like these authors we did not find any 
expression level of miR-200c and miR-203, as well. 
In summary, we can conclude that neither RAN nor methylation of the studied regions 
seems to influence miRNAs expression levels. However none of the hypothesis should be 
discarded but studied through other approaches, like high resolution melting or bisulfite 
sequencing in order to more effectively detect methylated regions. After the approach 
described in this Chapter, many other promoter regions of miRNAs were described. Thus, 
a new analysis of these regions concomitantly with the ones already performed by us but 





4. Functional analysis of miR-200c and miR-203 
in breast cancer cell lines MCF-7 and MDA-MB-231 
 
The work showed in this chapter allowed us to publish a review chapter about the 
involvement of miRNAs in several tumours and drugs resistance: 
 Gomes, B. C., Rueff, J., and Rodrigues, A. S. (2016). MicroRNAs and Cancer Drug 
Resistance. Methods Mol Biol 1395, 137-162. 
4.1. State of the art 
Breast cancer therapy is usually performed using radiotherapy, hormonotherapy (e.g. 
tamoxifen, anastrazole, letrozole and exemestane), chemotherapy (e.g. doxorubicin, 
cyclophosphamide, docetaxel, fluorouracil, epirubicin and methotrexate) and targeted 
therapy  (e.g. trastuzumab). Frequently the three types of therapy are used together, or in 
a combination of several chemotherapeutics, in order to achieve better outcomes. 
Nevertheless, in spite of the advances in drug discovery, many patients relapse due to drug 
resistance. 
As stated in Chapter 1, miRNAs expression deregulation can lead to altered phenotypes 
and consequently different cell behaviour. Being characterized as oncomiRs or tumour 
suppressors, miRNAs can influence all hallmarks of cancer (Hanahan and Weinberg, 2011; 
Ross and Davis, 2011). Drug resistance is an acquired phenotype of the tumour cells that is 
most undesired. The confirmation that it is influenced by miRNAs led quickly to studies 
that assessed the influence of miRNAs in drug resistance. Indeed, miRNAs can regulate 
drug resistance-related genes, alter drug targets, change drug concentrations, influence 
therapeutic-induced cell death, regulate angiogenesis and be involved in the development 
of tumour stem cells. Thereafter many groups have focused on the role of these small 





Tumour suppressor miR-200c and miR-203 have been associated with several targets, 
including in cancer drug resistance. It is known that the sensitivity to some cancer drugs 
like etoposide, taxol and epidermal growth factor receptor inhibitors is increased with E-
cadherin expression restoration. Chen and colleagues (Chen et al., 2013b) showed that 
miR-200c increases drug sensitivity of breast cancer cells to doxorubicin through the E-
cadherin-mediated up regulation of PTEN. Similarly, an increased expression of miR-200b 
and miR-200c enhances the sensitivity to growth inhibition by 4-hydroxytamoxifen (4-
OHT) and fulvestrant in breast cancer cells (Manavalan et al., 2013). Although it is known 
that miR-200 family regulates EMT through ZEB1 and E-cadherin, the real mechanism 
through which the miR-200 family regulates drug resistance is not known, thus being 
necessary further studies to understand these phenomena. In response to this question, 
interesting data about miR-200c and feedback circuits of miR-200c/ZEB1 and miR-
200c/ZNF217/TGF-β/ZEB1 were recently published (Bai et al., 2014). The authors 
showed that these circuits contribute to trastuzumab resistance and metastasis of breast 
cancers. Interestingly, this feedback circuits might be related with reverse EMT in 
metastases formation, since ZEB1 can inhibit miR-200c expression. The authors also 
showed that low levels of miR-200c activate the TGF-β signalling pathway and 
consequently trastuzumab resistance in breast cancer cells. Indeed, restoring miR-200c 
was sufficient to re-sensitize cells to trastuzumab and reverse the mesenchymal 
phenotype by inhibiting TGF-β signalling and ZEB1 expression. Similarly, another 
published report showed that a high MIG6 expression and a suppression of miR-200c 
expression is a consequence of TGF-β-induced EMT and a signature for resistance to 
erlotinib (Izumchenko et al., 2014a).  
Drug transport through cell membranes is a critical step in allowing access of 
pharmacologic agents to intracellular targets. The involvement of drug transport is 
probably the most studied mechanism in cancer drug resistance and one of the most 





chemotherapeutic-resistant cancer cell lines, ABCB1 is often observed to be up-regulated. 
The increased expression of ABCB1 leads to an increased resistance to several 
chemotherapeutics, such as taxanes (e.g. paclitaxel and docetaxel), epipodophyllotoxins 
derivatives (e.g. etoposide and teniposide), anthracyclines (e.g. doxorubicin), antibiotics 
(e.g. actinomycin D), vinca alkaloids (e.g. vinblastine and vincristine) and tyrosine kinase 
inhibitors (e.g. imatinib and erlotinib) (Gromicho et al., 2011; Gromicho et al., 2012; 
Kathawala et al., 2014). To date, some authors have published data about misexpression of 
miRNAs or ABCB1in breast cancer (Chen et al., 2012; Kovalchuk et al., 2008). Kovalchuck 
and colleagues (Kovalchuk et al., 2008) showed that the ABCB1 gene is highly expressed in 
the MCF-7/DOX breast tumour cell lines resistant to doxorubicin when compared with 
wild type MCF-7, while Chen and colleagues (Chen et al., 2012) showed a correlation of 
miR-200c with poor response to neo-adjuvant chemotherapeutics using breast cancer 
tissues. Thus, this poor prognosis could be due to misregulation of ABCB1 by miR-
200c. However, the confirmation of an inverse correlation between ABCB1 and miR-
200c in breast cancer need further validation. 
Relatively to miR-203, there is no direct evidence of its effect on drug resistance in breast 
cancer. However, association with other tumours like colon and CML has been published. 
Indeed, it was demonstrated that miR-203 can sensitize cells to paclitaxel (PAX) in colon 
cancer (Li et al., 2011a) and imatinib mesylate in CML (Li et al., 2013b) by targeting BCL2 
and BCR-ABL, respectively.  Ectopic expression of miR-203 in colorectal cancer cell lines 
lead to an increased resistance to oxaliplatin by targeting ATM (Zhou et al., 2014) and 
sensitises cells to 5-fluorouracil (5-FU) by targeting thymidylate synthase (TYMS) (Li et al., 
2015). 
Paclitaxel and 5-FU are two chemotherapeutic agents used in breast cancer. Due to the fact 
that there is no data regarding miR-200c and miR-203 and its influence in breast tumour 





231 cell lines (Figure 3.5), we aimed to assess the effect of the ectopic up-regulation and 
down-regulation of miR-200c and miR-203 in breast tumour cell lines in resistance to PAX 
and 5-FU.  
4.2. Material and Methods 
4.2.1. Cell lines and nucleic acid purification 
Cell lines culture and nucleic acid purification was done according to Cell lines and Nucleic 
acid purification from chapter 3, section Material and Methods. 
4.2.2. Ectopic expression and inhibition of miR-200c and miR-203 
Mimetic miRNAs (Pre-miR™ miRNA Precursor hsa-miR-200c-3p # PM11714 and hsa-miR-
203a #PM10152; Life Technologies) and inhibiting miRNAs (Anti-miR™ miRNA Inhibitor 
hsa-miR-200c-3p # AM11714 and hsa-miR-203a-3p # AM10152; Life Technologies) were 
transfected in MDA-MB-231 and MCF-7, respectively. As negative controls we used Pre-
miR™ miRNA Precursor Negative Control #1 (Life Technologies # AM17110) and Anti-
miR™ miRNA Inhibitor Negative Control #1 (Life Technologies # AM17010). These 
negatives controls are oligonucleotides similar to miRNA precursors and miRNA inhibitors 
but without biological effect. The transfection agent used was FuGENE HD transfection 
reagent (Promega # E2311). Pre-miR™ miRNA Precursor with respective negative control 
was used in a concentration of 30 nM and Anti-miR™ miRNA Inhibitor with respective 
negative control was used in a concentration of 50 nM. The transfection agent was used in 
a concentration of 0.3% (v/v). The transfection complex (oligo + transfection agent) was 
prepared in DMEM without any supplementation and incubated at room temperature for 
15 minutes. After this time, the transfection complex was added to the cells that already 






4.2.3. Cell viability assay (MTT) 
Approximately 3000 cells were cultured in complete medium in 96-well plates. The cells 
were allowed to grow for 24 h and then transfected as stated in 4.2.2. After 24 h of 
transfection, cells were exposed to different concentrations of paclitaxel (PAX; Sigma-
Aldrich # T7402)  (dissolved in DMSO, not exceeding 0.1%, in concentrations of 0, 10, 100, 
250, 500, 750, 1000 and 1250 nM for 72 h) and 5-Fluorouracil (5-FU; Sigma-Aldrich # 
F6627) (dissolved in DMSO, not exceeding 0.1%, in concentrations of 0, 5, 10, 20, 40, 80, 
160, 200 and 250 µM for 72 h). DMSO at 0.1% (v/v) was added to the wells without 
chemical (control cultures). After 72 h, the medium was removed and thiazolyl blue 
tetrazolium bromide (MTT; Sigma-Aldrich # M5655) dissolved in culture medium was 
added to each well at a concentration of 0.5 mg/ml. Cells were then incubated for 3 h and 
the MTT discarded. Next, 200 µl of DMSO was added to each well to dissolve the formazan 
crystals. Absorbance was read at 595 nm in a Zenyth 3100 microplate reader. Absorbance 
values presented by control cultures correspond to 100% cell viability. At least three 
independent experiments were performed. 
 
4.2.4. Reverse transcription qPCR 
Reverse transcription qPCR was done by using Universal cDNA synthesis kit II (Exiqon # 
203301) and ExiLENT SYBR® Green master mix (Exiqon # 203403).  This methodology 
was performed to detect miR-200c and miR-203 expression levels in MCF-7 and MDA-MB-
231 cell lines after ectopic inhibition or over-expression of the miR-200c and miR-203. 
The methodology was done as stated in 3.2.3. The real-time PCR was performed in ABI 
7300 real time PCR instrument with the following conditions: polymerase activation at 95 







4.2.5. Statistical analysis 
Data were analysed with GraphPad Prism 5 software, using one-way ANOVA with Dunn’s 
multiple comparison post hoc test and two-way ANOVA with Bonferroni multiple 
comparison post hoc test with confidence intervals of 95%. All graphs were made with 
GraphPad Prism 5 software and values represented are mean expression ± standard 
deviation. 
4.3. Results 
Ectopic expression or inhibition of miR-200c and miR-203 in human breast cell lines 
does not affect drug resistance 
In order to confirm if miR-200c and miR-203 influence PAX and 5-FU resistance in MCF-7 
and MDA-MB-231 cell lines, we performed a transfection on both cell lines with anti-
miRNAs (200c and 203) and pre-miRNAs (200c and 203), respectively. By itself, the 
transfection conditions do not affect cell viability when compared with the negative 
control that was transfected with an oligonucleotide with similar properties of anti-
miRNAs and pre-miRNAs but does not have a biological effect (Figure 4.1). In fact, cell 
viability remains practically the same after 24 h of transfection and 72 h of normal 
growing conditions in both cell lines. Subsequently, we tested the effect of PAX and 5-FU. 
Thus, after 24 h of transfection, cell lines were incubated with PAX and 5-FU for 72 h and 
then cell viability tested using MTT assay. As showed in Figure 4.2 and Figure 4.3, we do 
not detect any significant difference with the transfection of anti-miRNAs and pre-miRNAs. 
However some aspects need to be considered in what regards PAX (Figure 4.2). Although 
not statistically different, we can observe that MCF-7 cell line transfected with anti-miR-
200c has 50% cell viability at a lower dose of PAX then the other two conditions. While 
MCF-7 plus anti-miR-200c has 50% viability at approximately 500 nM of PAX, MCF-7 plus 
anti-miR-203 and negative control have 50% viability at approximately 1000 nM. In MDA-
MB-231 cell line we observe the same pattern, although, cells were transfected with pre-





viability at approximately 500 nM of PAX while transfection with negative control has 
50% viability at 750 nM. When MDA-MB-231 was transfected with pre-miR-203 it does 
not reach the 50% viability, even at the higher dose of 1250 nM. In Figure 4.4 we show the 
expression of miR-200c and miR-203 after transfection with inhibitory (anti-miR-200c 
and anti-miR-203) and precursor (pre-miR-200c and pre-miR-203) miRNAs. These graphs 
prove an effective transfection of MCF-7 and MDA-MB-231 cell lines. 
 
Figure 4.1 – Cell viability after ectopic inhibition of miR-200c and miR-203 in MCF-7 
cell line and ectopic over-expression of miR-200c and miR-203 in MDA-MB-231. 
Values represent mean values of three independent experiments ± standard deviation. 
There were no significant differences between negative control and inhibition or over-








Figure 4.2 - Cell viability after ectopic inhibition of miR-200c and miR-203 in MCF-7 
cell line and ectopic over-expression of miR-200c and miR-203 in MDA-MB-231 with 
Paclitaxel treatment. Cells were treated with Paclitaxel at concentrations of 0, 10, 100, 
250, 500, 750, 1000 and 1250 nM for 72 h. Values represent mean values of five 
independent experiments ± standard deviation. There were no significant differences 
between negative control and inhibition or over-expression of miR-200c and miR-203 in 






Figure 4.3 - Cell viability after ectopic inhibition of miR-200c and miR-203 in MCF-7 
cell line and ectopic over-expression of miR-200c and miR-203 in MDA-MB-231 with 
5-FU treatment. Cells were treated with 5-fluorouracil at concentrations of 0, 5, 10, 20, 
40, 80, 160, 200 and 250 µM for 72 h. Values represent mean values of five independent 
experiments ± standard deviation. There were no significant differences between negative 














Figure 4.4 – Expression of miR-200c and miR-203. Inhibition was done through anti-
miRNAs transfection (a) and insertion was done through pre-miRNAs transfection (b) 




Cancer drug resistance still a burden worldwide and a reason for cancer recurrence and 
ultimately, death. In spite of the numerous progresses made in the last decades in what 
regards cancer drug resistance knowledge, many other aspects still await discover. In fact, 
a comprehensive knowledge of cancer drug resistance can lead to a more effective 
personalized therapy and consequently better outcomes for cancer patients. MiRNAs have 
been pointed out as regulators of drug resistance, thus many studies have been published 
in the last few years (Table 1.1). MiR-200c and miR-203 are two tumour suppressor 
miRNAs widely studied as modulators of drug resistance. However, there are few reports 





broadly used in breast cancer, manly in more advanced and aggressive types of breast 
cancer. Thus, we decided to study the effect of these miRNAs in breast cancer cell lines 
MCF-7 and MDA-MB-231. Through exploratory data, we observed that miR-200c and miR-
203 are expressed in MCF-7 cells but not in MDA-MB-231, a more aggressive type of 
breast cancer cell line. Thus, we decided to inhibit these miRNAs in MCF-7 cells and 
ectopically express both miRNAs in MDA-MB-231 cells. Transfection with anti-miRNAs 
and pre-miRNAs, respectively, per se does affect viability in cell lines. Consequently, any 
differences found after treatment with a drug would be indicative that these miRNAs could 
be the reason for such differences. Under this assumption, we treated both cell lines with 
several concentrations of PAX and 5-FU. Interesting results were obtained regarding 
treatment with PAX. According to our data miR-200c has different roles in the resistance 
of PAX in MCF-7 and MDA-MB-231. While in MCF-7 cells the inhibition of miR-200c 
confers sensitivity to PAX, in MDA-MB-231 the insertion of miR-200c also confers 
sensitivity to PAX. In fact, comparing MCF-7 negative control treated cells with MCF-7 
miR-200c inhibited cells, the 50% survival concentration in inhibited cells is half (500 nM) 
of that showed by the negative control (1000 nM). Although there were no published 
results regarding miR-200c, PAX and breast cancer, the results obtained with MCF-7 cells 
are contrary to those published in other types of cancer. In particular, in ovarian cancer 
was demonstrated that restoration of miR-200c not only decreased tumour growth but 
also significantly enhanced the response to PAX (Brozovic et al., 2015; Cittelly et al., 2012). 
Furthermore, the study also suggested that restoration of miR-200c immediately before 
treatment with PAX could enhance the therapy and that miR-200c could be given 
concomitantly with paclitaxel as second-line therapy upon relapse (Cittelly et al., 2012). 
Similarly, a study published interesting data showing that patients with ovarian cancer 
that do not achieve a complete clinical response to PAX had much lower levels of miR-
200c than those that had complete clinical response (Leskela et al., 2011). The results 





insertion of miR-200c also reduced the concentration (500 nM) of PAX needed to achieve 
50% of cell viability. 
Regarding our miR-203 results there are also differences between both cell lines treated 
with PAX. While in MCF-7 cells, where miR-203 expression was supressed, we did not 
obtain any difference when compared to the negative control; in MDA-MB-231 cells, 
where miR-203 expression was ectopically increased, we observed an increased 
resistance to PAX. Regarding miR-203, the only study to our knowledge reports that miR-
203 ectopic expression in colon cancer cell lines chemosensitize cells to PAX (Li et al., 
2011a).  
We highlight the fact that to date there is no data regarding these miRNAs effect in 
resistance to PAX in breast cancer. These contradictory results obtained from two 
different breast cancer cell lines lead us to conclude that miR-200c and miR-203 are 
regulating different targets and consequently affecting different pathways depending on 
the aggressiveness of the cell line. Since PAX promotes the assembly of microtubules and 
reduces the concentration of tubulin subunits necessary for polymerization into 
microtubules, we hypothesize that these miRNAs target genes that exacerbate (MDA-MB-
231) or inhibit (MCF-7) microtubules polymerization in the presence of PAX, protecting it 
from the disassembly. Thus, cells entering mitosis produce abnormal spindles that lead to 
a long-term mitotic arrest and division of their chromosomes in multiple directions. This 
leads to aneuploidy and consequently cell death, presumably due to loss of essential 
chromosomes (Weaver, 2014). Therefore, we intend to study possible targets of these 
miRNAs involved in mitotic spindle formation and associate that with PAX resistance. 
Regarding 5-FU, we did not obtain any differences after inhibition or ectopic expression of 
miR-200c and miR-203. Although not expected, this might be due to the mechanism of 
action of 5-FU. 5-FU is an analogue of uracil with a fluorine atom in place of hydrogen that 





monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP)). These active metabolites disrupt RNA and DNA synthesis and the 
action of Thymidylate synthase (TS) (Longley et al., 2003). This mode of action might 
explain the sharp drop of cell viability at low 5-FU doses. Perhaps assessment of longer 
incubation periods could allow us to observe different outcomes of cell viability. In fact, 
due to the fact that these cell lines have their doubling time between 24 and 35 hours, the 
time of drug treatment, 72 hours, could be insufficient. Thus, in the future longer periods 
of treatment must be used. This approach has not been done yet because of technical 
problems in respect to miRNAs transfection. In our transfection technique optimization, 
72 hours was the longest time period that can assure reproducible results with transfected 
cell lines (data not showed). 
In conclusion, miR-200c seems to have contrary effects in MCF-7 cell line and MDA-MB-
231 and miR-203 seem to augment resistance to PAX in MDA-MB-231 cell line. Both 













5. Analysis of miR-200c and miR-203 expression 
levels, and their putative targets in human breast 
cancer tissues 
 
Part of the results and techniques presented in this chapter were published in:  
 Gomes, B.C., Santos, B., Rueff, J., and Rodrigues, A. S. (2016). Methods for Studying 
MicroRNA Expression and Their Targets in Formalin-Fixed, Paraffin-Embedded 
(FFPE) Breast Cancer Tissues.  Methods Mol Biol 1395, 189-205. 
 Gomes, B.C., Martins, M., Lopes, L., Morujão, I., Oliveira, M., Araújo, A., Rueff, J., and 
Rodrigues, A. S. (2016) Prognostic importance of microRNA-203 expression in 
breast cancer. Oncology Reports. In Press 
Or are submitted and under revision: 
 Gomes, B.C., Santos, B., Martins, M., Lopes, L., Morujão, I., Oliveira, M., Araújo, A., 
Rueff, J., and Rodrigues, A. S. (2016) Immunohistochemistry detection of Six1 and 
Sox2 in a Portuguese breast cancer patient cohort. Submitted to BMC Cancer. 
 
5.1. State of the art 
Breast cancer (BC) is still a worldwide burden with an estimated incidence of more than 
1.5 million new cases and approximately half a million deaths per year (Torre et al., 2015). 
Due to early detection, improvement in treatment options and changes in life style 
paradigms, mortality rates have been decreasing in developed countries. Conversely, 
developing countries are witnessing an increase in BC incidence and mortality rates, most 
probably due to weak awareness campaigns and changes in daily habits such as sedentary 
lifestyle, high consumption of sugars and fat that lead to overweight and obesity, known 
risk factors of BC (Torre et al., 2015). Moreover the proportion of cases diagnosed in less 
developed countries is meagre when compared to developed regions thus leading to 





Although the molecular mechanisms that underlie the development of breast cancer are 
being boldly investigated, our current knowledge is far from complete. BC is a 
heterogeneous malignancy and clinical diagnosis and prescribed therapy still reliy 
primarily on the TNM staging system based on tumour (T), node status (N) and metastasis 
(M). Oestrogen and progesterone receptor status, human epidermal growth factor 
receptor 2 (HER2/neu) status and the Ki-67 proliferative index, besides tumour-
infiltrating lymphocytes, as well as the age of the patient, are used to classify BC into 
various subtypes (Badve et al., 2011; De Abreu et al., 2014; Gyorffy et al., 2015). 
Nonetheless, these conventional breast cancer prognostic factors have intrinsic 
limitations, and their use does not allow an accurate prediction of treatment resistance or 
relapse. Defining new molecular prognostic factors to refine BC classification could be 
useful in improving the therapeutic schemes.  
Recently, various miRNAs have been characterized and identified as regulators and/or 
biomarkers in breast cancer development, including initiation, metastasis, and therapy 
resistance (Chen et al., 2008; Cheng et al., 2015; He et al., 2005; Ma et al., 2010a; 
Takamizawa et al., 2004; Vasudevan et al., 2007).  Due to their size, miRNAs are stable in 
human samples and can easily be used as molecular signatures in cancer (Andreasen et al., 
2010; Azam et al., 2015; Graveel et al., 2015; Hui et al., 2011; Sadeghian et al., 2015; Wang 
et al., 2014). Their targets although not so easily detected are nonetheless good tools to 
develop molecular signatures in cancer. 
MiR-203 was originally described as a keratinocyte-specific miRNA (Sonkoly et al., 2007) 
but was soon shown to play an important role in bladder cancer (Gottardo et al., 2007). It 
was also shown that is epigenetically silenced in hematopoietic cancers (Bueno et al., 
2008). Several studies have shown an association of miR-203 and chemotherapeutic 
resistance to cisplatin (Ru et al., 2011), invasiveness (Chen et al., 2015; Zhang et al., 2011), 
proliferation (Chen et al., 2015; Hailer et al., 2014; Wang et al., 2012a; Yu et al., 2012), 





al., 2015; Madhavan et al., 2012). Some miR-203 targets have been identified, such as 
SNAI2, SOCS3, BIRC5 and LASP1 (Chang et al., 2015; Chen et al., 2015; Ru et al., 2011; Wang 
et al., 2012a; Zhang et al., 2011), but a complete picture of the expression of miR-203 in 
different cohorts of BC, its mechanisms of action and the circuitry of its effects still 
remains by and large to be fully clarified. Recently, it was also shown that miR-203 directly 
binds to ATM (Zhou et al., 2014). ATM, encodes a serine/threonine kinase, a member of 
the phosphoinositide 3-kinase (PI3-kinase)-like family (PIKK), that is activated in 
response to double strand DNA breaks damage and is responsible for maintaining the 
stability of the genome by phosphorylation and activation of several downstream targets 
(e.g. H2AX, CHK2, BRCA1, p53 and MDC1) known to be implicated in cancer [for further 
reading see a very recent and complete review (Guleria and Chandna, 2016)].  
MiR-200c belongs to miR-200 family, a known family of miRNAs with tumour suppressor 
activity by inhibiting EMT by binding to ZEB1 and ZEB2 (Gregory et al., 2008; Wellner et 
al., 2009). However, many other putative targets can be found in on-line databases 
specialized in in silico detection of miRNAs targets (e.g. TargetScan v7.0 (Agarwal et al., 
2015)). Sine Oculis Homeobox Homolog 1 (SIX1) is one of the putative targets described. It 
has been described as involved in the development of many tissues and organs, and its 
levels vary, throughout developmental stages from embryo to adulthood (Wu et al., 
2015b). In adult life and health conditions, SIX1 is not expressed in somatic cells. However, 
some authors showed that gene amplification of SIX1 can increase BC risk (Reichenberger 
et al., 2005) and induce tumour cells to undergo EMT (Micalizzi et al., 2009), indeed a 
feedback loop between miR-204-5p and SIX1 promotes EMT in BC (Zeng et al., 2015). 
Recently, it was also described that SIX1 expression can be regulated by miR-185 (Imam et 
al., 2010), thus suppressing tumour growth and progression. Another putative target of 
miR-200c is SRY (Sex Determining Region Y)-Box 2 (SOX2). This is a transcription 
regulator that controls pluripotency and self-renewal in embryonic stem cells by 





Transcription Factor Nanog (NANOG), forming a protein complex that binds the 
promoters of numerous stem cell differentiation factors, suppressing their expression 
(Zhang and Cui, 2014). A meta analyses done by Li and colleagues showed that SOX2 is a 
good prognostic factor for head and neck cancer (Li et al., 2014) and non-small cell lung 
cancer (Chen et al., 2013a). Some studies showed that SOX2 has some relevance in 
promoting metastatic potential in breast cancer (Huang et al., 2014; Lengerke et al., 2011). 
Functional studies also support a pivotal role of miR-200c in regulating self-renewal of 
mammary stem cells through a direct targeting of B cell-specific Moloney murine leukemia 
virus integration site 1 (BMI1) (Shimono et al., 2009b). BMI1 was identified as a proto-
oncogene cooperating with c-Myc during the initiation of lymphomas. It has subsequently 
been identified as a transcriptional repressor belonging to the polycomb group (PcG) 
proteins, and is also a key factor in the polycomb repressor complex 1 (PRC1), which 
serves as an important epigenetic regulatory complex for modulation of chromatin 
remodelling. Over-expression of BMI1 has been found in a large number of human cancers, 
including breast cancer, which indicates that BMI1 might play important roles in cancer 
initiation and progression (Benetatos et al., 2014). BMI1 is also a putative target of miR-
203, however there are no functional studies showing their association. 
With the aim of contributing to a better understanding of the role of miR-203a and miR-
200c in breast cancer, we assessed here miR-203a and miR-200c expression and 
clinicopathological features in a Portuguese population with breast carcinoma. Since these 
two miRNAs have 4 targets (putative or/and proven with few studies done so far) we also 
aimed to study the expression of SIX1, SOX2, ATM and BMI1 in breast cancer samples by 
immunohistochemistry and correlate their expression with expression levels of their 





5.2. Material and methods 
5.2.1. Human FFPE samples collection  
Patients with breast carcinoma were recruited for the study at the Hospital de São José, 
from Centro Hospitalar de Lisboa Central, during 2013 and 2014. Each patient signed a 
written informed consent form and this study was reviewed and approved by the Ethical 
Committees of the NOVA Medical School and of the Centro Hospitalar de Lisboa Central. 
All clinical information was gathered by trained and specialized clinicians. All samples 
were originated from surgical sections (mastectomy or tumorectomy). A total of 109 
formalin-fixed paraffin-embedded (FFPE) paired normal and tumour tissue samples were 
collected. Normal tissue was adjacent to the tumour and in all cases was confirmed by the 
pathologist team as being only normal mammary tissue. Diagnosis and common 
immunohistochemical markers for breast cancer classification such as oestrogen and 
progesterone receptor (ER and PR), HER2 amplification status and Ki-67 proliferative 
index were evaluated by 2 highly trained and independent pathologists. Staging was done 
by tumour (T), node (N) and metastasis (M) classification (Singletary et al., 2002). 
Procedure for immunohistochemical detection was done according to the 
recommendations of the American Society of Clinical Oncology/College of American 
Pathologists (ASCO/CAP) guidelines (Hammond et al., 2010; Wolff et al., 2013) and the 
International Ki67 in Breast Cancer Working Group (Dowsett et al., 2011) at the time of 
sample collection. With the existing canons at the time, the molecular classification of 
breast tumours was as follows: Luminal A - ER or PR positive and Ki67 <13%; Luminal B - 
ER or PR positive and Ki67 ≥13%; HER2 positive - ER and PR negative, HER2 positive; 
Triple negative – ER, PR and HER2 negative. 
5.2.2. Total RNA purification from FFPE breast tissues 
Total RNA was purified from FFPE tissues using RecoverAll™ Total Nucleic Acid Isolation 
Kit (Ambion® # AM1975) and according to the manufacturer’s protocol with slight 





(eight slices of 10 μm) and heated for 3 minutes at 50 °C to melt the paraffin. The samples 
where then centrifuged for 2 minutes at room temperature at 14,000 rpm to pellet the 
tissue. The xylene was discarded without disturbing the pellet and two successive washes 
with 1 ml of 100% ethanol were done. The samples where centrifuged for 3 minutes at 
14,000 rpm. Any remaining drops of ethanol were removed and let to air dry for 30 
minutes at room temperature. Next, 200 µl of digestion buffer and 4 µl of protease, both 
provided with the kit, were added in each sample. The samples were then homogenized 
and macerated with a pestle and incubate for 15 minutes at 50 °C and next an extra 15 
minutes at 80 °C. An additive (from the kit)/ethanol mixture (240 µl/550 µl) was added to 
the mixtures and mixed by pipetting. Then, up to 700 µL of the mixture was added to a 
filter cartridge and centrifuged at 10,000 ⨯ g for 30 seconds. The flow-through was 
discarded and the process repeated until all the mixture had passed through the filter. 
Successive washes with 700 μl of wash 1 buffer (from the kit) and 500 μl of wash 2/3 
buffer (from the kit) were done and centrifuged at 10,000 ⨯ g for 30 seconds. After 
discarding the flow-through, 60 μl of DNase mix was added to the center of each filter 
cartridge and left to incubate for 30 minutes at room temperature. Again, successive 
washes with wash 1 buffer and wash 2/3 buffer were done and centrifuged at 10,000 ⨯ g 
for 30 seconds. Finally, 60 μl of nuclease-free water was added to each filter cartridge, 
incubated for 60 seconds at room temperature and centrifuged at full speed for 60 
seconds. Total RNA containing miRNAs was then stored at -80 °C until further use. 
5.2.3. Reverse transcription qPCR 
Reverse transcription qPCR was done by using Universal cDNA synthesis kit II (Exiqon # 
203301) and ExiLENT SYBR® Green master mix (Exiqon # 203403).  This methodology 
was performed to detect miR-200c and miR-203 expression levels in human cancer breast 
tissues and their counterpart adjacent normal tissues. 
First of all, a dilution of purified total RNAs to a concentration of 5 ng/μl in nuclease-free 





reaction mix was then prepared by mixing 4 μl of 5⨯ Reaction buffer, 10 μl of nuclease-
free water, 2 μl of enzyme mix and 4 μl of template RNA at 1 ng/μl. This mixture was 
incubated at 42 °C for 60 minutes, followed by an enzyme inactivation for 5 minutes at 95 
°C and immediately cooled to 4 °C. The cDNA was then stored at -20 °C until further use. In 
order to proceed to real-time PCR, cDNA previously synthesized was diluted 80⨯. Then, a 
PCR master mix was done by mixing 5 μl of SYBR® Green master mix, 1 μl of PCR primer 
mix, 4 μl of diluted cDNA template and 0.2 μl of ROX passive reference dye (Bio-Rad # 
1725858) to a total volume of 10.2 μl. The mixture was loaded into a 96-well PCR plate 
and then the real-time PCR was performed in ABI 7300 real time PCR instrument with the 
following conditions: polymerase activation at 95 °C for 10 minutes; 40 cycles of 
amplification at 95 °C for 10 seconds and 60 °C for 1 minute. The primers used were: hsa-
miR-203a (Exiqon, LNA™ PCR primer set # 204285); hsa-miR-200c-3p (Exiqon, LNA™ PCR 
primer set # 204482) and as endogenous control U6 snRNA (Exiqon, PCR primer set # 
203907). 
Relative expression of miRNAs in each FFPE sample was determined by 2-ΔCt, where ΔCt is 
Ct (miR-203a) - median Ct (U6 snRNA). Fold change was determined by 2-ΔΔCt, where ΔΔCt 
is ΔCt (tumor) – ΔCt (normal).  All samples were analysed in duplicate.  
5.2.4. Immunohistochemistry 
Serial 2-3μm paraffin sections of 44 FFPE breast cancer samples were cut onto 
Superfrost® Plus slides (Thermo Scientific, # J1800AMNZ). For proper adhesion, sections 
were left overnight at 37 °C and then put in microwave for 2 minutes at full potency. Then, 
they were deparaffinised in Xylene, and rehydrated in decreasing concentrations of 
ethanol (100%, 96% and 70%). Antigen retrieval was achieved in microwave at 80% for 
20 minutes with Tris-EDTA Buffer (10 mM Trizma.base, 1 mM EDTA solution with 0.05% 
Tween 20, pH 9.0), and endogenous peroxidase activity blocked with 3% hydrogen 
peroxide. Protein block was performed with ready-to-use (2.5 %) normal horse blocking 





incubated at room temperature with the following antibodies: Anti-ATM, rabbit, 
monoclonal, clone Y170 (Millipore # 04-200); Anti-BMI1, mouse, monoclonal, clone 229F6 
(Nordic-MUbio # MUB2004S); Anti-BMI1, mouse, monoclonal, clone 10H8 (Cell 
Applications # CB16351); Anti-SIX1, rabbit, polyclonal (Sigma-Aldrich # HPA001893); 
Anti-SIX1, mouse, monoclonal, clone CL0185 (Sigma-Aldrich # AMAb90544); Anti-SOX2, 
rabbit, polyclonal (Sigma-Aldrich # S9072); and Anti-SOX2, mouse, monoclonal, clone 
10F10 (Sigma-Aldrich # SAB5300177). Antibodies were diluted in phosphate buffer saline 
(PBS) (137mM NaCl, 2,7mM KCl, 10mM Na2HPO4, 1,8mM KH2PO4, pH 7.4) with 0.05% 
Tween 20. Bound antibody was visualized using ready-to-use ImmPRESS™ anti-mouse Ig 
detection kit (Vector Laboratories # MP-7402) for 30 minutes  and next to two successive 
washes with PBS with 0.05% Tween 20 the slides were incubated with 3,3’-
diaminobenzidine (DAB, Invitrogen # 88-2014) for 5 minutes and then washed in running 
water for 2 minutes. Subsequently, slides were counterstained with Mayer’s Hematoxylin 
(Sigma-Aldrich # MHS80) for 2 minutes, followed by wash in running water for 5 minutes. 
Dehydrate through increasing concentrations of ethanol (70%, 96%, 100%) clarified in 
xylene and mounted with Entellan® (Merck # 1.07961.0500). As positive controls we 
used normal breast tissue for ATM and BMI1, normal cervix for SIX1, and normal tonsil for 
SOX2. 
All slides were further evaluated by 3 observers that used the same criteria, previously 
validated by a pathologist. Sections were evaluated in its totality and positivity was 
considered when 10% or more of tumour cells stained specifically with a moderate to 
strong intensity. After an initial independent observation, all results were reviewed in 
group and a final result assigned to each case by consensus. Slide evaluation was blind to 
tumour characteristics and other clinical data. Subsquently images were captured at the 
Pathology Department of Egas Moniz Hospital with a Leica DFC320 digital camera coupled 





5.2.5. Statistical analysis 
All statistical analyses were performed using the SPSS statistical software package version 
21.0 (SPSS Inc., Chicago, IL, USA). Non-parametric Wilcoxon signed-rank test was used to 
analyse the differences between matched samples (normal vs. tumour tissues). The Mann–
Whitney U test and Kruskal-Wallis test were used to analyse the differences of miR-203a 
and miR-200c expression levels in the tumour tissue according to clinicopathological 
characteristics. For nominal variables, the relationships between clinicopathological 
characteristics and miR-203a and miR-200c status were studied using the chi-square test 
and Fisher’s exact test. The Mann–Whitney U test was used to analyse the differences of 
miR-200c expression levels in the tumour tissue according to SIX1 and SOX2 status. The 
relationships between clinicopathological features and SIX1 and SOX2 status were studied 
using the chi-square test and Fisher’s exact test. All graphs were made with GraphPad 
Prism 5 software.  
5.3. Results 
Study population 
Breast tumour tissue and adjacent normal mammary tissue was collected from 109 
patients. The study population comprised only Caucasian woman from the area of Lisbon 
and on the day of diagnosis the median age was 62 years (range: 30 – 85). The median age 
of menarche and menopause was 13 years (range: 8 – 17) and 50 years (range: 36 – 59), 
respectively, and approximately 66% of the population was diagnosed with breast 
carcinoma in post menopause status. Seventy seven percent of the women had one or 
more pregnancies and around 73% had one or more children. Forty five percent claim to 
have taken birth control pills. Around 50% were overweight or obese. Regarding general 
tumour characteristics, the median size was 18.5 mm (range: 6 – 130), about 51% showed 
no invasion of the lymph nodes, approximately 80% were ER positive, 72.5% were PR 





proliferation index. The most common histological type was Invasive Carcinoma NOS 
(83.5% of the cases), followed by invasive lobular carcinoma (9.2%), ductal carcinoma in 
situ (6.4%) and invasive lobular and ductal carcinoma (0.9%). The most common 
molecular subtype was Luminal A (47.4% of all cases). Luminal B represented about 40% 
of the remaining cases. Triple negative subtype represented approximately 12% of the 
cases. The most frequent stage was II (46.8%) followed by I (37.6%) and III (8.3%). Of all 
patients, 69.2% had radiotherapy, 43% had chemotherapy (of which 38.7% took 
doxorubicin + cyclophosphamide, 39.6% docetaxel, 2.8% fluorouracil + epirubicin + 
cyclophosphamide and 0.9% cyclophosphamide + methotrexate + fluorouracil and 12.3% 
took trastuzumab), 87.9% had hormonotherapy (of which 42.1% took tamoxifen, 29.9% 
took anastrazole,  13.1% took letrozole and 3.7% took exemestane). Only 5.6% had 
disease recurrence (0.9% local, 0.9% local and metastasis, 3.7% metastasis) and 3.8% 
died. 
All this data, together and with the stratification of some variables, is displayed in Table 
5.1, Table 5.2 and Table 5.3. 
MiR-203a is overexpressed in tumour tissue compared to normal tissue 
Analysing the levels of miR-200c and miR-203a, we detected a significant overexpression 
of miR-203a in tumour tissue (1.7 fold higher) compared to normal adjacent tissue from 
the 109 patients (p = 0.003; Wilcoxon signed-rank test to matched samples) (Table 5.1; 
Figure 5.1). Regarding miR-200c, we did not detect significant differences between normal 










Table 5.1 - Association of miR-203a and miR-200c relative expression with clinical characteristics. p value < 0.05 was considered significant 
according to Non-parametric Wilcoxon signed-rank test. 
      Median relative expression of miR-200c Median relative expression of miR-203 















No. of cases 109 
 
8.76 10.54 1.2 0.202 0.07 0.12 1.7 0.003 
Age at diagnosis, median (range) 62 (30 - 85)                 
30 - 39, N (%) 3 (2.8) 5.04 4.42 0.88 0.285 0.04 0.07 1.75 0.593 
40 - 49, N (%) 17 (15.6) 14.84 10.68 0.72 0.266 0.14 0.13 0.93 0.906 
50 - 59, N (%) 27 (24.8) 10.17 11.15 1.10 0.946 0.14 0.15 1.07 0.657 
> 60, N (%) 54 (49.5) 5.94 9,65 1.62 0.038 0.04 0.11 2.75 0.001 
missing 8 (7.3)                 
Age of menarche, median (range) 13 (8 - 17)                 
≤ 13, N (%) 65 (59.6) 7.82 10.88 1.39 0.320 0.06 0.12 2.00 0.066 
> 13, N (%) 35 (32.1) 9.11 10.33 1.13 0.177 0.06 0.14 2.33 0.003 
missing 9 (8.3)                 
Age of menopause, median (range) 50 (36 - 59)                 
≤ 50, N (%) 44 (52.4) 6.95 11.14 1.60 0.003 0.04 0.14 3.5 < 0.001 
> 50, N (%) 29 (34.5) 5.63 9.35 1.66 0.471 0.05 0.10 2.0 0.539 
missing 11 (13.1)                 
Menopause status, N (%) 
  
                
pre 25 (22.9) 10.89 9.72 0.89 0.130 0.14 0.12 0.86 0.607 
post 72 (66.1) 6.44 10.88 1.69 0.018 0.05 0.11 2.20 0.003 
peri 1 (0.9)                 
missing 11 (10.1)                 
Breastfeeding, N (%) 
  
                
No 32 (29.4) 9.24 10.44 1.13 0.184 0.04 0.11 2.75 0.170 








Table 5.1 (continued) - Association of miR-203a and miR-200c relative expression with clinical characteristics. p value < 0.05 was considered 
significant according to Non-parametric Wilcoxon signed-rank test. 
missing 10 (9.2)                 
No. of pregnancies, N (%)  
  
                
0 15 (13.8) 9.23 9.73 1.05 0.807 0.07 0.15 2.14 0.972 
1 - 2 42 (38.5) 9.70 11.28 1.16 0.368 0.06 0.11 1.83 0.046 
3 - 4 27 (24.8) 7.44 7.86 1.06 0.211 0.08 0.11 1.38 0.416 
> 4 15 (13.8) 5.41 18.59 3.44 0.004 0.04 0.16 4.00 0.001 
missing 10 (9.2)                 
No. of children, N (%) 
  
                
0 21 (19.3) 9.24 10.33 1.12 0.184 0.04 0.12 3.00 0.295 
1 - 2 64 (58.7) 9.11 10.88 1.19 0.549 0.08 0.11 1.38 0.012 
3 - 4 12 (11.0) 9.74 12.13 1.25 0.575 0.08 0.12 1.50 0.657 
> 4 4 (3.7) 5.33 8.68 1.63 0.068 0.03 0.21 7.00 0.068 
missing 8 (7.3)                 
Oral contraceptive, N (%) 
  
                
No 48 (44.0) 5.81 8.90 1.53 0.047 0.04 0.11 2.75 0.130 
Yes 49 (45.0) 9.46 11.1 1.17 0.584 0.08 0.12 1.50 0.004 












Table 5.2 - Association of miR-203a and miR-200c relative expression with life style habits. p value < 0.05 was considered significant according to Non-
parametric Wilcoxon signed-rank test. 
      Median relative expression of miR-200c Median relative expression of miR-203 















Body Mass Index, N (%) 
  
                
Underweight 2 (1.8) 48.02 11.59 0.24 0.180 0.22 0.31 1.41 0.655 
Normal 42 (38.5) 9.58 12.91 1.35 0.060 0.08 0.13 1.63 0.252 
Overweight 30 (27.5) 5.81 8.61 1.48 0.441 0.04 0.11 2.75 0.006 
Obese 23 (21.1) 9.11 11.39 1.25 0.550 0.06 0.11 1.83 0.073 
missing 12 (11.1)                 
Smoking habit, N (%) 
  
                
No 73 (67.0) 6.43 10.43 1.62 0.221 0.05 0.13 2.6 0.001 
Yes 22 (20.2) 9.59 10.75 1.12 0.088 0.09 0.11 1.22 0.465 
missing 14 (12.8)                 
Alcohol habits, N (%) 
  
                
No 54 (49.5) 9.27 9.74 1.05 0.532 0.07 0.13 1.86 0.059 
Sporadically 24 (22.0) 6.80 10.14 1.49 0.568 0.04 0.12 3.00 0.037 
Daily 17 (15.6) 10.89 9.72 0.89 0.130 0.14 0.12 0.86 0.607 












Table 5.3 - Association of miR-203a and miR-200c relative expression with pathological characteristics. p value < 0.05 was considered significant according to 
Non-parametric Wilcoxon signed-rank test. 
   
Median relative expression of miR-200c Median relative expression of miR-203 

















Size of the tumour,  
median mm (range) 
18.5 (6 - 130) 
        
≤ 18.5 mm, N (%) 54 (49.5) 9.11 9,29 1.02 0.843 0.08 0.12 1.50 0.019 
> 18.5 mm, N (%) 54 (49.5) 8.77 10.94 1.25 0.173 0.06 0.12 2.00 0.076 
missing 1 (1.0) 
        
Lymph node invasion, N (%) 
          
No 56 (51.4) 7.95 11.02 1.39 0.459 0.05 0.12 2.40 0.004 
Yes 52 (47.7) 9.10 9.39 1.03 0.315 0.09 0.11 1.22 0.199 
missing 1 (0.9) 
        
Oestrogen receptor status, N (%) 
          
Negative 16 (14.7) 5.78 10.28 1.78 0.221 0.07 0.15 2.14 0.074 
Positive 87 (79.8) 8.78 10.54 1.20 0.476 0.07 0.12 1.71 0.042 
missing 6 (5.5) 
        
Progesterone receptor status, N (%) 
          
Negative 22 (20.2) 7.05 10.28 1.46 0.117 0.04 0.12 3.00 0.091 
Positive 79 (72.5) 8.62 10.54 1.22 0.666 0.08 0.12 1.50 0.046 
missing 8 (7.3) 
        
HER2 status, N (%) 
          
Negative 87 (79.8) 7.05 10.03 1.42 0.450 0.08 0.12 1.50 0.016 
Positive 15 (13.8) 9.74 10.68 1.09 0.433 0.72 0.73 1.01 0.609 
missing 7 (6.4) 
        
Ki67 index status, N (%) 
          








Positive 48 (44.0) 9.10 10.94 1.20 0.218 0.08 0.10 1.25 0.253 
missing 8 (7.3) 
        
Histological type, N (%) 
          
Ductal Carcinoma In Situ 7 (6.4) 9.24 17.86 1.93 0.128 0.05 0.11 2.20 0.028 
Invasive Carcinoma NOS 91 (83.5) 7.82 10.61 1.36 0.230 0.07 0.12 1.71 0.009 
Invasive Lobular Carcinoma 10 (9.2) 14.48 9.29 0.64 0.173 0.13 0.11 0.84 0.575 
Invasive Lobular and Ductal 
Carcinoma 
1 (0.9) 
        
Molecular Type, N (%) 
          
Luminal A 48 (47.5) 6.80 9.29 1.37 0.717 0.07 0.13 1.86 0.054 
Luminal B (HER2-) 27 (26.7) 8.78 10.94 1.25 0.339 0.08 0.11 1.38 0.527 
Luminal B (HER2+) 13 (12.9) 9.43 10.68 1.13 0.239 0.07 0.08 1.14 0.221 
Triple Negative 12 (11.9) 5.46 12.90 2.36 0.203 0.06 0.15 2.50 0.139 
HER2+ 1 (1.0) 
        
Stage, N (%) 
          
0 7 (6.4) 9.24 17.86 1.93 0.128 0.05 0.11 2.20 0.028 
I 41 (37.6) 11.03 9.14 0,83 0.483 0.08 0.12 1.50 0.126 
II 49 (44.9) 6.44 12.13 1.88 0.010 0.06 0.13 2.17 0.009 
III 9 (8.3) 10.52 8.18 0.78 0.260 0.10 0.11 1.10 0.678 
missing 3 (2.8) 









Figure 5.1 - Differences in miR-203a (a) and miR-200c (b) relative expression in 
tumour tissue and adjacent normal tissue. The expression levels are shown in arbitrary 
units determined by 2-ΔCt method [ΔCt = Ct (miRNA) - median Ct (U6 snRNA)]. Lines 
represent median with interquartile range. p value < 0.05 was considered significant 
according to non-parametric Mann-Whitney test. 
 
 
Figure 5.2 – Fold change expression of miR-203 regarding number of pregnancies 







Association between miR-203a expression and reproductive characteristics 
The evaluation of clinical variables (Table 5.1) revealed a significantly different distribution 
of the fold change expression of miR-203a when considering the number of pregnancies 
(Kruskal-Wallis p = 0.006; Figure 5.2a). Specifically, there was a higher fold change 
expression in woman with four or more pregnancies comparing to the other classes (no 
pregnancies vs. >4 – p = 0.01; 1-2 vs. >4 – p = 0.03; 3-4 vs. >4 – p = 0.01; Figure 5.2a). 
Significant differences in age classes were also found (Figure 5.2b). 
Using Wilcoxon signed-rank test to matched samples with the same variables, patients 
with more than 60 years on the day of diagnosis (fold change = 2.75; p = 0.001), menarche 
age over 13 years (fold change = 2.33; p = 0.003) and menopause under 50 years (fold 
change = 3.50; p < 0.001), showed a significant overexpression of miR-203a when 
comparing tumour tissue with normal adjacent tissue. Patients diagnosed in post 
menopause status (fold change = 2.20; p = 0.003) and who had less than 40 years of fertile 
status (< 30 years: fold change = 3.75; p = 0.041; 30-40 years: fold change = 2.40; p = 
0.005) also presented an increased expression of miR-203a in tumour tissues compared to 
adjacent normal tissue. Regarding the number of pregnancies, patients with more than 4 
pregnancies showed a significantly increased expression of miR-203a in tumour tissue 
(fold change = 4.00; p = 0.001). These results are in accordance with the ones described 
above where the Kruskal-Wallis test was applied. In accordance, although not significantly, 
women with more than four children showed an increased expression of miR-203a. 
Patients with first childbirth before 20 years of age also showed an increased expression 
of miR-203a (fold change = 3.40; p = 0.033). Breastfeeding status and oral contraceptive 





Association between miR-200c expression and reproductive characteristics 
Regarding miR-200c, we did not obtain a significantly different distribution of the fold 
change expression with respect to variables in Table 5.1. However, applying Wilcoxon 
signed-rank test to matched samples with the same variables we obtained significant 
differences in patients with more than 60 years on the day of diagnosis (fold change = 
1.62; p = 0.038), menopause under 50 years (fold change = 1.60; p = 0.003), patients 
diagnosed in post menopause status (fold change = 1.69; p = 0.018), with more than 4 
(fold change = 3.44; p = 0.004) and oral contraceptive consumption (fold change = 1.53; p 
= 0.047). 
Association between miR-203a expression and lifestyle characteristics 
It is known that some lifestyle habits can be a risk factor for cancer. In our series we 
included body mass index and smoking and alcohol habits. Over-weighted patients 
showed an increase of miR-203a expression in tumour tissues (fold change = 2.75; p = 
0.006) and those who do not smoke (fold change = 2.60; p = 0.001) or sporadically drink 
(fold change = 3.00; p = 0.037) also showed an increased expression of miR-203a (Table 
5.2). We did not obtain significant results regarding miR-200c and lifestyle characteristics. 
Association between miR-203a expression and clinicopathological characteristics 
Several clinicopathological characteristics showed an association with miR-203a 
expression (Table 5.3). Tumours with diameter smaller or equal to 18.5 mm, showed 
significant difference, albeit with a slight fold change of 1.5 compared with adjacent 
normal tissue (p = 0.019), together with tumours positive for ER (fold change = 1.71; p = 
0.042), PR (fold change = 1.50; p = 0.046), negative for HER2 (fold change = 1.50; p = 
0.016) and Ki-67 index (fold change = 2.60; p = 0.024). Tumours that do not invade lymph 
nodes also presented higher expression of miR-203a (fold change = 2.40; p = 0.004). With 
regard to histological classification, ductal carcinomas in situ (fold change = 2.20; p = 





higher expression of miR-203a. Stage 0 and II also showed significant increased 
expression (fold change = 2.20; p = 0.028; fold change = 2.17; p = .009, respectively). When 
considering only invasive lobular tumours significant differences were found in staging, 
mainly when comparing stage III with stage I (Figure 5.3). 
 
Figure 5.3 - Fold change expression of miR-203 regarding number of pregnancies (a) and age at 
diagnostics (b). p value < 0.05 was considered significant according to non-parametric Kruskal-
Wallis. 
Immunohistochemistry optimization 
Due to a nonexistence of accurate protocols regarding ATM, BMI1, SIX1 and SOX2 
immunohistochemistry and in order to proceed with breast tumour samples 
characterization of these proteins it would be necessary to optimize all antibodies. Of the 
antibodies mentioned in the Material and Methods section, only Anti-SIX1, mouse, 
monoclonal, clone CL0185 (Sigma-Aldrich # AMAb90544) and Anti-SOX2, mouse, 
monoclonal, clone 10F10 (Sigma-Aldrich # SAB5300177) performed properly and with 
reproducible results. Regarding ATM antibodies, both revealed wrong stained structures. 
Mouse BMI1, monoclonal, clone 229F6 (Nordic-MUbio # MUB2004S) showed lack of 
staining; BMI1 mouse, monoclonal (Cell Applications # CB16351) showed  excessive 
staining; SIX1 rabbit, polyclonal (Sigma-Aldrich # HPA001893) showed unspecific 
staining; and finally, SOX2 rabbit, polyclonal (Sigma-Aldrich # S9072) showed excessive 






Figure 5.4 – Slide captures of SIX1 (a), SOX2 (b), ATM (c), and BMI1 (d). (a) – optimal 
staining of SIX1, only the nuclei of glandular epithelium of normal cervix is stained (20⨯). 
(b) – optimal staining of SOX2, only nuclei of stratified epithelium of normal tonsil is 
stained (20⨯). (c) – wrong structures stained by ATM antibodies, nuclei of normal breast 
glandular epithelium should be marked, however appears in blue. Only neutrophils appear 
to be stained in cytoplasm (20⨯). (d) – Excessive staining of BMI1 in slides with normal 
breast tissue. All structures appear to be stained, even at an antibody dilution of 1/1500, 
clearly indicating its unspecificity (20⨯). 
Six1 and Sox2 do not correlate with miR-200c and clinicopathological features 
Due to the fact that not all antibodies seemed to achieve a good staining, it was not 
possible to correlate ATM with miR-203 and BMI1 with miR-203 and miR-200c. Thus, we 
only report results regarding SIX1, SOX2 and their correlation with miR-200c and 
clinicopathological features. 
A total of 44 samples from 43 patients were analysed concerning SIX1 and SOX2 through 
IHC. Of that, 13.6% showed positive staining for SIX1 and 9.1% for SOX2 (Figure 5.5 and 





expression in the clinicopathological features. No statistical significance was reached with 
χ2 test. Association between SIX1 and SOX2 expression and miR-200c expression was not 
also verified.  
 
Figure 5.5 - Slide captures of SIX1 (a, b, c) and SOX2 (d, e). (a) - SIX1 positive invasive 
lobular carcinoma (40⨯). (b) – SIX1 positive invasive carcinoma NOS (20⨯). (c) - SIX1 
negative invasive carcinoma NOS (20⨯). (d) - SOX2 positive invasive carcinoma NOS 







Table 5.4 – Distribution of SIX1 and SOX2 expression in a Portuguese breast cancer 
population and their clinicopathological features. No statistical differences within each 
feature, thus, p values are not shown. 
  Six1 Sox2 
 Total* Negative Positive Negative Positive 
Total Population, N (%) 44 38 (86.4) 6 (13.6) 40 (90.9) 4 (9.1) 
Tumor Size, N (%) 
     
≤ 18.5 mm 25 (56.8) 24 (54.5) 1 (2.3) 23 (52.3) 2 (4.5) 
> 18.5 mm 19 (43.2) 14 (31.8) 5 (11.4) 17 (38.6) 2 (4.5) 
Histological Type, N (%) 
     
Ductal Carcinoma In Situ 2 (4.5) 2 (4.5) 0 2 (4.5) 0 
Invasive Carcinoma NOS 38 (86.4) 33 (75.0) 5 (11.4) 34 (77.3) 4 (9.1) 
Invasive Lobular Carcinoma 4 (9.1) 3 (6.8) 1 (2.3) 4 (9.1) 0 
Molecular Type, N (%) 
     
Luminal A 19 (43.2) 16 (38.1) 3 (7.1) 18 (42.9) 1 (2.4) 
Luminal B (HER2-) 14 (31.8) 11 (26.2) 3 (7.1) 11 (26.2) 3 (7.1) 
Luminal B (HER2+) 5 (11.4) 5 (11.9) 0 5 (11.9) 0 
Triple-Negative 4 (9.1) 4 (9.5) 0 4 (9.5) 0 
Stage, N (%) 
     
0 2 (4.5) 2 (4.7) 0 2 (4.7) 0 
I 19 (43.2) 16 (37.2) 3 (7.0) 17 (39.5) 2 (4.7) 
II 21 (47.7) 18 (41.9) 3 (7.0) 19 (44.2) 2 (4.7) 
III 1 (2.3) 1 (2.3) 0 1 (2.3) 0 
Lymph Node Invasion, N 
(%)      
No 19 (43.2) 15 (36.6) 4 (9.8) 17 (41.5) 2 (4.9) 
Yes 22 (50.0) 20 (48.8) 2 (4.9) 21 (51.2) 1 (2.4) 
ER status, N (%) 
     
Negative 6 (13.6) 6 (14.0) 0 6 (14.0) 0 
Positive 37 (84.1) 31 (72.0) 6 (14.0) 33 (76.7) 4 (9.3) 
PR status, N (%) 
     
Negative 9 (20.5) 6 (14.4) 3 (7.1) 8 (19.1) 1 (2.4) 
Positive 33 (75.0) 30 (71.4) 3 (7.1) 30 (71.4) 3 (7.1) 
HER2 status, N (%) 
     
Negative 38 (86.4) 32 (72.0) 6 (14.0) 33 (76.7) 4 (9.3) 
Positive 6 (13.6) 6 (14.0) 0 6 (14.0) 0 
Ki67 status, N (%) 
     
Negative 24 (54.5) 20 (46.5) 4 (9.3) 22 (51.1) 2 (4.7) 
Positive 19 (43.2) 17 (39.5) 2 (4.7) 17 (39.5) 2 (4.7) 
Age of Menarche, N (%) 
     
≤ 13 years 25 (56.8) 21 (52.5) 4 (10.0) 22 (55.0) 3 (7.5) 
> 13 years 15 (34.1) 14 (35.0) 1 (2.5) 14 (35.0) 1 (2.5) 
Age of Menopause, N (%) 
     
≤ 50 years 21 (47.7) 19 (61.2) 2 (6.5) 18 (58.1) 3 (9.7) 






Table 5.4 (continued) – Distribution of SIX1 and SOX2 expression in a Portuguese 
breast cancer population and their clinicopathological features. No statistical 
differences within each feature, thus, p values are not shown. 
  Six1 Sox2 
 Total* Negative Positive Negative Positive 
Age at diagnosis, N (%) 
     
40-49 years 6 (13.6) 5 (11.6) 1 (2.3) 6 (14.0) 0 
50-59 years 13 (29.5) 12 (27.9) 1 (2.3) 13 (30.2) 0 
> 60 years 24 (54.5) 20 (46.5) 4 (9.4) 20 (46.5) 4 (9.3) 
Menopausal status, N (%) 
     
Pre 8 (18.2) 7 (17.5) 1 (2.5) 8 (20.0) 0 
Post 32 (72.7) 28 (70.0) 4 (10.0) 28 (70.0) 4 (10.0) 
Body Mass Index, N (%) 
     
Normal 17 (38.6) 15 (38.5) 2 (5.1) 17 (43.6) 0 
Overweight 14 (31.8) 12 (30.8) 2 (5.1) 11 (28.2) 3 (7.7) 
Obese 8 (18.2) 7 (17.9) 1 (2.6) 7 (17.9) 1 (2.6) 
* The sum of the number of individuals in the clinicopathological features may not be 44 due to the 
fact that some individuals does not answered to all questions of the form. 
 
5.4. Discussion 
Several studies have established that specific miRNA expression patterns can be 
correlated with biological and clinical features. Studies of miRNA expression patterns in 
different cell populations are of utmost importance in order to unveil the significance of 
these molecules in the diagnosis and prognosis of breast cancer. In the present study we 
show that miR-203a is overexpressed in tumour tissues when compared to adjacent 
normal tissue in a Portuguese cohort.  To our knowledge this is the first study reporting 
miR-203a expression in a Portuguese breast cancer population. Our results are in 
accordance with another study published by Ru and colleagues (Ru et al., 2011). However, 
they did not compare adjacent normal tissue with tumour tissue but an independent 
disease-free population. The same pattern of overexpression was also observed in ovarian 
cancer (Iorio et al., 2007), cervical cancer (Gocze et al., 2013), kidney and bladder cancers 
(Gottardo et al., 2007), colon adenocarcinoma (Schetter et al., 2008) and head and neck 
squamous cell carcinoma (de Carvalho et al., 2015). Conversely, miR-203 expression levels 





support the notion that miR-203a plays an important role in the development of cancer in 
a tissue specific manner. 
With this study, we compared miR-203a expression levels of ductal carcinoma in situ (N = 
7), invasive carcinoma NOS (N = 91) and invasive lobular carcinoma (N = 10). Our sample 
population also comprised one mixed tumour (invasive ductal and lobular carcinoma) but 
this was not considered in the statistical analysis of histological subtypes. Comparing 
matched samples, we observed significant differences between miR-203a levels in tumour 
tissue and adjacent normal tissue in ductal carcinoma in situ and invasive carcinoma NOS. 
However, there were no significant differences between the two groups. Due to the fact 
that we are in the presence of two different types of breast tumours, ductal and lobular, it 
makes more sense to analyse ductal carcinoma in situ and invasive carcinoma NOS 
separately. However, we did not find statiscally significant differences either.  
Nevertheless, we highlight the fact that there is a decrease of miR-203a expression levels 
in invasive carcinoma NOS when compared with ductal carcinoma in situ. These results 
suggest that during tumour development, miR-203a might be down regulated, thus 
suggesting that miR-203a might be implicated in early tumour development stages. 
Indeed, this involvement of miR-203a in invasiveness through the inhibition of the 
polycomb group gene BMI1 was already reported in melanoma (Chang et al., 2015) and 
non-small cell lung cancer (Chen et al., 2015), in which miR-203a expression levels are 
inversely correlated with BMI1 expression levels according to the cell type. Zhang et al. 
(Zhang et al., 2011) also reported an increased expression of miR-203a in breast tumours 
compared to matched adjacent normal tissue, even though their cohort was smaller. 
Additionally, the authors determined miR-203a expression levels in several non-
tumorigenic, non-metastatic and metastatic breast cell lines and showed an increased 
expression of miR-203a in non-metastatic compared to non-tumorigenic and metastatic 
lines. These results led the authors to speculate that miR-203a is overexpressed in a 





most probably through epigenetic mechanisms, the tumour cells repress miR-203a 
expression to enable proliferation, invasion and metastasis through increased expression 
of the pro-metastatic gene SNAI2. In fact, our data are in accordance with this report, since 
when we stratify the tumours according to lymph node invasion, the tumours that 
metastasize have a decreased expression of miR-203a (fold change expression = 1.22; N = 
53; Table 5.3) compared to those that did not metastasize to lymph node (fold change 
expression = 2.40; N = 52; Table 5.3), although they do not statistically differ. Additionally, 
we also found that miR-203a has a decreased expression in tumours positive for HER2 and 
high levels for the proliferation index Ki67 (Table 5.3). Altogether these data are in 
accordance with the fact that miR-203a may act as a tumour suppressor and in early 
stages of cancer development may play a protective role but throughout tumour 
development it might be repressed in order to enable tumour cells to proliferate, invade 
and metastasize.  
Interestingly, miR-203a expression decreases from stage 0 to stage I, then increases in 
stage II, and again decreases in stage III. This up and down regulation across stages was 
unexpected, since as a putative tumour suppressor, miR-203a expression should decrease 
within stages. Petrovic et al. (Petrovic et al., 2014) observed a similar pattern in invasive 
breast carcinomas but with miR-21. MiRNA levels are dependent on cell differentiation, 
thus displaying differential expression levels according to stage. Analysing only invasive 
lobular carcinoma tumours, there are significant differences between stage I (N = 2), II (N 
= 6) and III (N= 2). Although the number of samples is small, we can observe a pronounced 
decrease in miR-203a expression within the stages (Figure 5.3). We can thus speculate that 
miR-203a expression levels have influence in invasive lobular carcinoma and it could be 
used as a marker to distinguish different stages. 
Breast cancer risk increases with age. However, individual risk depends on other factors, 
including reproductive history, lifestyle habits and family history, among others. Our data 





diagnosis presented an increased expression of miR-203a when tumour tissue was 
compared with adjacent normal tissue. As estimated by The Surveillance, Epidemiology, 
and End Results (SEER) Program of the National Cancer Institute (Howlader et al., 2012), 
there is a risk increment for developing breast cancer with age. Our stratification was 
done using the same criteria, and we observed a higher expression of miR-203a in patients 
above 60 years. Regarding age of menarche and age of menopause, known players for 
breast cancer, the expression levels were higher for matched samples for age of menarche 
above 13 years and for age or menopause less than 50 years. Although we observed 
significant differences in matched samples for the classes referred, there are no 
differences within age of menarche and menopause classes indicating that miR-203a 
expression levels are not influenced by it. 
Furthermore, it is known that female hormones, such as 17-β-estradiol (E2), regulate gene 
expression by binding to oestrogen receptors (Marino et al., 2006). Indeed, Yu and 
colleagues (Yu et al., 2012), showed that E2 can regulate miRNAs expression and thus 
control cell proliferation. The authors showed that miR-16, miR-143 and miR-203a 
expression is suppressed after E2 stimulation hence up-regulating BCL2, cyclin D1 and 
BIRC5. Thus, the authors propose a mechanism whereby cells that undergo stimulation by 
E2 increase proliferation by inhibiting tumour suppressor miRNAs involved in cell 
proliferation and survival. Additionally, the authors evaluated the expression levels of 
these miRNAs in triple positive and triple negative breast tumours and showed that they 
have increased levels of expression in triple positive tumours, indicating that these 
miRNAs may function as tumour suppressors in triple positive breast tumours. In contrast, 
our data shows that triple positive samples have lower expression of miR-203a than triple 
negative ones. Indeed, when we stratified our data according to hormone receptor status, 
individually, we always obtained an increased expression level of miR-203a in negative 
receptor status. When sample matching is analysed we find significant differences 





data, when we analysed the samples by stratifying them by molecular subtype, we 
observed that basal-like tumours have higher expression of miR-203a. Although the terms 
basal-like tumour and triple negative tumours are not used interchangeably (Badve et al., 
2011), in this case we can consider that all basal-like are triple negative tumours. 
Interestingly, women who have used oral contraceptives have less expression of miR-
203a. Thus, miR-203a expression might be influenced by oestrogen and progesterone (Yu 
et al., 2012).  
Summarizing miR-203a data, it seems that miR-203a is involved in breast cancer 
development, mainly in early stages of development. Early tumour cells might up-regulate 
miR-203a in a self-protective manner in order to manage the augmented cell proliferation 
and then, most probably, through epigenetic mechanisms or E2 mediated suppression, 
miR-203a might be down-regulated and its targets up-regulated. Accordingly, it could 
represent a potential marker for invasiveness. Here, we also show that miR-203a might be 
a potential marker to discriminate stages in invasive lobular carcinoma. Further studies 
with larger populations of invasive lobular carcinoma cases must be performed in order to 
validate these results. 
In what concerns miR-200c, we did not detect significant differences between normal 
breast and tumour tissue in our population. Moreover, we failed to correlate miR-200c 
with clinicopathological features. On the contrary, other authors had previously published 
results associating miR-200c and some clinicopathological features in cancer. Actually, (Xu 
et al., 2016) and (Wang et al., 2013b) reported contrary reports, the first showing an 
association between miR-200c under expression and an increased number of lymph node 
metastasis in breast cancer and the second the opposite. Another study associates poor 
outcome in patients without progesterone receptors expression and high levels of miR-
200c (Tuomarila et al., 2014). One possible explanation for our results is that our 
population only had 5.6% disease recurrence. In fact, 3.7% had long distance recurrence. 





good survival rate, we failed to detect significant alterations of miR-200c. However, these 
results are in accordance with a recent meta-analysis published by Wu and colleagues (Wu 
et al., 2015a). The authors stated that in the 17 studies included in the meta-analysis miR-
200c expression was not significantly associated with cancer prognosis. However, miR-
200c expression in blood serum it was significantly associated with prognosis, TNM stage, 
lymph node metastasis and distant metastasis. Indeed, another study showed the same 
pattern (Antolin et al., 2015) and stated that the miR-200c detection in blood holds 
promise as a diagnostic marker. Due to the fact that until now our population have a low 
frequency of recurrences and that we only studied tumour tissue, we cannot exclude miR-
200c as marker of disease and we need to perform further studies regarding circulating 
miRNAs and not only in tumour tissue.   
The gold standard to characterize breast cancer, according to molecular status, is ER, PR, 
HER2 and Ki-67 detection by IHC. This characterization helps in therapy decisions, 
however, as all methods of diagnosis, is not error free and some patients do not respond 
well to therapy. In order to better characterize tumours and consequently to improve 
therapy decisions, new molecular markers are needed. MiRNAs have been described as 
good markers as also their putative regulated genes. Functional studies showing 
interaction between miRNAs and putative targets have been published. Although some 
studies showing association between miRNAs and regulated targets in cancer tissues have 
been done, most of the studies are designed and performed in cell lines. Because miRNAs 
regulate their targets at a post-transcriptional level and regulatory complex does not 
undergo to an immediate degradation, it is more logical to analyse protein expression than 
mRNA levels of putative targets. Here, we correlate the expression of miR-200c and two 
putative targets, SIX1 and SOX2, by RT-qPCR and IHC, respectively.  
Given the fact that SIX1 and SOX2 have the ability to regulate cell proliferation, we 





and 9.1%, respectively, of the cases showed expression of these proteins. On the contrary, 
we expected a decreased expression of miR-200c in tumour tissues. In fact, we observed 
the opposite.  
SIX1 has been described as an important player in BC aetiology, being overexpressed by 
gene amplification (Reichenberger et al., 2005) and inducing EMT (Micalizzi et al., 2009). 
Recently, Jin and colleagues (Jin et al., 2014) showed that 61.8% of their BC population has 
strong positive rates of SIX1. They also determined that SIX1 protein expression was 
significantly correlated with clinical stage, lymph node metastasis and HER2 expression 
status, suggesting that SIX1 may be a useful marker for prognostic evaluation of breast 
cancer. Conversely, our results showed no association with any of the clinicopathological 
characteristics analysed. Additionally, there seems to be a variation in the accurate 
location of SIX1 using different antibodies since the protein has been seen in both 
cytoplasm and nucleus. Hence, further studies are required to elucidate the mechanism 
that regulates SIX1 localization in order to properly understand its expression and 
influence in a cellular context. Moreover, according to TargetScan v7.0 (Agarwal et al., 
2015), SIX1 mRNA is targeted by several miRNAs including miR-200c but, in our study it 
was not possibly to conclude that miR-200c levels could be related to SIX1 protein levels. 
Even more, none of the positive cases for SIX1 had miR-200c downregulated, as should be 
expected. 
With regard to SOX2 expression, our results do not agree with those of other studies such 
as the one of Lengerke and colleagues (Lengerke et al., 2011) performed in Germany in 
2011 with 95 patients, wherein 27.9% of analysed samples of invasive breast carcinoma 
were SOX2 positive. In another study of Huang and colleagues (Huang et al., 2014), carried 
out in 2014 in China with 609 samples, SOX2 was detected in 19.0% of invasive breast 
carcinomas. This study also showed that SOX2 expression was associated closely with high 





(preferably expressed in basal-like breast cancers), negative hormone receptors status 
and high proliferation index. Hence, SOX2 contributes to a less differentiated state, tumour 
progression and lymph node metastasis in breast cancer. However, in our study SOX2 
expression could not be associated with any of those characteristics, neither with the 
other characteristics assessed. Interestingly, all the SOX2 positive cases are also ER 
positive, even though this association is not statically relevant. Nonetheless, the number of 
positive cases did not allow us to draw a conclusion. Furthermore, although SOX2 mRNA 
is, according to Targetscan, a target of miR-200c and it is described in vivo in colorectal 
carcinoma as involved in a feedback loop regulation (Lu et al., 2014), we did not find any 
association between the two of them in our study and again, no positive cases were found 
with miR-200c downregulation. 
There are few studies regarding the expression of SIX1 and SOX2 in human patients with 
breast cancer and as far as we know, there are no studies that characterize the Portuguese 
population for expression of both proteins. A conclusion we can draw from our study, 
though is that, in our population of breast cancers we observe relatively low levels of SIX1 
and SOX2. Furthermore, we could not find a statistically significant association between 
the expression of both proteins and various clinicopathological parameters. Regarding the 
relationship between levels of miR-200c and expression of their putative targets, SIX1 and 
SOX2, it was also not possible to find a statistically significant association. This may be due 







6. Identification of putative miR-200c and miR-
203 targets 
 
6.1. State of the art 
Throughout this thesis we have been showing that miRNAs are differentially expressed in 
breast cancer and can influence carcinogenesis by deregulating several pathways of 
cellular homeostasis. We have also been showing some examples of experimentally 
validated targets of miRNAs. However, these targets do not explain all the cellular effects 
of miRNAs, leading us to conclude that other targets are being deregulated. In fact, as 
stated before, one miRNA can have more than one target and one target can be targeted by 
several miRNAs. 
Most studies rely on the study of one miRNA and one or two targets [as example please 
see: (He et al., 2010; Ikemura et al., 2013; Iorio et al., 2009; Johnson et al., 2005)] that are 
previously identified by bioinformatics tools [as example TargetScan (Agarwal et al., 
2015)]. Although this approach is effective and important, due to the mechanism of action 
of miRNAs, it does not show the real influence of a selected miRNA or a group of miRNAs 
in the cell. Thus, we believe that approaches that give us the notion of the cellular context 
in precise specific conditions, as ectopically expression or inhibition of miRNAs, can 
provide much more information about what pathways are being influenced by a miRNA. 
These approaches rely on the observation of several miRNAs targets through quantitative 
proteomics. 
In Chapter 3 we have shown a presumably adequate approach for the identification of 
putative cellular targets of microRNAs in MCF-10A, MCF-7 and MDA-MB-231 cell lines by 
protein analysis by 2-D SDS-PAGE Gels and MALDI-TOF/TOF.  Also in Chapter 5 we 
attempted to analyse miR-200c and miR-203 expression levels, and their putative targets 





low levels of expression of SIX1 and SOX2, at least at the threshold’s levels of detection of 
immunostaining methods. In order to attempt a deeper insight into the possible molecular 
targets of miR-200c and miR-203, our group has established a collaboration with 
Professor Peter James (Lund University, Sweden) and analysed differentially expressed 
proteins in MDA-MB-231 and MCF-10A cell lines when miR-200c and miR-203 were 
ectopically expressed or inhibited, respectively, by quantitative proteomics.  
Quantitative proteomics is widely used to show deregulated proteins in a given condition 
or to determine molecular portraits of different cancer subtypes. As an example, the group 
of Professor Peter James has been publishing data showing that breast-cancer-derived cell 
lines reveal poor similarity with breast tumours (Cifani et al., 2015), showing that 
proteomic analysis is capable of confirm the mRNA molecular subtypes in breast cancer 
(Waldemarson et al., 2016) and showing protein differences in cellular transformation in 
ovarian cancer (Waldemarson et al., 2012). This approach together with by miRNAs 
expression can be a powerful tool to experimentally identify new targets and/or confirm 
putative targets retrieved by bioinformatics tools. In fact, there were already published 
data regarding this matter. As an example, Geng and colleagues (Geng et al., 2016) 
published some results showing that miR-125a, miR-143, miR-150, miR-181c, miR-182, 
miR-183, miR-199a, miR-429 are capable of influencing proteins involved in cell 
apoptosis,  cell survival, cell cycle, inflammatory response and metabolism in rat liver 
regeneration. It was also shown that the integration of miRNA and protein expression data 
gives new insights into molecular processes that are related with differences in the genesis 
and clinical evolution of triple negative breast tumours (Gamez-Pozo et al., 2015). Lai and 
colleagues (Lai et al., 2012) do a more concise study and ectopically expressed miR-372 
and then through comparative proteomics analysed differently expressed proteins in lung 
adenocarcinoma. Thus, the authors identified new potential diagnostic biomarkers for 
lung adenocarcinoma in several pathways. Taking into account these studies and the 





Chapter the proteomic results of differentially expressed proteins in MDA-MB-231 and 
MCF-10A cell lines when miR-200c and miR-203 were ectopically expressed or inhibited, 
respectively. 
6.2. Materials and methods 
6.2.1. Cell lines  
Cell lines culture was done according to Cell lines and Nucleic acid purification from 
Chapter 3, section Material and Methods. 
6.2.2. Ectopic expression and inhibition of miR-200c and miR-203 
Ectopic expression and inhibition of miR-200c and miR-203 was done according to the 
section Materials and Methods from Chapter 4. 
6.2.3. Protein purification and quantification 
Protein purification and quantification was done according to the section Protein 
purification and quantification from Chapter 3. 
6.2.4. Protein identification through LC/MS 
Total protein was denatured in Laemmli buffer 2⨯ (4% (w/v) SDS 10%; 20% (v/v) 
glycerol 50%; 0.02% (w/v) bromophenol blue; 125 mM Tris.HCl pH 6.8; and 10% (v/v) 2-
Mercaptoethanol) in a proportion of 1:1 and heated at 95 °C for 10 minutes. The samples 
were then sent to Professor Peter James and proteins identified through LC/MS. 
6.2.5. Bioinformatics and Statistical analysis 
After identification of the proteins through LC/MS, we received a list of 2956 proteins that 
were then analysed according to their ontology using PANTHER internet tools. After this, 
we statistically tested all eligible proteins using two-way ANOVA with Bonferroni post-test 
(p value < 0,05) with GraphPad Prism 5 software. All graphs were made using Microsoft 






Differently expressed proteins ontology 
Through LC-MS we identified 2956 misexpressed proteins after transfection of MDA-MB-
231 cell line with pre-miR-200c and pre-miR-203; and MCF-10A cell line with anti-miR-
200c, anti-miR-203 and pre-miR-203. All these conditions compared with a negative 
control that was in the exact same conditions but without the pre-or anti-miR. However, 
not all proteins were eligible to study. Thus, we filtered and selected proteins according to 
their q value (lower than 0.01), that had concordant replicates and p value (Two-way 
ANOVA with Bonferroni post-test) lower than 0.05. In tables 6.2 to 6.5, we show this 
selection of proteins as well as their expression values under different conditions of cell 
culture (Appendix).  
Regarding the transfection of MDA-MB-231 cell line with pre-miR-200c, we obtained 47 
differently expressed proteins, being 14 up-regulated and the remaining down-regulated 
(Table 6.2). In order to classify according to their ontology, we used PANTHER internet 
tools. Thus, we observed that many proteins have catalytic or binding function (Figure 
6.1); and most proteins are involved in metabolic or cellular processes (Figure 6.2), being 
metabolic processes characterized as primary metabolic processes and cellular processes 
characterized as cell communication, cell cycle, cellular component movement and 
chromosome segregation. Most proteins are localized in cytoplasm or associated to sub-
cellular structures (nucleus, cytoskeleton, endoplasmic reticulum and endosome) (Figure 
6.3); most proteins have nucleic acid binding, transferase or hydrolase activity (Figure 
6.4); and finally, the majority of proteins are members of the Huntington disease pathway 
(Figure 6.5). After transection with pre-miR-203, we obtained 43 differently expressed 
proteins, being 7 up-regulated and the remaining 36 down-regulated (Table 6.3). The 
majority of proteins are involved in catalytic or binding functions (Figure 6.6); metabolic 





primary metabolic processes and cellular processes characterized as cell communication, 
cell cycle and cellular component movement; are localized in cytoplasm (cell part) or 
associated with sub-cellular structures (cytoskeleton, endoplasmic reticulum and 
mitochondrion)(Figure 6.8); and are classified as hydrolases (Figure 6.9); and belong to 
integrin signaling pathway (Figure 6.10). 
Regarding MCF10A cell line, it was transfected with anti-miR-200c, anti-miR-203 and pre-
miR-203. This last transfection was done due to the fact that miR-203 is poorly expressed 
in this cell line. Thus, we decided to lower its expression even more and augment it in 
order to see the differences. Considering the transfection with anti-miR-200c, we obtained 
82 differently expressed proteins, of which 54 were down-regulated and the remaining 28 
were up-regulated (Table 6.4). Of these 82 proteins, the most common belongs to, in what 
regards molecular function, to binding and catalytic activity proteins (Figure 6.11); to 
metabolic and cellular process (Figure 6.12), where metabolic processes is characterized 
as primary metabolic processes and cellular processes characterized as cell 
communication, cell cycle and cellular component movement; to cytoplasm and organelle-
associated (cytoskeleton, endoplasmic reticulum, mitochondrion, nucleus and cytoplasmic 
membrane-bounded vesicle) proteins (Figure 6.13); to nucleic acid binding class of 
proteins (Figure 6.14); and to ubiquitin proteasome pathway proteins (Figure 6.15). After 
transfection with anti-miR-203, we obtained 130 proteins differently expressed, of which 
93 were down-regulated and 37 up-regulated (Table 6.5). The majority of proteins are 
classified as having catalytic and binding activity (Figure 6.16); involved in metabolic and 
cellular processes (Figure 6.17), where metabolic processes is characterized as primary 
metabolic processes and cellular processes characterized as cell communication, cell cycle, 
cellular component movement and cytokinesis; are localized in cytoplasm or are 
organelle-associated (nucleus, cytoskeleton, endoplasmic reticulum and endosome) 
(Figure 6.18); and also belong to nucleic acid binding and hydrolase class of proteins 





condition is with the transfection of pre-miR-203. After this, 200 proteins were found 
differentially expressed when transfection was performed. Of these, 104 were up-
regulated and 96 were down-regulated (Table 6.6). The most common proteins have 
catalytic and binding activity (Figure 6.21); are involved in involved in metabolic and 
cellular processes (Figure 6.22) where metabolic processes is characterized as primary 
metabolic processes and cellular processes characterized as cell communication, cell cycle, 
cell proliferation, cellular component movement, chromosome segregation and 
cytokinesis; and with respect to their localization, are localized in cytoplasm or are 
organelle-associated (Figure 6.23) (chromosome, cytoplasmic membrane-bounded 
vesicles, cytoskeleton, endoplasmic reticulum, endosome, mitochondrion and nucleus); 
and last, belong to nucleic acid binding and transferase class of proteins (Figure 6.24). 
Putative targets of miR-200c and miR-203 
Of the differently expressed proteins in each condition we selected those with opposite 
expression of the respective miRNA. With this we select the putative direct targets of miR-
200c and miR-203. After this selection we performed an analysis of these putative targets 
in TargetScan and determined which one has homology with miR-200c and miR-203. 
These proteins are shown in Table 6.1. 
Table 6.1 – Putative direct targets of miR-200c and miR-203 identified using 































Figure 6.1 – Molecular function of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-200c. Of the 47 
proteins identified, PANTHER and the Gene Ontology Consortium retrieved 51 hits in molecular functions. Of these, the most common are proteins 




















































Figure 6.2 – Biological processes of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-200c. Of the 47 
proteins identified, PANTHER and the Gene Ontology Consortium retrieved 83 hits in biological processes. Of these, metabolic and cellular processes 
are the most common. Metabolic processes are characterized in greater number as primary metabolic processes and cellular processes are 





































































Figure 6.3 – Cellular components of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-200c. Of the 47 
proteins identified, PANTHER and the Gene Ontology Consortium retrieved 26 hits in cellular components. Of these, cell part (cytoplasmic proteins) 
and organelle-associated (nucleus, cytoskeleton, endoplasmic reticulum and endosome) proteins are the most common. PANTHER™ GO slim (version 





































Figure 6.4 – Protein classes of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-200c. Of the 47 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 62 hits in protein classes. Of these, nucleic acid binding, transferase and hydrolase 











































































































Figure 6.5 - Pathways of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-200c. Of the 47 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 30 hits in pathways. Of these, Huntington disease related proteins were the most 












































































































































Figure 6.6 – Molecular function of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-203. Of the 43 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 42 hits in molecular functions. Of these, the most common are proteins with 















































Figure 6.7 - Biological processes of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-203. Of the 43 
proteins identified, PANTHER and the Gene Ontology Consortium retrieved 56 hits in biological processes. Of these, metabolic and cellular processes 
are the most common. Metabolic processes are characterized in greater number as primary metabolic processes and cellular processes are 



































































Figure 6.8 - Cellular components of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-203. Of the 43 
proteins identified, PANTHER and the Gene Ontology Consortium retrieved 27 hits in cellular components. Of these, cell part (cytoplasmic proteins) 
and organelle-associated (cytoskeleton, endoplasmic reticulum and mitochondrion) proteins are the most common. PANTHER™ GO slim (version 
10.0, released 2015-05-15).  



































Figure 6.9 – Protein classes of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-203. Of the 43 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 51 hits in protein classes. Of these, hydrolase, cytoskeletal and chaperone proteins 
























































































































Figure 6.10 - Pathways of the differently expressed proteins in MDA-MB-231 after transfection with pre-miR-203. Of the 43 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 29 hits in pathways. Of these, Integrin signaling pathway related proteins were the 





























































































































Figure 6.11 – Molecular function of the differently expressed proteins in MCF-10A after transfection with anti-miR-200c. Of the 82 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 78 hits in molecular functions. Of these, the most common are proteins with 






























































Figure 6.12 - Biological processes of the differently expressed proteins in MCF10A after transfection with anti-miR-200c. Of the 82 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 122 hits in biological processes. Of these, metabolic and cellular processes are the 
most common. Metabolic processes are characterized in greater number as primary metabolic processes and cellular processes are characterized as 

































































Figure 6.13 - Cellular components of the differently expressed proteins in MCF10A after transfection with anti-miR-200c. Of the 82 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 52 hits in cellular components. Of these, cell part (cytoplasmic proteins) and 
organelle-associated (cytoskeleton, endoplasmic reticulum, mitochondrion, nucleus and cytoplasmic membrane-bounded vesicle) proteins are the 






































Figure 6.14 – Protein classes of the differently expressed proteins in MCF10A after transfection with anti-miR-200c. Of the 82 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 73 hits in protein classes. Of these, nucleic acid binding proteins are the most 










































































































Figure 6.15 - Pathways of the differently expressed proteins in MCF10A after transfection with anti-miR-200c. Of the 82 proteins identified, 
PANTHER and the Gene Ontology Consortium retrieved 20 hits in pathways. Of these, ubiquitin proteasome pathway related proteins were the most 































































































Figure 6.16 – Molecular function of the differently expressed proteins in MCF-10A after transfection with anti-miR-203. Of the 130 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 126 hits in molecular functions. Of these, the most common are proteins with 















































Figure 6.17 - Biological processes of the differently expressed proteins in MCF10A after transfection with anti-miR-203. Of the 130 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 176 hits in biological processes. Of these, metabolic and cellular processes are the 
most common. Metabolic processes are characterized in greater number as primary metabolic processes and cellular processes are characterized as 

































































Figure 6.18 - Cellular components of the differently expressed proteins in MCF10A after transfection with anti-miR-203. Of the 130 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 61 hits in cellular components. Of these, cell part (cytoplasmic proteins) and 
organelle-associated (chromosome, cytoskeleton, mitochondrion and nucleus) proteins are the most common. PANTHER™ GO slim (version 10.0, 






































Figure 6.19 – Protein classes of the differently expressed proteins in MCF10A after transfection with anti-miR-203. Of the 130 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 104 hits in protein classes. Of these, nucleic acid binding proteins and hydrolase 









































































































Figure 6.20 - Pathways of the differently expressed proteins in MCF10A after transfection with anti-miR-203. Of the 130 proteins identified, 
PANTHER and the Gene Ontology Consortium retrieved 42 hits in pathways. Of these, p53 pathway related proteins were the most common. 






























































































Figure 6.21 - Molecular function of the differently expressed proteins in MCF-10A after transfection with pre-miR-203. Of the 200 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 171 hits in molecular functions. Of these, the most common are proteins with 
















































Figure 6.22 - Biological processes of the differently expressed proteins in MCF10A after transfection with pre-miR-203. Of the 200 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 289 hits in biological processes. Of these, metabolic and cellular processes are the 
most common. Metabolic processes are characterized in greater number as primary metabolic processes and cellular processes are characterized as 
cell communication, cell cycle, cell proliferation, cellular component movement, chromosome segregation and cytokinesis. PANTHER™ GO slim 



































































Figure 6.23 - Cellular components of the differently expressed proteins in MCF10A after transfection with pre-miR-203. Of the 200 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 74 hits in cellular components. Of these, cell part (cytoplasmic proteins) and 
organelle-associated (chromosome, cytoplasmic membrane-bounded vesicles, cytoskeleton, endoplasmic reticulum, endosome, mitochondrion and 

















































Figure 6.24 – Protein classes of the differently expressed proteins in MCF10A after transfection with pre-miR-203. Of the 200 proteins 
identified, PANTHER and the Gene Ontology Consortium retrieved 177 hits in protein classes. Of these, nucleic acid binding proteins and hydrolase 













































































































MicroRNAs are conspicuous members of the cell circuitry of regulation of protein 
expression. Epigenetic regulation, particularly by microRNAs, besides DNA methylation or 
histone acetylation, plays an important role in carcinogenesis and therapy. There are 
approximately 2000 different human microRNA species identified that form a intertwined 
network of concurrently regulated proteins that mediate cancer cell survival even upon a 
challenge by cancer drugs (Rueff and Rodrigues, 2016).   
Validation of targets of miRNAs is a slow field of study since they can have virtually 
hundreds of targets. High-throughput analysis and the increasing resolution of some 
methodologies allowed investigators in the past few years to achieve better and 
trustworthy results. One of these techniques was mass spectrometry.  This allows the 
identification of several proteins in a given condition, such as a condition where we know 
the variation of a single miRNA. Assuming that this is the only variable, we can then make 
some assumptions regarding the differentially expressed proteins found by mass 
spectrometry. With this assumption, in collaboration with Professor Peter James, we 
designed experiments where we varied only one miRNA in a previous known expression 
cell line. This allowed us to infer that the differentially expressed proteins are in principle, 
subject to regulation by that miRNA.  
Analysing according to the ontology, we can conclude that most deregulated proteins after 
transfection with pre-miR-200c, pre-miR-203, anti-miR-200c and anti-miR-203 belong to 
metabolic processes and are located in the cytoplasm or associated with organelles or the 
nucleus. This is in accordance with their activity, that is catalytic and nucleic acid binding.  
Recent studies have been showing that metabolomics is a new field of study to better 
understand tumour biology (Huang et al., 2016; Kelly et al., 2016; Shao et al., 2016; 
Siminska and Koba, 2016). This field not only analyse metabolites (Hsu et al., 2016) but 





biomarkers are being found and new approaches to study cancer are being made, in 
particular, new therapeutic targets are being studied (Wishart, 2016). Thus, our work here 
presented reveals that miRNAs also modulate metabolism in breast cancer cell lines. 
Surprisingly, there are few studies showing association of miRNAs with metabolomics. 
This must be due to technological complexity and the fact that this is a recent field of 
study. However, a recent study already sowed that miR-155 regulates thiamine levels in 
breast cancer (Kim et al., 2015) and with the levels of serum lipids, metabolites associated 
with glucose metabolism and insulin resistance in cardiovascular risk (Raitoharju et al., 
2014). Therefore, we intend to prioritize our future work to this matter and study the 
association of these miRNAs with metabolic pathways. 
Along with ontology study of the deregulated proteins, with the approach here presented 
we can study putative direct targets of miR-200c and miR-203. In Table 6.1 we show a list 
of possible miR-200c and miR-203 targets that were already identified with 
bioinformatics tools and we show here an experimentally possible association. 
In MDA-MB-231 we show that IAH1 is a putative direct target of miR-200c. Until now 
there isn’t any study showing this association, thus our results need further studies with 
other approaches to prove that IAH1 is a direct target of miR-200c. Regarding miR-203, 
we identified more putative direct targets and of these, FKBP5 and CAB39 were already 
experimentally associated with miRNAs. FKBP5 is a chaperone protein and is regulated by 
miR-511 which then regulates neuronal differentiation (Zheng et al., 2016). Interestingly, 
FKBP5 also interact with AGO2 to facilitate RISC assembly in the miRNAs action pathway 
(Martinez et al., 2013). CAB39 is a calcium binding protein that acts like a scaffold protein 
and interacts with AMPK/AKT/mTOR pathway. Until now, only one miRNA was associated 
with CAB39. Several studies were already published regarding miR-451 and CAB39 and its 
involvement in different types of cancer, such as colorectal (Chen et al., 2014; Li et al., 





al., 2015) and cardiac hypertrophy (Kuwabara et al., 2015) are also influenced by miR-451 
and CAB39 by targeting AMPK/AKT pathway. 
In MCF-10A transfected with anti-miR-200c we detected three putative targets, being 
CRKL the only one that is associated with miR-200c in silico. CRKL is an oncogene by 
promoting cell proliferation, survival, migration and invasion and also by promoting 
growth factor independence (Kim et al., 2010). It was also proved that CRKL is a substrate 
of BCR-ABL in CML, thus prompting leukaemogenesis (Hemmeryckx et al., 2001).  
Previously, miR-200s family, in which miR-429 is included, was already experimentally 
associated with CRKL. In fact, miR-200s family were associated with cervical cancer 
(Wang et al., 2016b), nasopharyngeal carcinoma (Wang et al., 2016a) and  breast cancer 
(Ye et al., 2015). This data is in accordance with our results. However, we need to perform 
more assays to prove that CRKL is an effective target of miR-200c in breast cancer. CRKL is 
also regulated by miR-126 in gastric cancer (Wang et al., 2013a) and hepatocellular 
carcinoma (Ghosh et al., 2016). Regarding the transfection of MCF-10A with anti-miR-203, 
we detected also 3 proteins over-expressed. Of these only CTBP2 has miR-203 as putative 
regulator. Although not by miR-203, there were already some results published regarding 
the regulation of CTBP2 by miRNAs. In particular, regulated by miR-342 (Wang et al., 
2015), miR-132 (Salta et al., 2014) and miR-101(Cui et al., 2013). All of these seem to 
influence stem cells and development. When the MCF-10A cell line was transfected with 
pre-miR-203 we detected 4 putative targets of miR-203 and all of these have already been 
described as being regulated by miRNAs.  Specifically, miR-203 seems to be regulator of 
keratinocyte growth, differentiation, and skin inflammation in a skin incision through 
PLAA (Sun et al., 2012). Here we demonstrate a possible association with breast cancer. 
For PRKCI the only experimentally demonstration of miRNAs regulation was under miR-
219. This study was in tongue squamous cells carcinoma (Song et al., 2014). Regarding 
RRM1, it is regulated by miR-101 in pancreatic cancer and drug resistance. The authors 





therapy outcome (Fan et al., 2016). Finally, HDAC1 is regulated by several miRNAs, 
including miR-874 (Nohata et al., 2013), miR-34a (Wu et al., 2014) and miR-449a (Liu et 
al., 2015a). Interestingly, and showing the scheme of an intertwined epigenomic 
programme in the cell, is the demonstrated capability of HDAC1 to regulate some miRNAs 
through epigenetic mechanisms. Indeed, HDAC1 is capable of regulate miR-133a in cardiac 
fibrosis (Renaud et al., 2015), miR-34a/CD44 pathway in gastric cancer (Lin et al., 2015), 
miR-146a in osteoarthritis, where the authors showed that using HDAC1 inhibitors the 
expression of miR-146a was increased (Wang et al., 2013c) and miR-449 and miR-224 in 
hepatocellular carcinoma (Buurman et al., 2012; Wang et al., 2012d).  
Although not with miR-200c and miR-203, all these studies show that somehow these 
putative targets in breast cancer are good candidates to further studies. Thus, we intend to 
proceed with this approach and will perform a Selected Reaction Monitoring (SRM), once 
more in collaboration with Professor Peter James. This technique will allow us to perform 
a quantitative approach of selected proteins. Therefore we will select all inversely 
expressed proteins when compared with miRNAs expression and analyse through SRM. 
After this, we will proceed with more cell lines studies in order to confirm association of 
these miRNAs and the respective targets through luciferase assay. Not less important with 
this study we can conclude whether the miR-200c and miR-203 are important mediators 
in metabolic processes and homeostatic activity of the cell. Further studies concerning 











Table 6.2 – Differently expressed proteins after transfection of MDA-MB-231 cell line with pre-miR-200c. Values are presented as the mean of 
log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
 
log2(Intensity) MEAN   
ID_UNIPROT Negative control pre-miR-200c PROTEIN GENE 
A1L0T0 0,00 23,78 Acetolactate synthase-like protein ILVBL 
O15126 0,00 24,60 Secretory carrier-associated membrane protein 1 SCAMP1 
O43847 0,00 24,11 Nardilysin NRDC 
O60826 0,00 22,40 Coiled-coil domain-containing protein 22 CCDC22 
Q8WYK3 0,00 25,42 Thymidylate synthase TYMS 
Q6ICJ4 0,00 21,15 Glutathione S-transferase theta 2B GSTT2 
P13807-2 0,00 24,59 Glycogen [starch] synthase, muscle GYS1 
P20962 0,00 21,85 Parathymosin PTMS 
P42574 0,00 25,41 Caspase-3 CASP3 
P42858 0,00 27,19 Huntingtin HTT 
Q13418 0,00 26,03 Integrin-linked protein kinase ILK 
H0YK42 0,00 24,87 Sorting nexin-1 SNX1 
F5H702 0,00 21,81 39S ribosomal protein L48, mitochondrial MRPL48 
Q5VVM0 0,00 25,20 Phosphopantothenate--cysteine ligase PPCS 
Q9UI26 21,07 0,00 Importin-11 IPO11 
C9JQV0 21,08 0,00 Uncharacterized protein C7orf50 C7orf50 
B4DGU4 21,13 0,00 Catenin beta-1 CTNNB1 
Q9Y5V0 21,39 0,00 Zinc finger protein 706 ZNF706 
Q9BZ29-3 21,51 0,00 Dedicator of cytokinesis protein 9 DOCK9 









Table 6.2 (continued) – Differently expressed proteins after transfection of MDA-MB-231 cell line with pre-miR-200c. Values are presented 
as the mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
Q5JUV4 21,58 0,00 Cytosolic purine 5'-nucleotidase NT5C2 
Q9Y2Z4 21,76 0,00 Tyrosine--tRNA ligase, mitochondrial YARS2 
B4DMV3 21,79 0,00 Isoamyl acetate-hydrolyzing esterase 1 homolog IAH1 
Q16774 21,80 0,00 Guanylate kinase GUK1 
Q969Z0 21,83 0,00 Protein TBRG4 TBRG4 
O75976 22,05 0,00 Carboxypeptidase D CPD 
Q9BPX5 22,34 0,00 Actin-related protein 2/3 complex subunit 5-like protein ARPC5L 
E9PPY7 22,86 0,00 Arfaptin-2 ARFIP2 
O00762 22,90 0,00 Ubiquitin-conjugating enzyme E2 C UBE2C 
Q13451 23,32 0,00 Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 
Q9BQA1 23,66 0,00 Methylosome protein 50 WDR77 
Q01518-2 23,87 0,00 Adenylyl cyclase-associated protein 1 CAP1 
O00629 23,98 0,00 Importin subunit alpha-3 KPNA4 
Q9BS40 23,99 0,00 Latexin LXN 
O94925-3 24,07 0,00 Glutaminase kidney isoform, mitochondrial GLS 
P07602 24,24 0,00 Prosaposin PSAP 
Q9UBB4-2 24,28 0,00 Ataxin-10 ATXN10 
Q9NUJ1 24,41 0,00 Mycophenolic acid acyl-glucuronide esterase, mitochondrial ABHD10 
J3QT28 24,85 0,00 Mitotic checkpoint protein BUB3 BUB3 
Q13547 24,90 0,00 Histone deacetylase 1 HDAC1 
Q9H444 25,00 0,00 Charged multivesicular body protein 4b CHMP4B 
E9PNC7 25,01 0,00 Dr1-associated corepressor DRAP1 
Q12874 25,20 0,00 Splicing factor 3A subunit 3 SF3A3 









Table 6.3 - Differently expressed proteins after transfection of MDA-MB-231 cell line with pre-miR-203. Values are presented as the mean of 




ID_UNIPROT Negative control pre-miR-203 PROTEIN GENE 
O43464-2 0,00 22,87 Serine protease HTRA2, mitochondrial HTRA2 
Q8WYK3 0,00 25,05 Thymidylate synthase TYMS 
P13798 0,00 24,50 Acylamino-acid-releasing enzyme APEH 
P20962 0,00 21,99 Parathymosin PTMS 
Q13418 0,00 24,90 Integrin-linked protein kinase ILK 
Q9BZE1 0,00 24,18 39S ribosomal protein L37, mitochondrial MRPL37 
Q5VVM0 0,00 25,40 Phosphopantothenate--cysteine ligase PPCS 
Q9UPU5 19,86 0,00 Ubiquitin carboxyl-terminal hydrolase 24 USP24 
F5H1F6 20,37 0,00 Vacuolar protein sorting-associated protein 37B VPS37B 
P16989 20,58 0,00 Y-box-binding protein 3 YBX3 
H3BTA8 21,03 0,00 
Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain 
member 1 protein 
HERPUD1 
B4DGU4 21,13 0,00 Catenin beta-1 CTNNB1 
P51636-2 21,21 0,00 Caveolin-2 CAV2 
J3KTL8 21,35 0,00 
Structural maintenance of chromosomes flexible hinge domain-containing 
protein 1 
SMCHD1 
Q9Y5V0 21,39 0,00 Zinc finger protein 706 ZNF706 
Q9BTW9 21,56 0,00 Tubulin-specific chaperone D TBCD 
Q5JUV4 21,58 0,00 Cytosolic purine 5'-nucleotidase NT5C2 
Q9Y2Z4 21,76 0,00 Tyrosine--tRNA ligase, mitochondrial YARS2 
P01116-2 21,77 0,00 GTPase KRas KRAS 
B4DMV3 21,79 0,00 Isoamyl acetate-hydrolyzing esterase 1 homolog IAH1 









Table 6.3 (continued) - Differently expressed proteins after transfection of MDA-MB-231 cell line with pre-miR-203. Values are presented as 
the mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
O75976 22,05 0,00 Carboxypeptidase D CPD 
Q9Y2R0 22,06 0,00 Cytochrome c oxidase assembly factor 3 homolog, mitochondrial COA3 
Q9HBM1 22,16 0,00 Kinetochore protein Spc25 SPC25 
Q96ND0 22,22 0,00 Protein FAM210A FAM210A 
Q9BPX5 22,34 0,00 Actin-related protein 2/3 complex subunit 5-like protein ARPC5L 
P09543-2 22,78 0,00 2',3'-cyclic-nucleotide 3'-phosphodiesterase CNP 
O60716-8 22,95 0,00 Catenin delta-1 CTNND1 
Q9UGP8 22,98 0,00 Translocation protein SEC63 homolog SEC63 
Q96A49 23,00 0,00 Synapse-associated protein 1 SYAP1 
Q13451 23,32 0,00 Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 
Q53H82 23,45 0,00 Beta-lactamase-like protein 2 LACTB2 
Q9NZB2 23,57 0,00 Constitutive coactivator of PPAR-gamma-like protein 1 FAM120A 
Q9Y376 23,60 0,00 Calcium-binding protein 39 CAB39 
P12236 23,91 0,00 ADP/ATP translocase 3 SLC25A6 
O94925-3 24,07 0,00 Glutaminase kidney isoform, mitochondrial GLS 
Q9BV86-2 24,18 0,00 N-terminal Xaa-Pro-Lys N-methyltransferase 1 NTMT1 
O75348 24,20 0,00 V-type proton ATPase subunit G 1 ATP6V1G1 
O75436 24,23 0,00 Vacuolar protein sorting-associated protein 26A VPS26A 
P21281 24,66 0,00 V-type proton ATPase subunit B, brain isoform ATP6V1B2 
Q9Y5A9 24,69 0,00 YTH domain-containing family protein 2 YTHDF2 
Q14192 24,72 0,00 Four and a half LIM domains protein 2 FHL2 












Table 6.4 - Differently expressed proteins after transfection of MCF-10A cell line with anti-miR-200c. Values are presented as the mean of 
log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
 log2(Intensity) MEAN   
ID_UNIPROT Negative control anti-miR-200c PROTEIN GENE 
O14737 21,70 0,00 Programmed cell death protein 5 PDCD5 
O14773-2 24,15 0,00 Tripeptidyl-peptidase 1 TPP1 
O14979-3 22,42 0,00 Heterogeneous nuclear ribonucleoprotein D-like HNRNPDL 
P20338 21,83 0,00 Ras-related protein Rab-4A RAB4A 
P20962 18,51 0,00 Parathymosin PTMS 
P21964-2 22,19 0,00 Catechol O-methyltransferase COMT 
P30508 20,75 0,00 HLA class I histocompatibility antigen, Cw-12 alpha chain HLA-C 
P46934-4 20,07 0,00 E3 ubiquitin-protein ligase NEDD4 NEDD4 
P53007 23,36 0,00 Tricarboxylate transport protein, mitochondrial SLC25A1 
P80217 20,99 0,00 Interferon-induced 35 kDa protein IFI35 
F5GWE5 23,95 0,00 Phosphatidylinositol transfer protein alpha isoform PITPNA 
Q00688 25,70 0,00 Peptidyl-prolyl cis-trans isomerase FKBP3 FKBP3 
E7EWC2 25,48 0,00 Ras GTPase-activating-like protein IQGAP2 IQGAP2 
Q13618-3 23,86 0,00 Cullin-3 CUL3 
Q14258 20,82 0,00 E3 ubiquitin/ISG15 ligase TRIM25 TRIM25 
Q16527 22,33 0,00 Cysteine and glycine-rich protein 2 CSRP2 
Q27J81-2 23,08 0,00 Inverted formin-2 INF2 
Q71UM5 22,68 0,00 40S ribosomal protein S27-like RPS27L 
Q7Z7H5-3 21,26 0,00 Transmembrane emp24 domain-containing protein 4 TMED4 
Q8WUY1 21,07 0,00 Protein THEM6 THEM6 
C9JQV0 21,46 0,00 Uncharacterized protein C7orf50 C7orf50 
F5H702 21,60 0,00 39S ribosomal protein L48, mitochondrial MRPL48 









Table 6.4 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with anti-miR-200c. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
Q96C90 21,61 0,00 Protein phosphatase 1 regulatory subunit 14B PPP1R14B 
Q96E11-8 20,31 0,00 Ribosome-recycling factor, mitochondrial MRRF 
Q96GA3 21,69 0,00 Protein LTV1 homolog LTV1 
Q96P48-3 22,30 0,00 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 ARAP1 
Q96PY5-3 22,78 0,00 Formin-like protein 2 FMNL2 
Q99584 19,66 0,00 Protein S100-A13 S100A13 
Q9C0C9 21,60 0,00 (E3-independent) E2 ubiquitin-conjugating enzyme UBE2O 
Q9H0U6 22,33 0,00 39S ribosomal protein L18, mitochondrial MRPL18 
Q9H5X1 21,21 0,00 MIP18 family protein FAM96A FAM96A 
Q9H993 22,20 0,00 Protein-glutamate O-methyltransferase ARMT1 
Q9HAV4 21,73 0,00 Exportin-5 XPO5 
Q9NTJ5 22,32 0,00 Phosphatidylinositide phosphatase SAC1 SACM1L 
Q9NX08 21,41 0,00 COMM domain-containing protein 8 COMMD8 
Q9P107 20,05 0,00 GEM-interacting protein GMIP 
Q9Y3D0 20,98 0,00 Mitotic spindle-associated MMXD complex subunit MIP18 FAM96B 
B4DLN1 21,74 0,00 Uncharacterized protein  
F5H1S9 22,04 0,00 tRNA pseudouridine synthase PUS1 
Q9Y6C9 21,94 0,00 Mitochondrial carrier homolog 2 MTCH2 
Q9UG63 23,70 0,00 ATP-binding cassette sub-family F member 2 ABCF2 
B4DJG8 23,90 0,00 Charged multivesicular body protein 2b CHMP2B 
Q9UBT2 24,89 0,00 SUMO-activating enzyme subunit 2 UBA2 
Q93083 18,42 0,00 Metallothionein-1L MT1L 
H7C585 19,46 0,00 Frataxin, mitochondrial FXN 
G3V108 20,98 0,00 CCR4-NOT transcription complex subunit 7 CNOT7 









P47989 22,50 0,00 Xanthine dehydrogenase/oxidase XDH 
P42345 23,06 0,00 Serine/threonine-protein kinase mTOR MTOR 
C9JG32 23,83 0,00 Elongation factor Ts TSFM 
P42285 22,94 0,00 Superkiller viralicidic activity 2-like 2 SKIV2L2 
H3BM18 22,42 0,00 Gamma-interferon-inducible protein 16 IFI16 
H0YAT1 22,67 0,00 SH2 domain-containing protein 4A SH2D4A 
Q9BWS9 23,11 0,00 Chitinase domain-containing protein 1 CHID1 
P41247-2 0,00 20,20 Patatin-like phospholipase domain-containing protein 4 PNPLA4 
Q9Y3C1 0,00 21,33 Nucleolar protein 16 NOP16 
Q8WVC6 0,00 21,38 Dephospho-CoA kinase domain-containing protein DCAKD 
Q13043-2 0,00 21,38 Serine/threonine-protein kinase 4 STK4 
O00762 0,00 21,39 Ubiquitin-conjugating enzyme E2 C UBE2C 
Q9BYD2 0,00 21,79 39S ribosomal protein L9, mitochondrial MRPL9 
B5MCY6 0,00 22,30 Protein phosphatase 1 regulatory subunit 7 PPP1R7 
O14929-2 0,00 22,62 Histone acetyltransferase type B catalytic subunit HAT1 
O94804 0,00 22,66 Serine/threonine-protein kinase 10 STK10 
Q9Y2A7 0,00 22,77 Nck-associated protein 1 NCKAP1 
Q5VYS8-4 0,00 22,84 Terminal uridylyltransferase 7 ZCCHC6 
Q9NYT0 0,00 22,87 Pleckstrin-2 PLEK2 
Q5JVY0 0,00 22,97 E3 ubiquitin-protein ligase TRIM32 TRIM32 
Q14980-4 0,00 23,03 Nuclear mitotic apparatus protein 1 NUMA1 
P19784 0,00 23,29 Casein kinase II subunit alpha' CSNK2A2 
Q9NWU5 0,00 23,32 39S ribosomal protein L22, mitochondrial MRPL22 
O00560-2 0,00 23,34 Syntenin-1 SDCBP 
Q9BTE3-2 0,00 23,52 Mini-chromosome maintenance complex-binding protein MCMBP 
Q14240 0,00 23,72 Eukaryotic initiation factor 4A-II EIF4A2 
Q9UHD9 0,00 23,97 Ubiquilin-2 UBQLN2 









Table 6.4 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with anti-miR-200c. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
A8MU28 0,00 24,20 NEDD8-activating enzyme E1 regulatory subunit NAE1 
P23743 0,00 24,36 Diacylglycerol kinase alpha DGKA 
Q96JJ7 0,00 24,44 Protein disulfide-isomerase TMX3 TMX3 
P46109 0,00 24,50 Crk-like protein CRKL 
Q99614 0,00 24,58 Tetratricopeptide repeat protein 1 TTC1 
P13984 0,00 24,68 General transcription factor IIF subunit 2 GTF2F2 










Table 6.5 - Differently expressed proteins after transfection of MCF-10A cell line with anti-miR-203. Values are presented as the mean of 




ID_UNIPROT Negative control anti-miR-203 PROTEIN GENE 
O00625 22,02 0,00 Pirin PIR 
O14979-3 22,42 0,00 Heterogeneous nuclear ribonucleoprotein D-like 
HNRNPD
L 
O15067 25,54 0,00 Phosphoribosylformylglycinamidine synthase PFAS 
O15118 22,31 0,00 Niemann-Pick C1 protein NPC1 
O60711 22,30 0,00 Leupaxin LPXN 
O75368 21,58 0,00 SH3 domain-binding glutamic acid-rich-like protein SH3BGRL 
O75934 22,51 0,00 Pre-mRNA-splicing factor SPF27 BCAS2 
O96011-2 21,77 0,00 Peroxisomal membrane protein 11B PEX11B 
P01583 24,39 0,00 Interleukin-1 alpha IL1A 
P05121 24,46 0,00 Plasminogen activator inhibitor 1 
SERPINE
1 
B8ZZQ6 20,84 0,00 Prothymosin alpha PTMA 
P11387 25,76 0,00 DNA topoisomerase 1 TOP1 
C9J4G9 23,07 0,00 Beta-galactosidase GLB1 
B7Z708 22,41 0,00 
cDNA FLJ58698, highly similar to cAMP-dependent protein kinase, alpha-
catalytic subunit (EC 2.7.11.11)  
P20962 18,51 0,00 Parathymosin PTMS 
P23434 21,16 0,00 Glycine cleavage system H protein, mitochondrial GCSH 
P25205 23,45 0,00 DNA replication licensing factor MCM3 MCM3 
P30508 20,75 0,00 HLA class I histocompatibility antigen, Cw-12 alpha chain HLA-C 
H3BS44 23,73 0,00 Estradiol 17-beta-dehydrogenase 2 HSD17B2 
P38936 17,91 0,00 Cyclin-dependent kinase inhibitor 1 CDKN1A 









Table 6.5 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with anti-miR-203. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
P46934-4 20,07 0,00 E3 ubiquitin-protein ligase NEDD4 NEDD4 
P51610-2 22,28 0,00 Host cell factor 1 HCFC1 
P52895 24,46 0,00 Aldo-keto reductase family 1 member C2 AKR1C2 
E9PPY7 22,35 0,00 Arfaptin-2 ARFIP2 
P61599 19,36 0,00 N-alpha-acetyltransferase 20 NAA20 
P62158 22,89 0,00 Calmodulin CALM1 
B8ZZJ0 20,44 0,00 Small ubiquitin-related modifier 1 SUMO1 
C9JBI3 23,28 0,00 Phosphoserine phosphatase PSPH 
Q13217 24,14 0,00 DnaJ homolog subfamily C member 3 DNAJC3 
E7EWC2 25,48 0,00 Ras GTPase-activating-like protein IQGAP2 IQGAP2 
Q13618-3 23,86 0,00 Cullin-3 CUL3 
Q14011 20,63 0,00 Cold-inducible RNA-binding protein CIRBP 
Q14258 20,82 0,00 E3 ubiquitin/ISG15 ligase TRIM25 TRIM25 
Q14738-3 23,19 0,00 
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta 
isoform 
PPP2R5D 
Q15021 21,94 0,00 Condensin complex subunit 1 NCAPD2 
Q15293 24,45 0,00 Reticulocalbin-1 RCN1 
Q16527 22,33 0,00 Cysteine and glycine-rich protein 2 CSRP2 
Q27J81-2 23,08 0,00 Inverted formin-2 INF2 
B4DMV3 20,54 0,00 Isoamyl acetate-hydrolyzing esterase 1 homolog IAH1 
Q5J8M3-3 21,34 0,00 ER membrane protein complex subunit 4 EMC4 
Q5SW79 23,97 0,00 Centrosomal protein of 170 kDa CEP170 
Q66K14-2 21,26 0,00 TBC1 domain family member 9B TBC1D9B 
Q6PIU2 24,94 0,00 Neutral cholesterol ester hydrolase 1 NCEH1 









B4DLH2 23,97 0,00 Chromosome 2 open reading frame 18, isoform CRA_c C2orf18 
Q8IWE2 25,22 0,00 Protein NOXP20 
FAM114A
1 
Q8N183 21,35 0,00 Mimitin, mitochondrial NDUFAF2 
Q8NDC0 23,45 0,00 MAPK-interacting and spindle-stabilizing protein-like 
MAPK1IP
1L 
Q8NEY1-7 23,58 0,00 Neuron navigator 1 NAV1 
Q8NFW8 24,57 0,00 N-acylneuraminate cytidylyltransferase CMAS 
Q8TCT9-5 24,55 0,00 Minor histocompatibility antigen H13 HM13 
C9JQV0 21,46 0,00 Uncharacterized protein C7orf50 C7orf50 
E5RGY0 23,54 0,00 Derlin DERL1 
F5H702 21,60 0,00 39S ribosomal protein L48, mitochondrial MRPL48 
H0YLY7 21,41 0,00 Calcineurin B homologous protein 1 CHP1 
Q96C19 23,49 0,00 EF-hand domain-containing protein D2 EFHD2 
Q96C90 21,61 0,00 Protein phosphatase 1 regulatory subunit 14B 
PPP1R14
B 
Q96E11-8 20,31 0,00 Ribosome-recycling factor, mitochondrial MRRF 
Q96GA3 21,69 0,00 Protein LTV1 homolog LTV1 
Q96P48-3 22,30 0,00 
Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 
1 
ARAP1 
Q99622 18,50 0,00 Protein C10 C12orf57 
Q9BVP2-2 24,36 0,00 Guanine nucleotide-binding protein-like 3 GNL3 
H0Y6C7 20,42 0,00 Intraflagellar transport protein 27 homolog IFT27 
Q9C0C9 21,60 0,00 (E3-independent) E2 ubiquitin-conjugating enzyme UBE2O 
Q9H5X1 21,21 0,00 MIP18 family protein FAM96A FAM96A 
A6PVP4 20,67 0,00 Mediator of RNA polymerase II transcription subunit 20 MED20 
Q9H993 22,20 0,00 Protein-glutamate O-methyltransferase ARMT1 
Q9HAV4 21,73 0,00 Exportin-5 XPO5 









Table 6.5 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with anti-miR-203. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
Q9HD33-2 22,29 0,00 39S ribosomal protein L47, mitochondrial MRPL47 
Q9NRW3 20,20 0,00 DNA dC->dU-editing enzyme APOBEC-3C 
APOBEC3
C 
Q9NTJ5 22,32 0,00 Phosphatidylinositide phosphatase SAC1 SACM1L 
Q9NX08 21,41 0,00 COMM domain-containing protein 8 COMMD8 
Q9UNX3 20,90 0,00 60S ribosomal protein L26-like 1 RPL26L1 
Q9Y3A6 19,30 0,00 Transmembrane emp24 domain-containing protein 5 TMED5 
C9JA28 20,00 0,00 Translocon-associated protein subunit gamma SSR3 
Q9Y5S9-2 21,22 0,00 RNA-binding protein 8A RBM8A 
Q9Y5Y2 21,33 0,00 Cytosolic Fe-S cluster assembly factor NUBP2 NUBP2 
Q9UPT8 22,28 0,00 Zinc finger CCCH domain-containing protein 4 ZC3H4 
B4DLN1 21,74 0,00 Uncharacterized protein 
 
H0Y621 23,25 0,00 Endoplasmic reticulum-Golgi intermediate compartment protein 3 ERGIC3 
Q9UBT2 24,89 0,00 SUMO-activating enzyme subunit 2 UBA2 
H7C585 19,46 0,00 Frataxin, mitochondrial FXN 
H0YE25 18,95 0,00 Parkinson disease 7 domain-containing protein 1 PDDC1 
Q14160 22,30 0,00 Protein scribble homolog SCRIB 
Q9H0P0-3 22,52 0,00 Cytosolic 5'-nucleotidase 3A NT5C3A 
P47989 22,50 0,00 Xanthine dehydrogenase/oxidase XDH 
P42345 23,06 0,00 Serine/threonine-protein kinase mTOR MTOR 
Q92599-2 24,73 0,00 Septin-8 SEPT8 
P42285 22,94 0,00 Superkiller viralicidic activity 2-like 2 SKIV2L2 
P51857-2 24,66 0,00 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 
Q6S8J3 24,99 0,00 POTE ankyrin domain family member E POTEE 









Q9H3Z4-2 23,51 0,00 DnaJ homolog subfamily C member 5 DNAJC5 
D6RAX2 22,84 11,49 C-terminal-binding protein 1 CTBP1 
P51532-2 0,00 19,08 Transcription activator BRG1 SMARCA4 
Q9UI09 0,00 19,56 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 NDUFA12 
Q9UFN0 0,00 20,11 Protein NipSnap homolog 3A 
NIPSNAP
3A 
Q9BU89 0,00 21,07 Deoxyhypusine hydroxylase DOHH 
O15294-4 0,00 21,29 
UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa 
subunit 
OGT 
Q9Y2R0 0,00 21,34 Cytochrome c oxidase assembly factor 3 homolog, mitochondrial COA3 
O95168-2 0,00 21,56 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 NDUFB4 
P82675 0,00 21,63 28S ribosomal protein S5, mitochondrial MRPS5 
B7Z358 0,00 21,80 39S ribosomal protein L50, mitochondrial MRPL50 
E7ESI2 0,00 21,82 Cyclin-dependent kinase 2 CDK2 
Q14980-4 0,00 21,87 Nuclear mitotic apparatus protein 1 NUMA1 
Q13043-2 0,00 21,91 Serine/threonine-protein kinase 4 STK4 
Q9P0J0 0,00 22,56 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 NDUFA13 
O00762 0,00 22,59 Ubiquitin-conjugating enzyme E2 C UBE2C 
Q13619-2 0,00 22,67 Cullin-4A CUL4A 
Q9Y3E7-2 0,00 22,78 Charged multivesicular body protein 3 CHMP3 
Q71UI9 0,00 22,90 Histone H2A.V H2AFV 
P09669 0,00 22,92 Cytochrome c oxidase subunit 6C COX6C 
Q9UI12-2 0,00 23,12 V-type proton ATPase subunit H ATP6V1H 
O14929-2 0,00 23,13 Histone acetyltransferase type B catalytic subunit HAT1 
B4DKZ7 0,00 23,19 cDNA FLJ55704, highly similar to Transcriptional repressor p66 alpha 
 
Q9NXH9-2 0,00 23,21 tRNA (guanine(26)-N(2))-dimethyltransferase TRMT1 
Q5RI15 0,00 23,24 Cytochrome c oxidase protein 20 homolog COX20 











Table 6.5 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with anti-miR-203. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
O75828 0,00 23,46 Carbonyl reductase [NADPH] 3 CBR3 
Q8WZA9 0,00 23,49 Immunity-related GTPase family Q protein IRGQ 
O00560-2 0,00 23,53 Syntenin-1 SDCBP 
O00515 18,31 23,70 Ladinin-1 LAD1 
O60678-2 0,00 23,75 Protein arginine N-methyltransferase 3 PRMT3 
P56545 0,00 23,97 C-terminal-binding protein 2 CTBP2 
Q8NHH9-3 0,00 24,22 Atlastin-2 ATL2 
P14866-2 0,00 24,22 Heterogeneous nuclear ribonucleoprotein L HNRNPL 
Q9UHD9 0,00 24,26 Ubiquilin-2 UBQLN2 
P13984 0,00 24,30 General transcription factor IIF subunit 2 GTF2F2 
Q9BTE3-2 0,00 24,49 Mini-chromosome maintenance complex-binding protein MCMBP 
B7Z8U9 0,00 24,56 cDNA FLJ52831, highly similar to Tripartite motif-containing protein 29 
 
Q86U42-2 0,00 24,84 Polyadenylate-binding protein 2 PABPN1 
O94776 0,00 25,03 Metastasis-associated protein MTA2 MTA2 










Table 6.6 - Differently expressed proteins after transfection of MCF-10A cell line with pre-miR-203. Values are presented as the mean of 




ID_UNIPROT Negative control pre-miR-203 PROTEIN GENE 
O43760 0,00 21,98 Synaptogyrin-2 SYNGR2 
O43852 0,00 25,55 Calumenin CALU 
O60613 0,00 19,06 15 kDa selenoprotein SEP15 
O60869-2 0,00 19,23 Endothelial differentiation-related factor 1 EDF1 
E5RGS4 0,00 19,02 Prefoldin subunit 1 PFDN1 
O75323 0,00 23,73 Protein NipSnap homolog 2 GBAS 
O75368 0,00 20,34 SH3 domain-binding glutamic acid-rich-like protein SH3BGRL 
O75477 0,00 23,64 Erlin-1 ERLIN1 
O94855 0,00 23,34 Protein transport protein Sec24D SEC24D 
O95295 0,00 20,88 SNARE-associated protein Snapin SNAPIN 
O95721 0,00 21,88 Synaptosomal-associated protein 29 SNAP29 
O95816 0,00 21,94 BAG family molecular chaperone regulator 2 BAG2 
P00533 0,00 22,91 Epidermal growth factor receptor EGFR 
E7EWZ6 0,00 21,81 Integrin alpha-V ITGAV 
E9PJS4 0,00 21,41 Signal recognition particle receptor subunit alpha SRPRA 
F8VZY9 0,00 24,63 Keratin, type I cytoskeletal 18 KRT18 
P07311 0,00 19,24 Acylphosphatase-1 ACYP1 
P09104 0,00 24,75 Gamma-enolase ENO2 
Q5TCU3 0,00 23,70 Tropomyosin beta chain TPM2 
P11047 0,00 22,87 Laminin subunit gamma-1 LAMC1 
P15927 0,00 22,83 Replication protein A 32 kDa subunit RPA2 
P16949 0,00 22,03 Stathmin STMN1 









Table 6.6 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with pre-miR-203. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
P19388 0,00 21,66 DNA-directed RNA polymerases I, II, and III subunit RPABC1 POLR2E 
P20962 0,00 23,23 Parathymosin PTMS 
B4DIT7 0,00 24,74 
cDNA FLJ58187, highly similar to Protein-glutamine gamma-glutamyltransferase 
2(EC 2.3.2.13)  
P23634-5 0,00 24,79 Plasma membrane calcium-transporting ATPase 4 ATP2B4 
P31930 0,00 23,94 Cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 
B1AK13 0,00 22,74 
3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
(Hydroxymethylglutaricaciduria), isoform CRA_b 
HMGCL 
P40937-2 0,00 21,75 Replication factor C subunit 5 RFC5 
P42858 0,00 21,72 Huntingtin HTT 
B4DF38 0,00 24,05 
cDNA FLJ52123, highly similar to Platelet-activating factor acetylhydrolase IB 
alpha subunit  
P46934-4 0,00 20,26 E3 ubiquitin-protein ligase NEDD4 NEDD4 
B4DWK0 0,00 21,58 Selenide, water dikinase 1 SEPHS1 
P51610-2 0,00 22,23 Host cell factor 1 HCFC1 
E9PPY7 0,00 21,51 Arfaptin-2 ARFIP2 
P54727 0,00 22,43 UV excision repair protein RAD23 homolog B RAD23B 
J3QR71 0,00 21,90 Developmentally-regulated GTP-binding protein 2 DRG2 
P62158 0,00 22,03 Calmodulin CALM1 
B8ZZJ0 0,00 20,64 Small ubiquitin-related modifier 1 SUMO1 
F5GWE5 0,00 20,53 Phosphatidylinositol transfer protein alpha isoform PITPNA 
Q01085 0,00 23,52 Nucleolysin TIAR TIAL1 
Q01105 0,00 27,60 Protein SET SET 
Q07352 0,00 23,04 Zinc finger protein 36, C3H1 type-like 1 ZFP36L1 











Q12874 0,00 22,47 Splicing factor 3A subunit 3 SF3A3 
Q12965 0,00 21,78 Unconventional myosin-Ie MYO1E 
Q13217 0,00 23,11 DnaJ homolog subfamily C member 3 DNAJC3 
Q13641 0,00 22,41 Trophoblast glycoprotein TPBG 
Q13795 0,00 20,57 ADP-ribosylation factor-related protein 1 ARFRP1 
Q14061 0,00 20,75 Cytochrome c oxidase copper chaperone COX17 
Q14192 0,00 22,88 Four and a half LIM domains protein 2 FHL2 
Q16539 0,00 23,59 Mitogen-activated protein kinase 14 MAPK14 
H0Y6C3 0,00 21,88 Pyrroline-5-carboxylate reductase 3 PYCRL 
B1AJQ6 0,00 22,97 Syntaxin-12 STX12 
Q8N138-4 0,00 19,14 ORM1-like protein 3 ORMDL3 
Q8TBC4-2 0,00 24,48 NEDD8-activating enzyme E1 catalytic subunit UBA3 
Q92542-2 0,00 24,09 Nicastrin NCSTN 
Q99622 0,00 19,92 Protein C10 C12orf57 
Q9C0C9 0,00 20,32 (E3-independent) E2 ubiquitin-conjugating enzyme UBE2O 
C9JAG1 0,00 21,98 Ethanolaminephosphotransferase 1 EPT1 
Q9H3P7 0,00 23,78 Golgi resident protein GCP60 ACBD3 
Q9H444 0,00 23,98 Charged multivesicular body protein 4b CHMP4B 
A6PVP4 0,00 19,37 Mediator of RNA polymerase II transcription subunit 20 MED20 
Q5VVM0 0,00 22,98 Phosphopantothenate--cysteine ligas PPCS 
Q9NP77 0,00 20,00 RNA polymerase II subunit A C-terminal domain phosphatase SSU72 SSU72 
Q9NRX4 0,00 24,71 14 kDa phosphohistidine phosphatase PHPT1 
Q9UBS4 0,00 23,19 DnaJ homolog subfamily B member 11 DNAJB11 
Q9UJK0 0,00 19,42 Ribosome biogenesis protein TSR3 homolog TSR3 
E9PQR7 0,00 21,94 Vacuolar protein sorting-associated protein 28 homolog VPS28 
J3KT51 0,00 21,98 Hematological and neurological-expressed 1 protein HN1 
Q9UL26 0,00 22,09 Ras-related protein Rab-22A RAB22A 









Table 6.6 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with pre-miR-203. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
G3V158 0,00 21,94 2-deoxyribose-5-phosphate aldolase homolog (C. elegans), isoform CRA_a DERA 
Q9Y3A3-2 0,00 22,64 MOB-like protein phocein MOB4 
B8ZZF8 0,00 20,65 U6 snRNA-associated Sm-like protein LSm5 LSM5 
C9JNE2 0,00 18,39 O-acetyl-ADP-ribose deacetylase 1 OARD1 
Q9Y5J9 0,00 19,38 Mitochondrial import inner membrane translocase subunit Tim8 B TIMM8B 
Q9Y5Z4 0,00 20,60 Heme-binding protein 2 HEBP2 
B4DLN1 0,00 21,79 Uncharacterized protein 
 
B5MC72 0,00 20,01 Endoplasmic reticulum lectin 1 ERLEC1 
Q9BWJ5 0,00 19,25 Splicing factor 3B subunit 5 SF3B5 
O15091-3 0,00 20,10 Mitochondrial ribonuclease P protein 3 
KIAA039
1 
F5H871 0,00 20,51 WASH complex subunit FAM21C FAM21C 
H0YBZ9 0,00 19,61 Survival motor neuron protein SMN1 
F5GZP6 0,00 21,11 Liprin-beta-1 PPFIBP1 
Q9Y657 0,00 20,49 Spindlin-1 SPIN1 
Q8WVC6 0,00 21,16 Dephospho-CoA kinase domain-containing protein DCAKD 
Q9Y6Y8 0,00 21,99 SEC23-interacting protein SEC23IP 
Q96AY3 0,00 22,23 Peptidyl-prolyl cis-trans isomerase FKBP10 FKBP10 
F8W943 0,00 22,83 Argininosuccinate lyase ASL 
Q9BRR6-2 0,00 22,92 ADP-dependent glucokinase ADPGK 
O43819 0,00 22,50 Protein SCO2 homolog, mitochondrial SCO2 
Q9Y697-2 0,00 22,54 Cysteine desulfurase, mitochondrial NFS1 
P51857-2 0,00 25,35 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 
H7C207 0,00 20,46 R3H domain-containing protein 1 R3HDM1 









O15027-2 0,00 19,73 Protein transport protein Sec16A SEC16A 
P63313 0,00 19,79 Thymosin beta-10 TMSB10 
Q6PI78 0,00 19,58 Transmembrane protein 65 TMEM65 
Q15651-2 0,00 19,61 High mobility group nucleosome-binding domain-containing protein 3 HMGN3 
F8VUA7 0,00 20,96 Oxysterol-binding protein OSBPL8 
H3BM18 0,00 21,84 Gamma-interferon-inducible protein 16 IFI16 
P33316-2 0,00 20,80 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial DUT 
Q8IYS1 0,00 22,43 Peptidase M20 domain-containing protein 2 PM20D2 
P49841 0,00 23,40 Glycogen synthase kinase-3 beta GSK3B 
O43933 0,00 25,73 Peroxisome biogenesis factor 1 PEX1 
Q02224-3 0,00 26,40 Centromere-associated protein E CENPE 
A6ND91 0,00 28,94 Putative L-aspartate dehydrogenase ASPDH 
F5H7C4 18,51 0,00 Methionine-R-sulfoxide reductase B3 MSRB3 
Q9P016-2 20,33 0,00 Thymocyte nuclear protein 1 THYN1 
P80294 20,38 0,00 Metallothionein-1H MT1H 
Q8IYA2 20,64 0,00 Putative coiled-coil domain-containing protein 144C 
CCDC144
CP 
Q9Y3C4 20,71 0,00 EKC/KEOPS complex subunit TPRKB TPRKB 
Q15382 21,20 0,00 GTP-binding protein Rheb RHEB 
P02792 21,42 0,00 Ferritin light chain FTL 
O60443 21,42 0,00 Non-syndromic hearing impairment protein 5 DFNA5 
Q9Y2V2 21,74 0,00 Calcium-regulated heat-stable protein 1 CARHSP1 
P82912-2 21,82 0,00 28S ribosomal protein S11, mitochondrial MRPS11 
C9JTE9 21,85 0,00 B-cell receptor-associated protein 29 BCAP29 
Q9UI14 21,93 0,00 Prenylated Rab acceptor protein 1 RABAC1 
Q9BRJ2 21,94 0,00 39S ribosomal protein L45, mitochondrial MRPL45 
Q5TBE9 21,94 0,00 Iron-sulfur cluster assembly 1 homolog, mitochondrial ISCA1 









Table 6.6 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with pre-miR-203. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
B4DQ47 22,11 0,00 
cDNA FLJ58036, highly similar to Homo sapiens sterile alpha motif and leucine zipper 
containing kinase AZK (ZAK), transcript variant 2, mRNA 
P61769 22,16 0,00 Beta-2-microglobulin B2M 
Q9BV81 22,21 0,00 ER membrane protein complex subunit 6 EMC6 
Q9BYN0 22,26 0,00 Sulfiredoxin-1 SRXN1 
E9PP29 22,32 0,00 Transmembrane protein 41B 
TMEM41
B 
Q2M389-2 22,35 0,00 WASH complex subunit 7 
KIAA103
3 
B4E2V5 22,38 0,00 cDNA FLJ52062, highly similar to Erythrocyte band 7 integral membrane protein FKBP2 
B8ZZV5 22,38 0,00 39S ribosomal protein L30, mitochondrial MRPL30 
Q9BQ67 22,40 0,00 Glutamate-rich WD repeat-containing protein 1 GRWD1 
P18827 22,42 0,00 Syndecan-1 SDC1 
Q96DV4 22,44 0,00 39S ribosomal protein L38, mitochondrial MRPL38 
Q02952-3 22,47 0,00 A-kinase anchor protein 12 AKAP12 
P55769 22,50 0,00 NHP2-like protein 1 SNU13 
Q9Y224 22,52 0,00 UPF0568 protein C14orf166 
C14orf16
6 
A1L0T0 22,53 0,00 Acetolactate synthase-like protein ILVBL 
H0YBW4 22,54 0,00 Phospholipase A-2-activating protein PLAA 
Q8N4V1 22,59 0,00 Membrane magnesium transporter 1 MMGT1 
O14737 22,62 0,00 Programmed cell death protein 5 PDCD5 
Q9BX68 22,62 0,00 Histidine triad nucleotide-binding protein 2, mitochondrial HINT2 
P62330 22,65 0,00 ADP-ribosylation factor 6 ARF6 
Q8IUR0 22,69 0,00 Trafficking protein particle complex subunit 5 TRAPPC5 









P61457 22,78 0,00 Pterin-4-alpha-carbinolamine dehydratase PCBD1 
P41743 22,78 0,00 Protein kinase C iota type PRKCI 
P09669 22,80 0,00 Cytochrome c oxidase subunit 6C COX6C 
Q9H7D0 22,83 0,00 Dedicator of cytokinesis protein 5 DOCK5 
Q3ZAQ7 22,85 0,00 Vacuolar ATPase assembly integral membrane protein VMA21 VMA21 
Q96EL3 22,87 0,00 39S ribosomal protein L53, mitochondrial MRPL53 
H0YNG3 22,89 0,00 Signal peptidase complex catalytic subunit SEC11 SEC11A 
P00918 22,92 0,00 Carbonic anhydrase 2 CA2 
C9JW69 22,93 0,00 Regulator of chromosome condensation RCC1 
Q15796-2 22,94 0,00 Mothers against decapentaplegic homolog 2 SMAD2 
O15235 22,94 0,00 28S ribosomal protein S12, mitochondrial MRPS12 
Q86WQ0 22,95 0,00 Nuclear receptor 2C2-associated protein NR2C2AP 
Q9BUB7 22,96 0,00 Transmembrane protein 70, mitochondrial TMEM70 
Q53FT3 23,12 0,00 Protein Hikeshi C11orf73 
P47224 23,18 0,00 Guanine nucleotide exchange factor MSS4 RABIF 
F8VYE8 23,22 0,00 Serine/threonine-protein phosphatase PPP1CC 
C9JFE4 23,24 0,00 COP9 signalosome complex subunit 1 GPS1 
Q9H936 23,24 0,00 Mitochondrial glutamate carrier 1 
SLC25A2
2 
B4DRF4 23,28 0,00 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 HACD3 
P82932 23,30 0,00 28S ribosomal protein S6, mitochondrial MRPS6 
P32321 23,31 0,00 Deoxycytidylate deaminase DCTD 
P01034 23,32 0,00 Cystatin-C CST3 
B4DZ70 23,33 0,00 NADP-dependent malic enzyme ME1 
Q8N6M0 23,33 0,00 OTU domain-containing protein 6B OTUD6B 
P05976 23,35 0,00 Myosin light chain 1/3, skeletal muscle isoform MYL1 
Q9NZT2-2 23,39 0,00 Opioid growth factor receptor OGFR 









Table 6.6 (continued) - Differently expressed proteins after transfection of MCF-10A cell line with pre-miR-203. Values are presented as the 
mean of log2(Intensity) of two independent experiments. Protein and gene nomenclature is according to UNIPROT database. 
F8VRL4 23,44 0,00 Diphosphoinositol polyphosphate phosphohydrolase 2 NUDT4 
P61970 23,66 0,00 Nuclear transport factor 2 NUTF2 
Q96KB5 23,68 0,00 Lymphokine-activated killer T-cell-originated protein kinase PBK 
Q5TGH5 23,75 0,00 Elongation of very long chain fatty acids protein 5 ELOVL5 
O14979-3 23,76 0,00 Heterogeneous nuclear ribonucleoprotein D-like 
HNRNPD
L 
Q9Y3E5 23,76 0,00 Peptidyl-tRNA hydrolase 2, mitochondrial PTRH2 
P62837 23,77 0,00 Ubiquitin-conjugating enzyme E2 D2 UBE2D2 
Q13547 23,89 0,00 Histone deacetylase 1 HDAC1 
P40763-2 23,95 0,00 Signal transducer and activator of transcription 3 STAT3 
Q7Z2W4 24,00 0,00 Zinc finger CCCH-type antiviral protein 1 ZC3HAV1 
Q9Y4Z0 24,06 0,00 U6 snRNA-associated Sm-like protein LSm4 LSM4 
Q6P1L8 24,20 0,00 39S ribosomal protein L14, mitochondrial MRPL14 
Q9P258 24,34 0,00 Protein RCC2 RCC2 
Q9H6S3 24,43 0,00 Epidermal growth factor receptor kinase substrate 8-like protein 2 EPS8L2 
Q96CX2 24,53 0,00 BTB/POZ domain-containing protein KCTD12 KCTD12 
O00170 24,55 0,00 AH receptor-interacting protein AIP 
P50416-2 24,77 0,00 Carnitine O-palmitoyltransferase 1, liver isoform CPT1A 
P42224 24,95 0,00 Signal transducer and activator of transcription 1-alpha/beta STAT1 
O96005 25,01 0,00 Cleft lip and palate transmembrane protein 1 CLPTM1 
F8W7Q4 25,04 0,00 Protein FAM162A FAM162A 
E9PL69 25,05 0,00 Ribonucleoside-diphosphate reductase large subunit RRM1 
E5RGY0 25,20 0,00 Derlin DERL1 
Q6UW68 25,34 0,00 Transmembrane protein 205 
TMEM20
5 









Q14566 25,45 0,00 DNA replication licensing factor MCM6 MCM6 
Q8N8S7-2 25,92 0,00 Protein enabled homolog ENAH 
Q15125 26,43 0,00 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase EBP 
P61077 26,47 0,00 Ubiquitin-conjugating enzyme E2 D3 UBE2D3 
C9JYQ9 26,53 0,00 60S ribosomal protein L22-like 1 RPL22L1 
P13807-2 27,21 0,00 Glycogen [starch] synthase, muscle GYS1 
















7. Conclusions and future perspectives 
Precision cancer medicine is more than a glimmer of hope on the horizon to become a 
desirable objective of cancer research. It can lead to a combination of diagnosis and 
treatment strategies that can be used to integrate patient and tumour variables with an 
outcome oriented approach. In fact, this approach can guide to personalized therapy, 
improve drug response and avoid the morbidity associated with treatments that could 
hamper the desired effect due to side effects. 
Many approaches have been followed to attain precision medicine. Its lexicon embraces 
genomics, transcriptomics, proteomics and more recently metabolomics (Lumachi et al., 
2015; Shajahan-Haq et al., 2015; Song et al., 2015; Xu et al., 2014). All these approaches 
aim to find a biomarker or a set of biomarkers that can help define which patients have a 
clinical indication for a selected therapy, whom can have a relapse that lead to a poor 
outcome and if a tumour has gained the capability to metastasize to a different organ. 
MiRNAs have also been used in this pursuit for precision medicine, however we have 
much to learn about miRNAs biology. In fact, much is still unknown about miRNAs 
biogenesis, which includes expression regulation and maturation, mode of action and 
target regulation. 
In order to better understand the biology of miRNAs this thesis aimed to answer the 
relevant questions previously stated in Chapter 2 of this thesis: 
How do tumour cells deregulate miRNAs expression in order to gain a benefit? 
The work performed in order to answer this question is presented in Chapter 3. We 
followed two different approaches, analysis of methylated CpG islands in miRNAs genes 
promoter regions and proteomics in non-tumoural and tumoural breast cell lines. 
Many DNA methylation changes are observed between benign and tumour cells (Gyorffy et 





tumour cell an adaptive phenotype depending on the microenvironment and the needs in 
a given condition. In fact, tumours can take advantage of this mechanism in embryo 
development where genes are switched on and off by epigenetic mechanisms like 
methylation (Bird, 2002). The discovery of miRNAs and the development of better 
techniques to analyse methylation statuses allowed studies comparing normal and tumour 
tissues and tumour cell lines to find possible biomarkers. Here we analysed a set of 20 
promoter region of several miRNAs in breast cell lines. With this study we can conclude 
that these regions may not be the promoter regions of the miRNAs studied, since DNA 
methylation statuses does not correlate with the respective miRNAs expression levels. 
However, we cannot exclude the fact that methylation is not affecting miRNAs expression 
levels. Thus, a possible future approach will be to find new regions upstream in the 
miRNAs coding sequences but now using bisulfite sequencing a more sensitive technique 
of detecting methylated CpG islands.  
Through proteomics analysis we also can conclude that RAN is not regulating miRNAs 
expression levels. Also, with this approach we cannot exclude the role of other miRNAs 
biogenesis machinery proteins in the regulation of it expression levels. In fact, as stated 
before, there are already evidences that regulatory-like proteins affect the levels of 
miRNAs in the cell. In order to gain deeper insights in the proteome controlled by miR-
200c and miR-203 we searched through LC/MS analysis the proteome putatively 
controlled by those two miRNAs. If this approach could lead to a set of proteins whose 
expression is dependent upon the levels of miR-200c and miR-203, it still awaits further 
data to deeper interpret the role those proteins might have in breast cancer pathogenesis 
and, also what proteins may be candidates of the regulation circuitry involving miRNAs. 
How do miRNAs influence tumour cells? 
After analysing the possible mechanisms of miRNAs expression regulation we analysed 





resistance to some chemotherapeutic agents used in breast cancer. In Chapter 1 and 4 of 
this thesis we stated the importance of miRNAs in modulating drug resistance with several 
examples in many types of tumours. With our experiments we can conclude that miR-200c 
and miR-203 are differently expressed in breast tumour cell lines. Specifically, miR-200c 
and miR-203 are not expressed in MDA-MB-231 while they are in the MCF-7 cells. With 
these data we decided to ectopically express miRNA-200c and miR-203 in MDA-MB-231 
cells and inhibit the expression of the same miRNAs in MCF-7 cells. This strategy allowed 
us to analyse the possible effect of these miRNAs in resistance to PAX and 5-FU. Thus, miR-
200c seems to have an opposite effect in MCF-7 and MDA-MB-231 cells and miR-203 seem 
to increase resistance to PAX in MDA-MB-231 cell line. None of the miRNAs showed any 
effect in cell treated with 5-FU. To our knowledge this was the first study showing these 
results in breast cancer.  
What is the real expression of miRNAs in patient tumour cells? 
Last but not least, we analysed a set of 109 patients’ tissues in order to profile the miR-
200c, miR-203 and putative targets SIX1 and SOX2. With this approach we aimed to 
understand if these molecules could function as biomarkers to better classify cancer, 
which later could end up in a better therapy scheme. To our knowledge the work here 
presented was the first done in a Portuguese population on the role of the miR-200c, miR-
203 as regulators of SIX1 and SOX2. According to our data, miR-203a could be involved in 
breast cancer development, mainly in early stages of development. We also observed that 
miR-203a might be a potential marker to discriminate stages in invasive lobular 
carcinoma. Regarding miR-200c we did not detect significant differences between normal 
breast and tumour tissues and also cannot correlate miR-200c with clinicopathological 
features. Further studies with larger populations are needed to validate our data 





Concerning the putative targets of our studied miRNAs, we could not substantiate a 
control of expression of the two studied proteins by the miRNAs under study. However, 
due to the small sized population we used in the IHC study, we cannot exclude a possible 
association. 
Three years have passed since we started to collect our samples of FFPE from patients 
with breast cancer. Thus, until now we do not have sufficient data to infer if there are any 
patients with drug resistance. Our close collaboration with the department of Pathology 
and Breast Pathology Unit from Central Lisbon Hospital Centre will allow us in the future 
to correlate our miRNAs expression levels and putative targets with therapy and possibly 
associate them with a specific outcome, ending in a better prognostic. 
What other proteins may be controlled or dependent on miR-200c and miR-203? 
In order to gain insight into this question and more thoroughly clarify the role of miR-200c 
and miR-203 in the proteomic profile of cells, we analysed the role of ectopically 
expression of miRNA-200c and miR-203 in MDA-MB-231 cells and inhibition of the 
expression of the same miRNAs in MCF-10A cells and the respective effect in the 
proteomic profile of those cells under miRNAs control within a close collaboration with 
Professor Peter James of Lund University. The data allowed the identification of a set of 
proteins differentially expressed under control of any of the miRNAs. Although this is still 
a first approach, it suggests that a number of these proteins are involved in breast cancer 
and may potentially be used for earlier detection of cancer relapse and as putative 
biomarkers of prognosis. 
Future Perspectives/Work 
We believe that this work adds more knowledge in the pursuit of the personalized 
medicine. In fact, as future perspectives we aim to follow several “omics” and validate the 
current diagnostic methodology. Currently, breast cancer diagnosis relies, apart from 





biopsy in order to validate imaging results. Although breast cancer can be detected earlier, 
there is some concern about the dose of radiation necessary to perform a mammography. 
Moreover, some breast cancers are not found by mammograms, either because the test 
was not done or because even under ideal conditions mammograms do not detect every 
breast cancer.  Although breast cancers found during screening exams are more likely to 
be smaller and still confined to the breast, the size of a breast cancer and how far it has 
spread are some of the most important factors in predicting the prognosis of a woman 
with this disease. Early detection of breast cancer improves the chances that breast cancer 
can be treated successfully. Thus, early detection tests for breast cancer help save 
thousands of lives each year, and many more lives could be saved if even more women and 
their health care providers took advantage of these tests, provided they are minimally 
invasive, low cost, usable in primary care settings, and sensitive to early, curable, clinically 
significant lesions. Within this framework, the new medical and scientific paradigm of 
precision medicine is claiming new minimally invasive methods which may reliably help in 
a personalized diagnosis of cancer and allow an early detection of recurrence of the 
disease guiding in the therapeutic schemes to be adopted. Recent technology development 
allows the identification of molecules in blood shed from tumours. These molecules 
include metabolites of sugars, lipids, amino acids, fatty acids, phenolic compounds, 
alkaloids, DNA and RNA. In spite of the great efforts worldwide and the elucidating studies 
in this matter, to our knowledge, there are no studies validating medical imaging and 
biopsy analysis with metabolomics and liquid biopsies. Thus, in the future we propose a 
comprehensive study with women undergoing medical imaging, with or without tumour 
detection, of metabolites shed from primary tumour cells, ctDNA, circulating tumour cells 
(CTC’s) and exosomes (containing microRNAs, mRNAS and proteins shed from primary 
tumour cells) in blood samples, in order to validate the imaging and biopsy diagnosis 
(Figure 7.1). If successful we shall develop a minimally-invasive methodology to detect 





same patients after surgery, performing the same biomedical analysis in order to compare 
and validate our data with pathology-driven IHC classification and follow-up medical 
imaging, thus gaining insight on the prognosis of disease relapse and metastization of the 
primary tumour to other organs. Concomitantly we intend to continue the analyses of 
tumour and adjacent normal tissue of the same patients in order to find new biomarkers 







Figure 7.1 – Future approach in order to achieve a better diagnosis, tumour 
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